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Abstract 
Tight junctions are formed from a complex of different individual proteins.  These 
complexes are expressed by epithelial cells and form an intercellular barrier which 
restricts and regulates paracellular permeability.  Tight junction proteins have also 
been shown to be expressed in non-epithelial cells which do not form tight junctions, 
including astrocytes.  The function(s) of these proteins within non-epithelial cells, 
however, remains unclear.  This study aims to characterise the expression of tight 
junction proteins in astrocytes and investigate the function(s) of these proteins in 
these cells. 
The expression of the tight junction proteins occludin, claudin-5 and zonula 
occludens-1 (ZO-1) was characterised in vitro in both human primary astrocytes and 
the 1321N1 human astrocytoma cell line and in vivo in human autopsy brain 
samples.  The function(s) of occludin was investigated using a pull-down protein 
binding assay and mass spectrometry analysis to identify putative binding partners 
for this protein in astrocytes. 
The current study demonstrates astrocytic and nuclear expression of occludin and 
ZO-1 in vitro and in vivo.  The expression of claudin 5 in astrocytes remains difficult 
to determine due to contradictory evidence in which the astrocytic expression of this 
protein in vitro is not supported in vivo.  Putative binding partners were also 
identified for the N- and C-terminal domains of occludin.  Many of these proteins 
have functions in RNA metabolic processes, consequently their identification as 
putative occludin binding partners implicates occludin in functions beyond the 
formation of the tight junction complex.  Although these interactions have not yet 
been validated, this study’s findings provide a platform upon which future research 
can be constructed.   
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1. Introduction 
 
2 
 
1.1 Astrocytes  
Astrocytes are highly heterogeneous, multifunctional glial cells located throughout 
the central nervous system (CNS) which are typically characterised by a highly 
branched morphology (Hu et al., 2016).  Astrocytes are a functional component in 
synaptic transmission capable of influencing neuronal signalling and are also 
involved in the modulation of cerebral blood flow.   
1.1.1 Astrocytes & the Tripartite Synapse 
The tripartite synapse is structurally composed of neuronal pre- and post-synaptic 
terminals surrounded by astrocytic processes with synaptic transmission being 
defined by the dynamic communication which occurs between these components 
(Alberto and Alfonso, 2013; Allen, 2014; Araque et al., 1999).  Neurotransmitters 
released from pre-synaptic terminals bind to receptors located at both the post-
synaptic terminal and astrocytic processes.  Unlike neurons, astrocytes are 
incapable of generating action potentials, instead astrocytic receptor activation 
elicits dynamic changes in the intracellular concentration of calcium (Ca2+) ions 
within these cells, known as calcium transients (Shigetomi et al., 2016).  These 
transients trigger the release of gliotransmitters which influence synaptic 
transmission and consequently neuronal signalling. 
Astrocytes express ionotropic and metabotropic receptors for many 
neurotransmitters including glutamate and γ-aminobutyric acid (GABA), respectively 
the principal excitatory and inhibitory neurotransmitters within the CNS (Bradley and 
Challiss, 2012; Lalo et al., 2011; Lee et al., 2011; Meier et al., 2008).  Ionotropic 
receptors are ligand-gated ion channels.  Metabotropic receptors do not form ion-
permeable channels and instead function through a signal transduction mechanism 
mediated by G-proteins, consequently these receptors are known as G protein-
coupled receptors (GPCRs) (Allen, 2014).   
Astrocytes also express transporters to remove neurotransmitters from the synaptic 
cleft.  Excitatory amino acid transporters 1 and 2 (EAAT1 and EAAT2) transport 
glutamate into astrocytes where it is metabolised into glutamine by glutamine 
synthase (Lee and Pow, 2010).  Glutamine is transported to neurons where it is 
converted back into glutamate by glutaminase (Lee and Pow, 2010). 
Astrocytes also express GABA transporters 1 and 3 (GAT-1 and GAT-3) (Conti et 
al., 2004).  GABA is formed from glutamine by glutamic acid decarboxylase (GAD) 
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of which two isoforms have been identified, GAD 67 and GAD 65 (Lee et al., 2011; 
Soghomonian and Martin, 1998).  GABA is also metabolised back to glutamine by 
GABA transaminase (GABA-T).  Immunohistochemical analysis of human tissue 
shows that GAD 67 and GABA-T are expressed within astrocytes throughout the 
brain demonstrating that these cells are capable of metabolising this 
neurotransmitter (Lee et al., 2011). 
1.1.2 Astrocytes and Calcium Transients 
Membrane-permeable fluorescent Ca2+ indicator dyes, examples of which include 
fura-2, fluo-3 and fluo-4, are used extensively in studying astrocytic intracellular 
calcium signalling (Gee et al., 2000; Grynkiewicz et al., 1985; Kao et al., 1989).  
These dyes, however, do have limitations as they fail to capture astrocytic 
processes beyond approximately 25 μm and also underestimate the quantity of 
primary astrocytic processes (Reeves et al., 2011).  Consequently these dyes are 
able to reliably measure calcium transients located only in the astrocyte soma but 
are unable to reliably detect calcium transients within fine astrocytic processes 
(Reeves et al., 2011; Tong et al., 2013).   
Genetically encoded Ca2+ indicators (GECIs) are also used to measure intracellular 
calcium transients.  These probes utilise green fluorescent protein (GFP) variants 
which are hybridized with the calcium binding protein calmodulin and the calmodulin 
binding peptide M13 (Nakai et al., 2001; Pérez Koldenkova and Nagai, 2013).  
GECIs circumvent many of the problems presented by indicator dyes as they are 
transfected into cells, instead of being applied through bulk-loading like indicator 
dyes, and can be designed to target specific cellular compartments or subcellular 
regions (Reeves et al., 2011; Tong et al., 2013).  Consequently GECIs are able to 
detect and measure calcium transients located in astrocytic processes which 
indicator dyes are unable to access. 
1.1.2.1. Intrinsic Intracellular Calcium Fluctuations 
Astrocytes express the metabotropic glutamate receptor mGlu5, the activation of 
which is responsible for the release of Ca2+ ions from the endoplasmic reticulum 
(ER), a subcellular organelle whose functions include the intracellular storage of 
Ca2+ ions (Biber et al., 1999).  Activation of the mGlu5 receptor results in the 
activation of phospholipase C (PLC) and the subsequent hydrolysis of 
phosphoinositide phospholipids within the cell membrane to produce inositol 1,4,5-
triphosphate (IP3) (Shigetomi et al., 2016).  IP3 binds to and activates receptors 
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located in the ER resulting in the release of intracellular Ca2+ ions.  Three IP3 
receptor (IP3R) isoforms have been identified, IP3R1, IP3R2 and IP3R3 (Foskett et 
al., 2007), of which IP3R2 is enriched in astrocytes (Holtzclaw et al., 2002; Zhang et 
al., 2014).   
The role of IP3R2 receptors in calcium signalling has been investigated in 
hippocampal astrocytes and neurons using an IP3R2 knockout (KO) mouse model.  
IP3R2 KO mice are viable and fertile with no effect upon mortality (Li et al., 2005a).  
Histological analysis of the hippocampus, cortex and cerebellum shows no apparent 
structural differences between mutant and wildtype mice (Petravicz et al., 2008).  
Electrophysiological analysis of hippocampal slices taken from wildtype and mutant 
loaded with fluo-4 and calcium green-1 indicator dyes shows that hippocampal 
astrocytes in the IP3R2 KO do not exhibit any GPCR-mediated increase in 
intracellular calcium and demonstrate a complete loss of calcium activity (Petravicz 
et al., 2008).  There are, however, no significant differences in IP3R-mediated 
calcium signalling in CA1 pyramidal neurons in IP3R2 KO mice compared with the 
wildtype, suggesting that IP3R2 receptors are responsible for mediating calcium 
transients in astrocytes but not in neurons (Petravicz et al., 2008).   
Subsequent research using GECIs has, however, identified GPCR-mediated 
calcium transients which are preserved in the astrocytic processes of IP3R2 KO 
mice (Haustein et al., 2014; Kanemaru et al., 2014; Srinivasan et al., 2015).  
Electrophysiological analysis of hippocampal slices taken from wildtype and IP3R2 
knockout mice utilising the GECI GCaMP6f demonstrates that calcium transients 
persist in the processes but are lost in the soma of KO mice.  (Srinivasan et al., 
2015).  The GRCR agonist endothelin elicits a significant elevation in somatic 
calcium signalling in wildtype astrocytes which is not exhibited in the mutant, 
however, a comparable elevation in calcium signalling in both wildtype and mutant 
is present in astrocyte processes (Srinivasan et al., 2015).  This demonstrates that 
calcium signalling in the astrocytic soma and processes is mediated by different 
receptors.  These findings contradict those of previous studies which used indicator 
dyes.  It appears that, due to their limitations, the indicator dyes used in these 
studies failed to reveal the full complexity of astrocytic calcium signalling (Petravicz 
et al., 2014; Petravicz et al., 2008).   
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1.1.2.2. Transmembrane Microdomains 
Astrocytic processes also exhibit brief, spotty calcium transients located close to the 
membrane which were first observed in rat hippocampal astrocytes co-cultured with 
neurons using Lck-GCaMP2; a GECI modified to include Lck, a membrane-tethering 
domain (Shigetomi et al., 2010).  These transients are known as microdomains and 
are mediated by transient receptor potential A1 (TRPA1) channels (Shigetomi et al., 
2012).  Not all microdomain signals in the CA3 region of the hippocampus, however, 
are blocked by a TRPA1-selective antagonist, suggesting the involvement of other 
receptors in the generation of these signals (Haustein et al., 2014). 
1.1.3 Gliotransmitters 
Astrocytes influence neuronal signalling through the release of chemicals known as 
gliotransmitters which include glutamate, adenosine triphosphate (ATP) and D-
serine, as well as variety of metabolic substrates, peptides and eicosanoids (Petrelli 
and Bezzi, 2016).  Gliotransmitter release can occur via several different 
mechanisms including vesicle-mediated exocytosis (Zorec et al., 2015).  Vesicle-
mediated exocytosis is a Ca2+-dependent process which requires extensive 
molecular machinery involving soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE) proteins (Petrelli and Bezzi, 2016).  Astrocytes express 
SNARE proteins which suggests that vesicle-mediated exocytosis is a mechanism 
by which these cells release gliotransmitters (Jeftinija et al., 1997; Montana et al., 
2006; Wilhelm et al., 2004; Zhang et al., 2004).   
Cytosolic glutamate is loaded into exocytotic vesicles by vesicular glutamate 
transporters (VGLUTs) which are driven by a proton gradient generated by vacuolar 
proton ATPase (V-ATPase).  Astrocytes express all three known VGLUT isoforms 
(Bezzi et al., 2004; Kreft et al., 2004; Montana et al., 2004).  Astrocytic glutamate 
release is abolished by clostridial neurotoxins, which cleave SNARE proteins, and 
reduced by the V-ATPase inhibitor bafilomycin A1 demonstrating that astrocytic 
glutamate release occurs by vesicle-mediated exocytosis (Araque et al., 2000; 
Bezzi et al., 2004; Montana et al., 2004; Zhang et al., 2004).  Figure 1.1 depicts the 
functional roles of astrocytes within a glutamatergic tripartite synapse. 
The release of D-serine from cultured rat astrocytes is mediated by an elevation in 
intracellular Ca2+ which occurs in response to AMPA and mGlu receptor activation 
(Mothet et al., 2005).  The release of D-serine from astrocytes is a Ca2+-dependent 
process which is significantly reduced in the presence of tetanus toxin, a clostridial 
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neurotoxin, suggesting that astrocytic D-serine release also occurs by vesicle-
mediated exocytosis (Mothet et al., 2005).  This is further supported by the fact that 
D-serine is stored along with glutamate in vesicles bearing synaptobrevin 2, a 
SNARE complex protein, in rat cortical astrocytes (Martineau et al., 2013).  The 
vesicular D-serine transporter (VSERT) has not yet been identified although the 
vesicular uptake of D-serine is blocked by bafilomycin A1 and concanamycin A both 
of which are V-ATPase inhibitors, demonstrating that the vesicular uptake of this 
gliotransmitter requires a proton gradient generated by V-ATPases (Martineau et al., 
2013; Mothet et al., 2005).  
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Figure 1.1: The Tripartite Synapse  1) Glutamate release from the pre-synaptic 
terminal activates ionotropic α-amino-3-hydroxy-5-methyl-4isozole propionic acid 
(AMPA) and N-methyl-D-aspartate (NMDA) glutamate receptors located at the post-
synaptic terminal and metabotropic glutamate receptors located at astrocytic 
processes.  2) The activation of astrocytic metabotropic glutamate receptors elicits 
an increase in intracellular Ca2+ ions through IP3-mediated release from the ER.  3) 
This triggers Ca2+-dependent vesicle-mediated exocytosis of gliotransmitters which 
bind to receptors located at both the pre-and post-synaptic terminal and 
subsequently influence neuronal signalling.  4) Astrocytes also remove glutamate 
from the synaptic cleft through EAAT transporters where it is metabolised into 
glutamine by glutamine synthase. 
1.1.4 Astrocytes and Gap Junctions 
Connexins (Cx) are tetra-span transmembrane proteins with two extracellular loops, 
a small intracellular loop and cytoplasmic N- and C-terminal domains (Decrock et 
al., 2015).  Six connexin proteins oligomerise to form a structure known as a 
connexon or connexin hemichannel (HC), which are expressed in the membrane of 
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adjacent cells where they bind to create an intercellular pore known as a gap 
junction channel (GJC), Figure 1.2 (Decrock et al., 2015).  These channels exist in 
structures within the cell membrane known as gap junction plaques which are dense 
lateral clusters formed from intracellular proteins (Stout et al., 2015).  The coupling 
of connexin hemichannels to create gap junctions produces a connectivity network 
enabling intercellular communication and trafficking (De Bock et al., 2014).   
Pannexins are structurally similar to connexin proteins and oligomerise to create 
pannexin channels (Penuela et al., 2013).  There are three human pannexins, 
Panx1, Panx2 and Panx3 and, as with connexins, six Panx1 protein subunits 
oligomerise to create a pannexin hemichannel (Penuela et al., 2013).  Panx2 
proteins do not oligomerise into hexamers but instead form heptamers or octamers 
(Ambrosi et al., 2010).  The ability of pannexins to form intercellular channels was 
initially controversial, but has since been robustly established (Sahu et al., 2014).   
Currently 21 human connexin proteins have been identified with differential tissue 
expression (De Bock et al., 2014; Söhl and Willecke, 2003).   Astrocytes express 
Cx26, Cx30, Cx43, Cx40 and Cx45 which are responsible for creating an extensive 
astrocytic network within the CNS, with Cx30 and Cx43 being of particular functional 
importance (Dermietzel et al., 1991; Ezan et al., 2012; Giaume et al., 2013; Nagy et 
al., 1999).  GJCs allow the intercellular movement of metabolites, signalling 
molecules and ions including Ca2+ and IP3 both of which enable the propagation of 
calcium signalling between astrocytes, known as intercellular calcium waves (ICWs) 
(De Bock et al., 2014).   
Astrocytes are also able to release gliotransmitters, including glutamate and ATP 
through hemichannels (Stout et al., 2002; Ye et al., 2003).  Connexin 43 
hemichannels are permeable to ATP in C6 rat glioma cells and in rat hippocampal 
astrocytes (Kang et al., 2008).  Electrophysiological analysis of murine hippocampal 
slices shows that the release of ATP from astrocytes in response to glutamate is 
lost in Cx43/Cx30 knockout mice and reduced in the presence of carbenoxolone, a 
hemichannel blocker (Torres et al., 2012).  The release of glutamate from rat 
astrocytes is also reduced by Gap26, a connexin 43 hemichannel inhibitor (Jiang et 
al., 2011).   
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Figure 1.2: Connexin, Hemichannel and Gap Junction Structure  A) Each 
connexin subunit is structurally composed of four transmembrane domains, two 
extracellular loops, a short intracellular loop and cytoplasmic N- and C-terminal 
domains.  B) The oligomerisation of six connexin subunits forms a connexin 
hemichannel.  C) Two connexin hemichannels expressed on adjacent cells 
oligomerise to generate a gap junction channel.  These channels allow the 
intercellular movement of metabolites, molecules and ions. 
1.1.5 Astrocytes and the Blood-Brain Barrier 
The blood-brain barrier (BBB) is comprised of CNS endothelial cells which are 
connected by intercellular tight junctions (TJ) to create a continuous and non-
fenestrated endothelial cellular sheet (Chow and Gu, 2015).  This barrier isolates 
the brain from circulating blood, consequently allowing brain homeostasis to be 
precisely maintained and shielding the brain from potentially harmful or toxic agents, 
thus preserving neuronal survival (Chow and Gu, 2015).  The CNS vasculature is 
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then sheathed in pericytes, astrocytic endfeet and neurons forming a structure 
known as the neurovascular unit (NVU), Figure 1.3. 
 
Figure 1.3: The Neurovascular Unit  CNS endothelial cells are connected by tight 
junction complexes to create a continuous and non-fenestrated endothelial cellular 
sheet known as the BBB.  These sheets form the CNS vascualture which is 
sheathed in pericytes, astrocytic endfeet and neurons to form the NVU. 
Paracellular permeation and transcellular permeation are the two pathways by 
which molecules are able to cross epithelial/endothelial cellular sheets.  Paracellular 
permeation occurs between cells through pores formed by intercellular tight 
junctions (TJs).  Transcellular permeation occurs through cells and involves various 
different mechanisms including carrier-mediated transport and endocytosis (De 
Bock et al., 2016).  Figure 1.4 shows a schematic depicting these two permeation 
pathways.  
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Figure 1.4: Permeation Pathways across Epithelial/Endothelial Cellular Sheets 
Paracellular permeation and transcellular permeation are the two pathways by 
which molecules cross epithelial/endothelial cellular sheets.  Paracellular 
permeation occurs between the cells through paracellular pores formed by 
intercellular tight junctions.  Transcellular permeation occurs through the cells and 
involves processes such as carrier-mediated transport and endocytosis. 
Tight junctions are multiprotein complexes.  The protein constituents within this 
complex determine the paracellular permeation properties of the tight junctions and 
consequently epithelial/endothelial cellular sheets (Chiba et al., 2008; Guillemot et 
al., 2008).  Some tight junction proteins act as barriers which restrict paracellular 
permeation whilst others form ion-selective pores which facilitate the paracellular 
permeation of these molecules between epithelial/endothelial cells (Chiba et al., 
2008).  In the case of the BBB, paracellular permeation is highly restricted and 
transcellular permeation is tightly regulated (De Bock et al., 2016). 
The components of the NVU engage in complex functional interactions which allow 
cerebral blood flow to be modulated by neuronal activity.  The functional 
relationships between NVU components is known as neurovascular coupling (NVC) 
(Filosa et al., 2016).  Astrocytes form an intrinsic component in NVC as they form a 
link between neuronal signalling and the cerebral vasculature. 
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1.1.6 Astrocytes and Neurovascular Coupling  
In vitro experiments involving rat cortical slices demonstrate that vasodilation occurs 
in response to an increase in neuronal activity and is mediated by an elevation in 
astrocytic intracellular Ca2+ ions (Zonta et al., 2003).  This mechanism of 
vasodilation involves cyclooxygenase (COX) (Zonta et al., 2003).  In vivo 
experiments in mice show that an increase in astrocytic intracellular calcium 
activates the enzyme phospholipase A2 (PLA2), which releases arachidonic acid 
(AA) from membrane phospholipids (Takano et al., 2006).  AA is then metabolised 
by COX-1 to produce prostaglandin E2 (PGE2) which mediates vasodilation (Takano 
et al., 2006). 
Astrocytes have, however, also been shown to elicit vasoconstriction (Mulligan and 
MacVicar, 2004).  An increase in astrocytic intracellular calcium activates PLA2 and 
produces AA which diffuses to vascular smooth muscle cells where it is metabolised 
into 20-hydroxyeicosatetraenioc acid (20-HETE), a vasoconstrictor (Mulligan and 
MacVicar, 2004).  The duality of astrocytic vasomotor control is illustrated in the 
retina as the stimulation of retinal astrocytes and Müller cells elicits both 
vasoconstriction and vasodilation (Metea and Newman, 2006).   Vasoconstriction in 
the mammalian (rat) retina occurs in response to 20-HETE whilst vasodilation is 
mediated by other AA metabolites known as epoxyeicosatrienoic acids (EETs) 
(Metea and Newman, 2006). 
The factors which determine and influence the duality of astrocytic vasomotor 
control have not yet been fully established.  Nitric oxide (NO) can elicit both 
vasoconstriction and vasodilation and the levels of this molecule may influence 
astrocytic vasomotor responses (Metea and Newman, 2006).  Metabolic state may 
also influence astrocytic vasomotor control (Gordon et al., 2008).  In hippocampal 
and neocortical murine brain slices, an astrocytic elevation in intracellular calcium 
levels in response to an mGluR agonist causes arteriolar dilation in low (20%) O2 
levels whilst arterial constriction occurs in high (95%) O2 levels.  Anaerobic 
respiration is elevated in low O2 causing an increase in extracellular levels of lactate 
which reduces the efficiency of prostaglandin transporters, thus increasing PGE2 
levels and producing vasodilation (Gordon et al., 2008).  Changes in the AA 
pathway due to different O2 levels have also been observed in ex vivo rat retina 
where low O2 levels elicit vasodilation mediated by PGE2 and EETs, whilst high O2 
levels elicit vasoconstriction mediated by 20-HETE (Mishra et al., 2011). 
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Potassium (K+) ions also mediate vasomotor responses as an increase in 
extracellular K+ ions in the perivascular space elicits vasodilation by increasing the 
conductance of inwardly rectifying K+ (Kir) channels expressed by vascular smooth 
muscle cells (Filosa et al., 2006).  Astrocytes were initially thought to facilitate 
potassium-mediated vasodilation through a mechanism known as K+ siphoning in 
which neuronal activation increases the extracellular K+ concentration generating a 
passive influx of these ions into astrocytic processes resulting in astrocytic 
depolarisation and a subsequent passive efflux of K+ ions from astrocytic endfeet 
into the perivascular space (Paulson and Newman, 1987).  It has since been shown, 
however, that this mechanism does not significantly contribute to neurovascular 
coupling (Metea et al., 2007).  Instead, neuronal signalling elicits an elevation in 
astrocytic intracellular Ca2+ which activates Ca2+-sensitive potassium (BK) channels 
located in perivascular astrocytic endfeet (Filosa et al., 2006; Price et al., 2002).  
Activated BK channels release K+ ions into the perivascular space which activate 
smooth muscle Kir channels and elicit vasodilation (Filosa et al., 2006). 
1.2 Tight Junctions 
Tight junctions are multiprotein complexes which form intercellular barriers which 
can either restrict or facilitate paracellular permeation (Haseloff et al., 2015).  The 
permeation properties of tight junctions is determined by the protein composition of 
the tight junction complex (TJC) (Chiba et al., 2008).  Tight junctions also give 
epithelial/endothelial cells polarity by dividing the apical membrane from the 
basolateral membrane resulting in the selective distribution of membrane 
constituents (Haseloff et al., 2015).  The proteins which form tight junctions are 
categorised into integral membrane proteins and cytoplasmic scaffolding proteins 
(Guillemot et al., 2008; Haseloff et al., 2015).   
Tight junction integral membrane proteins are membrane-spanning proteins which 
have both extracellular and intracellular domains (Haseloff et al., 2015).  Proximate 
integral membrane proteins in the cell membrane interact through intracellular cis-
oligomerisation (Krause et al., 2008; Van Itallie and Anderson, 2014).  The 
extracellular domains of integral membrane proteins expressed by adjacent cells 
also interact through intercellular trans-oligomerisation, Figure 1.5 (Krause et al., 
2008; Van Itallie and Anderson, 2014).  It is through these interactions that tight 
junction integral membrane proteins create an intercellular barrier.  TJ integral 
membrane proteins are further categorised into three families: claudins, tight 
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junction-associated marvel proteins (TAMPs) and junctional adhesion molecules 
(JAMs) (Haseloff et al., 2015).   
 
Figure 1.5: The Cis- and Trans-oligomerisation of Tight Junction Integral 
Membrane Proteins  Tight junction integral membrane proteins create an 
intercellular barrier through oligomerisation.  Proximate integral membrane proteins 
within the cell membrane interact through intracellular cis-oligomerisation.  The 
extracellular domains of integral membrane proteins expressed on adjacent 
endothelial cells interact through intercellular trans-oligomerisation.  Collectively 
these protein interactions create an intercellular barrier which can either restrict or 
facilitate paracellular permeation.  The paracellular permeation properties of this 
barrier are determined by tight junction integral membrane proteins. 
Tight junction cytoplasmic scaffolding proteins are structurally composed of multiple 
protein binding domains which enable them to link the integral membrane proteins 
to the actin cytoskeleton and strengthen the intercellular barrier (Guillemot et al., 
2008).  These proteins are also involved in cell signalling pathways (Guillemot et al., 
2008).  Tight junction cytoplasmic scaffolding proteins consist of numerous protein 
families which can be categorised into those with and without PDZ domains.  PDZ is 
an acronym derived from the first three proteins identified with this structural 
domain: Psd-95, Dlg and ZO-1 (Guillemot et al., 2008).   
This project focuses specifically on TAMPs and claudin proteins, consequently 
JAMs will not be discussed further.  For a review of JAMs see (Garrido-urbani et al., 
2014).  This project also focuses on one cytoplasmic scaffolding protein family 
known as zonula occludens (ZO) proteins.  For a comprehensive review of all the 
cytoplasmic scaffolding proteins see (Guillemot et al., 2008; Van Itallie and 
Anderson, 2014).   
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1.2.1 Tight Junction-associated Marvel Proteins 
The TAMP family consists of occludin, tricellulin and MarvelD3 (Ikenouchi et al., 
2005; Steed et al., 2009).  TAMPs are defined by a conserved four-transmembrane 
(TM1-TM4) domain known as the MARVEL (MAL and related proteins for vesicle 
trafficking and membrane link) domain (Haseloff et al., 2015; Sánchez-Pulido et al., 
2002).  This project specifically focuses on occludin. 
Occludin was first identified through experiments conducted on junctional fractions 
sourced from chicken liver tissue (Furuse et al., 1993).  Human occludin is a 522 
amino acid (aa), 59.144 kDa protein of which several isoforms have currently been 
identified, Table 1.1 (Ando-Akatsuka et al., 1996; Kohaar et al., 2010).   
Occludin Isoform No. of amino acids Protein Size (kDa) Uniprot Identifier 
WT-OCLN 522 59.144 Q16625-1 
OCLN-ex4del 468 52.706 Q16625-2 
OCLN-ex7ext 479 54.124 Q16625-3 
OCLN-ex3del 271 31.602 Q16625-4 
OCLN-ex3-4del 200 23.324 Q16625-5 
OCLN-ex3p-9pdel 69 8.033 Q16625-6 
OCLN-ex3p-7pdel 70 8.175 Q16625-7 
Table 1.1: Occludin Isoforms  A list of all the occludin isoforms currently identified. 
Beyond the MARVEL domain, the structure of occludin consists of a cytoplasmic N-
terminal domain, two extracellular loops (ECL1 and ECL2), a short cytoplasmic loop 
and a long cytoplasmic C-terminal domain which is divided into the membrane-
proximal and membrane distal domains, Figure 1.6 (Haseloff et al., 2015; Li et al., 
2005b).   
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Figure 1.6: A Schematic depicting the general structure of Occludin  Occludin 
is a tight junction integral membrane protein and a member of the TAMP family.  
TAMPs are structurally defined by the four-transmembrane MARVEL domain (TM1-
TM4).  Occludin has two extracellular loops (ECL1 and ECL2) which interact 
through trans-oligomerisation with the ECLs of occludin proteins expressed on 
adjacent endothelial cells.  Occludin is also composed of a cytoplasmic N-terminal 
domain, a short cytoplasmic loop which links TM2 with TM3 and a long cytoplasmic 
C-terminal domain.  The C-terminal domain is composed of the membrane-proximal 
domain (blue) and the membrane-distal domain (purple). 
Occludin’s N-terminal domain contains a PPPY motif which binds to E3 ubiquitin 
ligases (Raikwar et al., 2010; Traweger et al., 2002).  ECL1 is rich in tyrosine and 
glycine residues and ECL2 contains two conserved cysteine residues which form a 
redox sensitive disulphide bond essential to the cis- and trans-oligomerisation of this 
protein (Bellmann et al., 2014).  Occludin cis-oligomerisation is also mediated by the 
MARVEL domain (Yaffe et al., 2012).  The ECL2 disulphide bond is maintained in 
an oxidative environment but is disrupted in a reducing environment such as in a 
state of hypoxia.  This results in a loss of occludin trans-oligomerisation and 
accounts for the tight junction disruption produced in response to hypoxia (Bellmann 
et al., 2014; Mark and Davis, 2002). 
The C-terminal membrane-distal domain is homologous to the conserved C-terminal 
domain present in a group of RNA polymerase II elongation factors known as the 
eleven-nineteen lysine-rich leukaemia (ELL) proteins (Li et al., 2005b).  This domain 
is also the only part of occludin that has been successfully crystalized (Li et al., 
2005b).  Conserved lysine and arginine residues within the membrane-distal domain 
create a positively charged surface which facilitates the binding of occludin to ZO 
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proteins (Fanning et al., 1998; Li et al., 2005b).  A more detailed diagram of 
occludin’s structure is shown in Figure 1.7.  
 
Figure 1.7:  Occludin Protein Domain Structure, Motifs & Phosphorylation 
Sites  Occludin is a 522 aa protein.  The cytoplasmic N-terminal domain (aa 1-66) 
contains a conserved PPPY motif which mediates interactions with E3 ubiquitin 
ligases.  ECL2 (aa 196-243) contains two conserved cysteine (C) residues which 
form a redox sensitive disulphide bond.  This bond is required for the cis- and trans-
oligomerisation of occludin.  TM4 (aa 244-265) contains aa 255-265 (shown in 
yellow) which are involved in trafficking occludin to the cell membrane.  The C-
terminal membrane-distal domain is composed of aa 266-372 and the membrane-
distal domain is composed of aa 373-522.  The C-terminal membrane-distal domain 
contains conserved residues which enable occludin to bind to ZO proteins.  This 
domain also contains a YETDYTT motif.  The phosphorylation of the two tyrosine 
residues in this motif (shown in red) inhibits the interaction between occludin and 
ZO-1.  Serine 490 is also located in the C-terminal membrane-distal domain and is a 
known phosphorylation site.  Other putative post-translational modification sites 
have been identified throughout occludin, however, they have not yet been 
experimentally confirmed. 
1.2.1.1. Occludin Post-translational modifications 
Occludin’s function is regulated by the phosphorylation of serine, threonine and 
tyrosine residues.  Serine/threonine phosphorylation produces higher molecular 
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weight occludin protein bands ranging from 62-82 kDa (Sakakibara et al., 1997).  
Highly phosphorylated occludin is predominantly present in tight junctions 
suggesting that phosphorylation may influence the trafficking and inclusion of this 
protein into tight junctions (Sakakibara et al., 1997; Wong, 1997).  Conversely, the 
dephosphorylation of occludin by protein phosphatase A2 (PPA2) increases 
paracellular permeability (Nunbhakdi-Craig et al., 2002). 
The phosphorylation of occludin at serine 490 (S490) in the C-terminal membrane-
distal domain reduces the interaction between occludin and ZO-1 by changing the 
charge distribution of the occludin binding surface (Sundstrom et al., 2009).  
Phosphorylation at this site increases in response to vascular endothelial growth 
factor (VEGF) (Sundstrom et al., 2009).  The phosphorylation of tyrosine residues 
398 and 402 in occludin’s C-terminal YETDYTT motif by tyrosine-protein kinase Src 
(c-Src ) also inhibits the interaction between occludin and ZO-1 (Elias et al., 2009).  
Mass spectrometry analysis has identified many putative phosphorylation sites in 
occludin with the majority of these sites located in the C-terminal domain (Butt et al., 
2012a; Sundstrom et al., 2009).  Phosphorylation at these sites, however, has not 
yet been verified experimentally. 
Mass spectrometry analysis has also identified putative occludin serine and 
threonine residues which may be modified by O-β-glycosylation (Butt et al., 2012a).  
Serine residues 408 and 490 located in occludin’s C-terminal membrane distal 
domain are also putative Yin Yang sites (Butt et al., 2012a).  Yin Yang sites are 
serine or threonine residues which can be alternately modified by either 
phosphorylation or O-β-glycosylation (Haltiwanger et al., 1997; Wells et al., 2001).  
Residues within the C-terminal domain of RNA polymerase II are alternately 
subjected to either phosphorylation or O-β-glycosylation (Kelly et al., 1993).  
Currently, however, there is no experimental evidence confirming the presence of 
O-β-glycosylation or Ying Yang sites in occludin. 
Ubiquitination is another post-translational modification which can affect protein 
function.  Ubiquitin is a 76 aa protein with binds at lysine residues through an 
isopeptide bond (Swatek and Komander, 2016).  The attachment of a single 
ubiquitin molecular is known as monoubiquitination, however, ubiquitin itself can be 
ubiquitinated in a process known as polyubiquitination to generate a polyubiquitin 
chain (Swatek and Komander, 2016).  Monoubiquitination appears to elicits 
changes in protein trafficking whilst polyubiquitination generally mediates 
proteasome-dependent protein degradation (Pickart and Fushman, 2004). 
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A yeast two-hybrid screen shows that occludin interacts with Itch, an E3 ubiquitin 
ligase (Traweger et al., 2002).  This interaction is further substantiated by the co-
immunoprecipitation of endogenous Itch with endogenous occludin from 
homogenised embryonic mouse tissue (Traweger et al., 2002).  This interaction 
occurs between the conserved occludin N-terminal PPPY motif and the Itch WW 
domain (Traweger et al., 2002). 
VEGF induces occludin ubiquitination and increases the interaction between 
occludin and Itch which requires the phosphorylation of the occludin S490 residue 
(Murakami et al., 2009).  Occludin is disrupted at cell borders and co-localises in 
intracellular puncta with lysosome-associated membrane protein 1, a marker for late 
endosomes and lysosomes, in bovine retinal endothelial cells (BRECs) treated with 
VEGF (Murakami et al., 2009).  The ubiquitination of occludin induced by VEGF 
results in the clathrin-mediated endocytosis and endosomal trafficking of this protein 
leading to an increase in paracellular permeability (Murakami et al., 2009).  It is 
during this process that occludin interacts with Epsin-1, epidermal growth factor 
receptor substrate 15 (Esp15) and hepatocyte growth factor-regulated tyrosine 
kinase substrate (Hrs).  These proteins are ubiquitin receptor proteins which contain 
an ubiquitin-interacting motif (UIM) and mediate the endocytosis and endosomal 
trafficking of occludin (Murakami et al., 2009).  
Occludin also interacts with Nedd4-2, another E3 ubiquitin ligase, at the N-terminal 
PPPY motif (Raikwar et al., 2010).  The ubiquitination of occludin by Nedd4-2 also 
reduces the localisation of this protein to the membrane and increases paracellular 
permeability (Raikwar et al., 2010). 
1.2.1.2. Occludin Trafficking 
The intracellular trafficking of proteins to the cell membrane is a highly regulated 
process.  The intracellular membrane trafficking of occludin appears to be 
functionally dependent upon aspects of this protein’s molecular structure, although it 
remains unclear precisely which domains are required for this process.  The C-
terminal domain has been implicated in mediating the trafficking of occludin to the 
cell membrane (Furuse et al., 1994; Matter and Balda, 1998).  Immunofluorescence 
analysis of Madin-Darby canine kidney (MDCK) cells transfected with wildtype and 
truncated occludin constructs, however, shows that neither the partial not complete 
loss of the C-terminal domain prevents the trafficking of occludin to the membrane 
(Subramanian et al., 2007).   
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Occludin splice variants in human intestinal cells which lack the fourth 
transmembrane domain (TM4) do not co-localise with ZO-1 at the cell membrane 
and instead remain in intracellular compartments, suggesting that this domain is 
involved in the trafficking of occludin (Mankertz et al., 2002).  Mutant occludin 
lacking aa 260-265 in the TM4 domain localises in the cytoplasm of most MDCK 
cells (Subramanian et al., 2007).  Further deletion of TM4 aa 255-259 results in a 
complete loss of membrane trafficking and the retention of occludin in the ER 
(Subramanian et al., 2007).  A construct composed only of the TM4 and C-terminal 
domain (aa 244-522) is, however, also retained in the ER demonstrating that 
although the TM4 domain is required, it alone is unable to traffic occludin to the cell 
membrane (Subramanian et al., 2007).   
The trafficking of vesicles containing occludin requires an intact microtubule and 
microfilament network.  Confocal imaging of MDCK cells transfected with wildtype 
occludin tagged with GFP and treated with either nocodazole, a microtubule-
disrupting agent, or cytochalasin D (Cyto D), an actin depolymerising agent, shows 
that the trafficking of occludin-carrying vesicles to the membrane is disrupted in the 
presence of either compound (Subramanian et al., 2007).   Disruption of actin 
microfilaments also affects the localisation of occludin within the membrane causing 
this protein to disassemble from junctional complexes in a process facilitated by the 
activation of myosin light chain kinase (MLCK) (Subramanian et al., 2007).   
1.2.1.3. The Effect of Changes in Occludin Expression 
Overexpression of occludin increases the number of tight junctions and the 
transepithelial electrical resistance (TER) of MDCK cells (McCarthy et al., 1996).  
Freeze fracture analysis comparing wildtype and occludin-deficient embryoid bodies 
differentiated from embryonic stem cells shows no significant difference in the 
number or morphology of TJCs (Saitou et al., 1998).  The aggregation of occludin-
deficient stem cells in suspension culture demonstrates that intercellular interactions 
are maintained in the absence of occludin and suggests that the TJC is formed from 
other protein components besides occludin (Saitou et al., 1998).  ZO-1 also remains 
capable of localising to the TJC in occludin-deficient embryoid bodies with no 
apparent changes in the level of protein expression suggesting that occludin is not 
functionally involved in junctional assembly (Saitou et al., 1998).   
Occludin KO mice do not exhibit a lethal phenotype but do show a significant 
retardation in postnatal growth (Saitou et al., 2000).  Immunofluorescence 
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microscopy of intestinal epithelial tissue demonstrates that there are no differences 
in the expression or localisation of other tight junction proteins such as claudin 3, 
ZO-1 and ZO-2 in either KO or wildtype mice, again suggesting that occludin is not 
functionally involved in the assembly of TJCs (Saitou et al., 2000).  There is no 
significant difference in the intestinal epithelial resistance between either KO or 
wildtype mice, however, histological analysis shows the accumulation of granular 
mineral deposits, predominantly composed of calcium, located around the 
capillaries of the cerebellum and basal ganglia in occludin KO mice which are 
absent in the wildtype (Saitou et al., 2000).  Occludin KO mice also exhibit 
significantly thinner bones compared with wildtype mice as well as abnormalities in 
the salivary glands, testis and gastric mucosa (Saitou et al., 2000).  Although 
occludin does not appear to be fundamental to the formation of tight junctions, the 
complex phenotypes exhibited by occludin KO mice do suggest that occludin does 
influence the functional properties of these complexes (Saitou et al., 2000). 
1.2.2 Claudin Proteins  
Currently, 27 mammalian claudin genes have been identified (Mineta et al., 2011).  
The general structure of all claudin proteins consists of a tetra-span transmembrane 
domain (TM1-TM4), two extracellular loops (ECL1 is larger than ECL2), a short 
cytoplasmic N-terminal domain, a cytoplasmic loop and a cytoplasmic C-terminal 
domain, Figure 1.8 (Suzuki et al., 2014).  The ECL1 of all claudin proteins contains 
a conserved motif, W-[X]15-20-G(N)LW-[X]2-C-[X]8-10-C-[X]15-16-R(Q), in which the two 
cysteines form a disulphide bond (Günzel and Yu, 2013).  Most claudin proteins 
also have a PDZ-binding (YV) motif located at the end of the C-terminal domain 
which enables these proteins to bind to tight junction cytoplasmic scaffolding 
proteins (Günzel and Yu, 2013).   
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Figure 1.8: A Schematic depicting the general structure of Claudin Proteins  
Claudins are another family of tight junction integral membrane proteins.  The 
general structure of claudin proteins consists of a tetra-span transmembrane 
domain (TM1-TM4), two extracellular loops (ECL1 is larger than ECL2), a short 
cytoplasmic N-terminal domain, a cytoplasmic loop and a cytoplasmic C-terminal 
domain.  A PDZ-binding motif is located at the end of the C-terminal domain on 
most claudin proteins.  This motif comsists of a tyrosine and a valine (YV). 
ECL2 mediates the trans-oligomerisation of claudin proteins.  Oligomerisation can 
occur between the same or different claudin proteins, known as homo- or 
heterophilic protein interactions respectively (Krause et al., 2015).  Currently, only a 
few heterophilic claudin interactions have been investigated.  Heterophilic trans-
interactions have been identified between claudin 1/claudin 3, claudin 2/claudin 3 
and claudin 3/claudin 5 (Daugherty et al., 2007; Furuse et al., 1999).  Conversely, 
there are claudin proteins which appear unable to form heterophilic trans-
interactions including claudin 1 with claudin 2, 4 and 5, claudin 3/claudin 4 and 
claudin 4/claudin 5 (Daugherty et al., 2007; Furuse et al., 1999). 
The paracellular permeation properties of tight junctions is determined by claudin 
proteins.  Some claudins tighten the intercellular barrier and restrict paracellular 
permeation whilst others form pores which facilitate the selective movement of ions 
between cells through the paracellular permeation pathway, Figure 1.9 (Krause et 
al., 2015).  The charge and size-selectivity of claudin pores is determined by amino 
acids in ECL1 of these proteins (Krause et al., 2015). 
23 
 
 
Figure 1.9: A model of Tight Junction Paracellular Pores  Tight junctions create 
an intercellular barrier between epithelial/endothelial cells which can either restrict 
or facilitate paracelluar permeation.  Paracellular permeation is facilitated across 
this barrier by intercellular pores.  These pores are formed from the extracellular 
loops of pore-forming claudin proteins.  These pores facilitate the selective 
movement of ions between cells via the paracellular permeation pathway.  
1.2.2.1. Pore-forming Claudin Proteins 
The paracellular pores formed by claudin proteins are size and charge-selective.  
This selectivity is determined by amino acids in ECL1 of pore-forming claudin 
proteins (Krause et al., 2015).   Claudin 10 is a pore-forming claudin protein of 
which there are two splice variants, claudin 10a, which is anion-selective, and 
claudin 10b, cation-selective (Van Itallie and Anderson, 2006).  Claudin 10a is 
preferentially permeable to anions due to two arginines present in the ECL1 of this 
protein, whilst a phenylalanine present in the ECL1 of claudin 10b contributes to the 
cationic selectivity of this pore (Li et al., 2013; Van Itallie et al., 2006).  
Claudin 2 also forms cation-selective paracellular pores.  The selectivity of these 
pores is conferred by an aspartic acid and a tyrosine located in ECL1 of this protein 
(Angelow and Yu, 2009a, b; Li et al., 2013).  Cysteine-scanning mutagenesis has 
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also identified the amino acids which line the claudin 2 paracellular pore, Figure 
1.10 (Li et al., 2014). 
 
Figure 1.10: Claudin 2 Protein Domain Structure & Motifs  Claudin 2 is a 230 aa 
protein which forms cation-selective paracellular pores.  The ECL1 domain of this 
protein (aa 29-81) contains the conserved claudin protein W-[X]15-20-G(N)LW-[X]2-C-
[X]8-10-C-[X]15-16-R(Q) motif in which the two cysteines (C) form a disulphide bond.  
Aspartic acid (D65) and tyrosine (Y67) amino acids (shown in red) determine the 
cationic-selectivity of claudin 2 pores.  The amino acids in blue also line the 
paracellular pore.  The PDZ-binding motif (YV) is situated at the end of the C-
terminal domain.  
Claudin 15 creates paracellular pores which are selective for sodium ions (Na+) 
while claudin 4 create pores which restrict the paracellular permeation of these ions 
(Colegio et al., 2002; Van Itallie et al., 2001; Van Itallie et al., 2003).  The Na+-
selectivity of claudin 15 pores is reduced when acidic amino acids located in ECL1 
are mutated to basic residues (Colegio et al., 2002).  Similarly, the substitution of a 
positively charged lysine for a negatively charged aspartic acid in claudin 4 ECL1 
enables the paracellular permeation of Na+ ions through claudin 4 pores (Colegio et 
al., 2002).  A lysine situated in ECL1 of claudin 17 has also been found to be 
essential to the anionic selectivity of the paracellular pores formed by this claudin 
protein (Krug et al., 2012).   
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Heterophilic claudin protein paracellular pores have also been identified.  The cis-
oligomerisation of claudin 4 and claudin 8 produces an anion-selective pore in 
mouse kidney cells (Hou et al., 2010).  Claudin 16 and claudin 19 also engage in a 
heterophilic cis-interactions to produce cation-selective tight junctions in pig kidney 
epithelial cells (Hou et al., 2008). 
1.2.2.2. Claudin Proteins as barriers 
Some claudin proteins do not form pores and instead tighten the intercellular barrier 
and restrict paracellular permeation (Haseloff et al., 2015).  Claudin 1, claudin 3 and 
claudin 5 are examples of claudin proteins which restrict paracellular permeation, 
consequently all three of these claudin proteins are present in the junctional 
complexes which form the BBB (Liebner et al., 2000; Neuhaus et al., 2008; Wolburg 
et al., 2003).   
The barrier function of claudin 5 is determined by tyrosine 148 (Y148), tyrosine 158 
(Y158) and glutamic acid 159 (E159) located in ECL2, Figure 1.11 (Piehl et al., 
2010).  These residues are essential to the homo- and heterophilic trans-
oligomerisation interactions which enable claudin 5 to tighten the intercellular barrier 
and restrict paracellular permeation (Piehl et al., 2010). 
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Figure 1.11: Claudin 5 Protein Domain Structure, Motifs & Post-translational 
Modification Sites  Claudin 5 is a 218 aa protein which tightens the intercellular 
barrier and resticts paracellular permeation.  It is due to these properties that this 
protein an important component in the BBB.  The ECL1 domain of this protein (aa 
29-81) contains the conserved claudin protein W-[X]15-20-G(N)LW-[X]2-C-[X]8-10-C-
[X]15-16-R(Q) motif in which the two cysteines (C) form a disulphide bond.  The barrier 
function of this claudin protein is determined by three amino acids in ECL2.  These 
are tyrosine 148 (Y148), tyrosine 158 (Y158) and glutamic acid 159 (E159) (shown 
in red).  Claudin 5 is polyubiquitinated at lysine 199 (K199) in the C-terminal 
domain. Claudin 5 is also phosphorylated at threonine 207 (T207) which is located 
in the C-terminal domain.  Both K199 and T207 are highlighted in purple.  The PDZ-
binding motif (YV) is situated at the end of the C-terminal domain.  
Claudin 5 KO mice exhibit a lethal phenotype in which the mice do not survive more 
than 10 hours after birth (Nitta et al., 2003).  Although brain endothelial cells remain 
capable of forming tight junctions in the absence of claudin 5, the integrity of the 
intercellular barrier is considerably compromised resulting in increased paracellular 
permeation and the diffusion of small molecules less than approximately 800 Da in 
size (Nitta et al., 2003).   
1.2.2.3. Claudin Protein Regulation & Post-Translational Modifications  
Post-translational modifications influence the membrane trafficking of claudin 
proteins and also affect the barrier function of the TJC.  The phosphorylation of C-
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terminal T203 in claudin 1 by mitogen-activated protein kinase (MAPK) enhances 
the barrier function of the junction complex (Fujibe et al., 2004).  The 
dephosphorisation of claudin 1 by PPA2 increases paracellular permeability whilst 
the inhibition of this enzyme promotes claudin 1 phosphorylation and the 
recruitment of this protein to the TJC (Nunbhakdi-Craig et al., 2002).  Similarly, the 
phosphorylation of claudin 2 at S208 in the C-terminal domain promotes membrane 
localisation of this protein (Van Itallie et al., 2012).  Putative Ying Yang sites have 
been identified by computational analysis in claudin 1, claudin 3 and claudin 4, 
although there is currently no experimental evidence to confirm these predictions 
(Butt et al., 2012b).   
Claudin 5 is phosphorylated at the C-terminal T207 by protein kinase A (PKA) 
(Ishizaki et al., 2003).  Cyclic adenosine monophosphate (cAMP) enhances the 
phosphorylation of claudin 5 by PKA which promotes the membrane localisation of 
this protein but conversely rapidly decreases TER and increases the permeability of 
small molecules in porcine brain capillary endothelial cells (Soma et al., 2004).  
cAMP has previously been shown to increase the barrier function of the tight 
junction proteins in endothelial cells (Birukova et al., 2007; Rubin et al., 1991; 
Spindler et al., 2010).  These contradictory observations suggest that other tight 
junction proteins may be involved in maintaining barrier integrity in response to 
cAMP.   
Palmitoylation also promotes the membrane trafficking of some claudin proteins.  
Claudin proteins have four conserved cysteine residues, two of which are located in 
the cytoplasmic terminal of the TM2 domain and two in the cytoplasmic terminal of 
the TM4 domain (Van Itallie et al., 2005).  The palmitoylation of these cysteine  
residues in claudin 14 is required for the efficient trafficking of this protein to the TJC 
(Van Itallie et al., 2005).  Cysteine-serine claudin 14 mutants do maintain some 
membrane localisation, but ICC shows that the mutant protein predominantly 
localises to lysosomes (Van Itallie et al., 2005).  Claudin 1 and claudin 2 are also 
palmitoylated although the effect of this modification upon the function of these 
proteins remains to be determined (Lynch et al., 2007).  Occludin is not 
palmitoylated which, given the effect of this modification on claudin 14, suggests 
that the trafficking of occludin to the TJC does not require palmitoylation (Lynch et 
al., 2007).  Putative palmitoylation sites have also been predicted in claudin 3 and 
claudin 4 (Butt et al., 2012b).   
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Ubiquitination mediates the endocytosis and degradation of some claudin proteins 
from the TJC.  The ubiquitin E3 ligase LNX1p80 interacts directly with claudin 1, 
reduces the junctional expression of claudin 1, claudin 2 and claudin 4 in MDCK 
cells and promotes the ubiquitination of all three of these proteins (Takahashi et al., 
2009).  MDCK cells cultured in the presence of the lysosome inhibitor chloroquine 
contain higher levels of claudin-1 whilst the level of this protein remains unchanged 
in the presence of a proteasome inhibitor, suggesting that claudins are degraded by 
lysosomes (Takahashi et al., 2009).  ICC shows LNX1p80 and claudin-2 co-localise 
in vesicular structures with either Rab7, a late endosome marker, or the lysosome 
enzyme cathepsin D.  This further indicates that claudins are removed from the TJC 
by endocytosis and trafficked to lysosomes for degradation and suggests that this 
mechanism is facilitated by ubiquitination (Takahashi et al., 2009).   
Claudin 5 is polyubiquitinated at lysine 199 and proteasome inhibition leads to the 
intracellular accumulation of polyubiquitinated claudin 5 in HeLa cells (Mandel et al., 
2012).  Lysosomal inhibition slightly increases the level of claudin 5 in HeLa cells, 
although it does not elicit an accumulation of ubiquitinated claudin 5 protein 
suggesting that the lysosome is involved in claudin 5 regulation through a 
mechanism that is not dependent upon ubiquitination (Mandel et al., 2012).  It 
appears that the polyubiquitination of claudin 5 mediates the proteasomal 
degradation of this protein (Mandel et al., 2012). 
1.2.3 Zonula Occludens (ZO) Proteins  
Zonula occludens (ZO) proteins are a subset of a larger protein family known as 
membrane-associated guanylate kinase (MAGUK) like proteins (Guillemot et al., 
2008).  MAGUK proteins have multiple protein binding domains which are integral to 
their function as scaffolding proteins, as they serve to bind to and subsequently 
connect many different proteins to create a functional multiprotein complex 
(Guillemot et al., 2008).  ZO-1 (195 kDa) was identified in epithelial cells and was 
the first tight junction protein to be identified (Stevenson et al., 1986).  ZO-2 (160 
kDa) and ZO-3 (130 kDa) are the two other members of the ZO protein family, both 
of which were discovered through co-immunoprecipitation with ZO-1 (Haskins et al., 
1998; Jesaitis and Goodenough, 1994). 
ZO proteins are structurally defined by the presence of three PDZ domains (PDZ-1, 
PDZ-2 and PDZ-3), a Src homology 3 (SH3) domain and a guanylate kinase (GUK) 
domain (Guillemot et al., 2008).  A proline-rich region is located in the C-terminal 
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domain of ZO-1 and ZO-2 but is located between PDZ-2 and PDZ-3 in ZO-3 
(González-Mariscal et al., 2000).  These conserved domains are separated by six 
unique (U) domains, Figure 1.12 (Fanning et al., 2007). 
 
 
Figure 1.12: ZO Protein Structure  ZO proteins are a family of cytoplasmic 
scaffolding proteins of which there are three members, ZO-1, ZO-2 and ZO-3.  ZO 
proteins are structurally defined by the presence of three PDZ domains (PDZ-1, 
PDZ-2 and PDZ-3), a Src homology 3 (SH3) domain and a guanylate kinase (GUK) 
domain.  These binding sites are integral to the scaffolding function of these 
proteins.  Key protein binding partners are disclosed in this figure.  The PDZ-1 
domain binds to claudin proteins.  The PDZ-2 domain binds to connexins and also 
enables ZO proteins to heterodimerise. 
All three ZO proteins bind to claudins proteins at the PDZ-1 domain (Itoh et al., 
1999).  ZO proteins are able to heterodimerise through interactions which are 
mediated by  PDZ-2 (Wittchen et al., 1999).  ZO-1 is also able to form homodimers 
in vivo (Utepbergenov et al., 2006).  The SH3 domain is approximately 60 amino 
acids in size and binds to proline-rich ligands initially considered to possess a PxxP 
binding motif, in which x denotes any amino acid (Feller et al., 1994).  Further 
research has shown that SH3 domain peptide ligands are able to bind in two 
orientations.  The orientation is determined by the location of a positively charged 
amino acid relative to the PxxP motif and gives rise to two classes of SH3 ligand, 
class I and class II (KAY et al., 2000).  The SH3 domain present in MAGUK 
proteins, however, displays an atypical binding specificity as it does not bind to 
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proline-rich sequences but instead engages in intramolecular interactions with the 
GUK domain (McGee and Bredt, 1999; Shin et al., 2000).    
The SH3-U5-GUK-U6 region in ZO proteins forms an intracellular hairpin which 
binds occludin (Fanning et al., 2007).  The U5 domain within this intramolecular 
structure is crucial to this binding interaction and also mediates the localisation of 
ZO-1 to the tight junction complex whilst the U6 domain is able to negatively 
regulate U5 (Fanning et al., 2007).  ZO proteins bind to F-actin through the actin-
binding region (ABR) which is located in the proline-rich region of these proteins 
(Fanning et al., 1998; Fanning et al., 2002; Wittchen et al., 1999).  The series of 
interactions between integral membrane proteins, cytoplasmic scaffolding proteins 
and the actin cytoskeleton which comprises the tight junction complex is illustrated 
in Figure 1.13. 
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Figure 1.13: The Tight Junction Complex  The barrier is generated through the 
intracellular cis-oligomerisation and intercellular trans-oligomerisation of integral 
membrane proteins.  Cytoplasmic scaffolding proteins such as ZO-1 possess 
multiple binding domains which enable these proteins to bind to the cytoplasmic 
domains of integral membrane proteins and the actin cytoskeleton, consequently 
strengthening the integrity of the barrier. 
ZO-1 also has a C-terminal ZU-5 domain which mediates the direct interaction of 
this protein with myotonic dystrophy kinase-related CDC42-binding kinase β 
(MRCKβ) (Huo et al., 2011).  The interaction between ZO-1 and MRCKβ requires 
cell division control protein 42 homologue (CDC42) which binds to the kinase, 
inducing a conformational change which reveals the ZU-5 binding site (Huo et al., 
2011).  ZO-1 is responsible for the localisation of MRCKβ to the leading edge of 
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migrating cells and the complex formed from this interaction is required for cell 
migration (Huo et al., 2011).  The ZU-5 domain implicates ZO-1 in cell migration and 
motility, demonstrating that the functional capacity of this protein is not restricted to 
the TJC.  
1.2.3.1. Nuclear Localisation of ZO Proteins 
The nucleus is separated from the cytoplasm by two concentric membranes known 
as the inner and outer nuclear membrane (INM and ONM) which are collectively 
known as the nuclear envelope (Webster and Lusk, 2016).  Nuclear transport 
proteins facilitate the translocation of proteins across the nuclear envelope through 
nuclear pore complexes (NPCs).  Proteins which possess nuclear localisation or 
exportation signals (NLS or NES) are able to bind to nuclear import proteins or 
nuclear export proteins respectively (Christie et al., 2015; Sloan et al., 2015). 
ZO-1 is expressed diffusely throughout the nucleus of MDCK cells whilst ZO-2 
exhibits a speckled staining pattern in these cells (González-Mariscal et al., 1999; 
Islas et al., 2002).  Immunofluorescence shows that the localisation of ZO-2 is 
affected by confluency; a strong ZO-2 signal is detectable in both the nucleus and at 
the cell borders of sparse cultures whilst cell border staining with a weak nuclear 
signal is seen in confluent cultures (Islas et al., 2002).  Putative nuclear localisation 
signals were initially identified in both ZO-1 and ZO-2 from MDCK cells using the 
PSORT program (González-Mariscal et al., 1999).  Subsequently, the presence of 
nuclear localisation and export signals in all three ZO proteins has been confirmed 
experimentally (González-Mariscal et al., 2006).  
ZO-2 partially co-localises with the pre-mRNA-splicing protein SC-35 in MDCK cells 
(Islas et al., 2002).  ZO-2 also co-immunoprecipitates with Lamin B1, a component 
of the nuclear lamina, demonstrating that this protein associates with the nuclear 
matrix (Jaramillo et al., 2004).  ZO-2 localises with Scaffold Attachment Factor-B 
(SAF-B) in the nucleus of MDCK cells (Traweger et al., 2003).  This interaction 
between these two proteins is mediated by the PDZ-1 domain of ZO-2 and the C-
terminal domain of SAF-B (Traweger et al., 2003).  ZO-2 also appears to be 
recruited to the nucleus from the cytoplasm in response to chemical stress in LLC-
PK1 porcine kidney cells (Traweger et al., 2003). 
The SH3 domain of ZO-1 binds to ZO-1 associated nucleic acid-binding protein 
(ZONAB), a Y-box transcription factor.  The interaction between ZO-1 and ZONAB 
occurs within the tight junction complex, although ZONAB also localises to the 
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nucleus.  (Balda and Matter, 2000).  The interaction between these two proteins has 
been shown to regulate the expression of the erbB-2 gene, which encodes for 
receptor tyrosine-protein kinase-2, and is involved in epithelial differentiation and 
morphogenesis (Balda and Matter, 2000).  The interaction between ZO-1 and 
ZONAB also regulates epithelial cell proliferation (Balda et al., 2003). 
ZO-2 has also been shown to associate with the transcription factors Jun, Fos and 
C/EBP in MDCK cells (Betanzos et al., 2004) and to repress the transcription of 
Cyclin D1 which is involved in cell cycle progression (Huerta et al., 2007).  ZO-2 
forms a complex with c-Myc and HDAC1 which binds to the E-box promoter of the 
Cyclin D1 gene consequently repressing transcription. 
1.2.3.2. ZO Proteins and Connexins  
ZO-1 binds to many gap junction proteins including connexin 43 at the PDZ-2 
domain (Giepmans and Moolenaar, 1998; Toyofuku et al., 1998) and with connexin 
45 (Kausalya et al., 2001).  ZO-1 has been shown to regulate gap junction size and 
also to facilitate the endocytosis and degradation of gap junction proteins (Akoyev 
and Takemoto, 2007; Gilleron et al., 2008; Hunter et al., 2005).  Research involving 
cortical astrocytes isolated from mice also demonstrates in vitro that a dissociation 
between ZO-1 and connexin 43 occurs in response to intracellular acidification 
resulting in the persistent localisation of ZO-1 at the cell membrane whilst connexin 
43 translocates into the cytoplasm (Duffy et al., 2004).  In vivo experiments utilising 
mice have also observed the co-localisation of ZO-1 with Cx30 and Cx43 in 
astrocytes (Penes et al., 2005).  Co-immunoprecipitation and in vitro pull-down 
assay experiments show that both Cx30 and Cx43 co-immunoprecipitate with ZO-1 
and that Cx30 binds at the PDZ-2 domain (Penes et al., 2005).  ZONAB also co-
localises with ZO-1 and Cx32 in astrocytes and with ZO-1 and Cx47 
oligodendrocytes  (Penes et al., 2005).  
1.3 Tight Junction Proteins in Astrocytes 
Tight junction proteins are also expressed in non-epithelial cells including 
astrocytes.  Rat primary cortical astrocytes and rat C6 glioma cells have been 
shown to express ZO-1 through ICC and immunoblotting techniques (Howarth et al., 
1992).  Occludin is highly expressed in undifferentiated astrocytes, astrocytes of the 
second to fourth passage, derived from new-born mice but is weakly expressed by 
both differentiated astrocytes, astrocytes of a higher passage with glial fibrillary 
acidic protein (GFAP) reactivity, and neurons derived from mice embryos (Bauer et 
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al., 1999).  Human foetal cortical astrocytes have been shown to express occludin, 
ZO-1 and ZO-2 in vitro (Duffy et al., 2000).  ZO-3, however, does not appear to be 
expressed in these cells (Duffy et al., 2000).  ZO-1 also co-localises with transient 
receptor potential channel-4 (TRPC4), a cation channel which may be involved in 
astrocytic Ca2+-mediated glutamate release in human foetal astrocytes in vitro 
(Song et al., 2005)   
Increased expression of occludin in astrocytes and neurons has also been observed 
in post-mortem human brain tissue from different neurodegenerative diseases, 
including Alzheimer’s Disease (AD) and vascular dementia (VD) (Romanitan et al., 
2007).  In the frontal cortex and head of the caudate nucleus occludin 
immunoreactivity is predominantly associated with pyramidal neurons with the ratio 
of neurons expressing occludin in cortex and striatum significantly higher in AD and 
VD cases compared with non-neurological controls.  Occludin expression is also 
observed in both astrocytes and oligodendrocytes (Romanitan et al., 2007).  A 
qualitative analysis of this staining determined that more astrocytes than 
oligodendrocytes are positive for occludin in the basal ganglia and, in the white 
matter of the frontal cortex, more occludin positive astrocytes and oligodendrocytes 
are observed in AD and VD cases compared with non-neurological controls.  It also 
appears that, in the basal ganglia, astrocytic occludin expression is preferentially 
localised to the nucleus (Romanitan et al., 2007).   
The same cohort was also used to investigate the expression of claudin 2, claudin 5 
and claudin 11 in the frontal cortex (Romanitan et al., 2010).  All three claudins are 
expressed in pyramidal neurons, oligodendrocytes and astrocytes, with a significant 
increase in the ratio of astrocytes expressing claudin 2 and claudin 11, but not 
claudin 5, in AD and VD cases compared with non-neurological controls (Romanitan 
et al., 2010).   
Glial expression of occludin and ZO-1 is also observed in research investigating the 
effect of BBB dysfunction in the pathology of age-associated cerebral white matter 
lesions (WMLs) whilst claudin 5 expression is exclusively associated with 
endothelial cells (Simpson et al., 2010).  These findings are supported by research 
investigating the role of BBB dysfunction in the ageing brain in relation to Alzheimer-
type pathology as glia in the cerebral cortex are similarly shown to express occludin 
and ZO-1, but not claudin-5 (Viggars et al., 2011). 
A microarray analysis investigating changes in the astrocyte transcriptome in 
relation to the pathogenesis of age-related neurodegenerative pathology shows that 
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there is a significant reduction in transcripts which encode for TJPs in association 
with increasing Alzheimer-type pathology (Simpson et al., 2011).  The astrocytic 
expression of mRNA sequences encoding for TJPs determined by this microarray 
analysis provides further support to immunohistochemical evidence regarding the 
expression of TJPs in astrocytes.  The pathogenesis of many neurodegenerative 
disorders including AD is associated with neurovascular dysfunction and BBB 
disintegration, the latter being partially caused by a disruption in endothelial TJP 
expression (Nelson et al., 2016; Zlokovic, 2011).   
1.4 Hypothesis & Aims 
Astrocytes both in vitro and in vivo have been shown to express tight junction 
proteins.  Astrocytes, however, do not form tight junctions, consequently the 
function of these proteins within these cells is unclear and has not yet been 
explored.  There is also evidence to suggest that the astrocytic expression of tight 
junction proteins changes with AD pathogenesis.      
Occludin, claudin 5 and ZO-1 were selected for investigation in this project.  These 
proteins were selected because they were all identified in the microarray study 
investigating changes in the astrocyte transcriptome in relation to the pathogenesis 
of age-related neurodegenerative pathology (Simpson et al., 2011).   
This initial aim of this study was to characterise the expression of these three tight 
junction proteins in human primary astrocytes and 1321N1 astrocytoma cells.  This 
study also aimed to define the cellular localisation of occludin, claudin 5 and ZO-1 in 
the temporal cortex and investigate whether the expression of these proteins is 
altered in MCI and AD cases compared with controls.  This study also aimed to 
investigate the function of these proteins in astrocytes by identifying protein binding 
partners.  
It is hypothesised that tight junction proteins in astrocytes display functions beyond 
the formation of intercellular barriers and that changes in astrocytic tight junction 
protein expression may contribute to AD progression.   
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2. Materials and Methods
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2.1 Tissue Culture  
2.1.1 Cells and Culture Medium 
Human embryonic primary astrocytes (HA) isolated from the cerebral cortex were 
purchased from ScienCell Research Laboratories and were cultured in either 
Astrocyte Medium (AM) or MEMα/F-10 medium.  AM composition: 500 ml Astrocyte 
Basal Medium, 2% (v/v) Foetal Bovine Serum (FBS), 1% (v/v) Astrocyte Growth 
Supplements (AGS) and 1% (v/v) Penicillin (10, 000 units/ml) / Streptomycin (10, 
000 g/ml) solution (P/S).  All reagents purchased from ScienCell Research 
Laboratories.  MEMα/F-10 medium composition: 250 ml Minimum Essential Medium 
α (MEMα) (Gibco), 250 ml Ham’s F-10 nutrient mix (Gibco), 10% (v/v) FBS (Sigma) 
and 1% (v/v) Penicillin (50 units/ml) / Streptomycin (50 g/ml) solution (P/S) (Lonza). 
1321N1 human astrocytoma cell line and human embryonic kidney 293 (HEK 293) 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco), 
supplemented with 10% (v/v) FBS (Sigma), 1% (v/v) Penicillin (50 units/ml) / 
Streptomycin (50 g/ml) solution (P/S) (Lonza).   
Human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell 
and were cultured in Endothelial Cell Medium (ECM) supplemented with 5% (v/v) 
FBS, 1% Endothelial Cell Growth Supplements (ECGS) and 1% (v/v) Penicillin (10, 
000 units/ml) / Streptomycin (10, 000 g/ml) solution (P/S).  All reagents purchased 
from ScienCell Research Laboratories.   
2.1.2 Culture Conditions 
Cells were cultured in 75 or 175 cm2 tissue culture flasks (Thermo Fisher Scientific), 
10 cm tissue culture dishes and 12 or 24-well cell culture plates.  Cells were grown 
at 37 oC in a humidified atmosphere of 5% CO2/95% air.  The culture medium was 
changed at least every third day of culture.  Cells were passaged when cultures 
were 80% confluent and re-seeded at the required cell density.  Primary cells were 
not cultured beyond passage 10 in accordance with company recommendations.  
All experiments requiring primary cells were conducted using cells cultured between 
passage 4 and passage 6.  Experiments comparing human primary astrocytes 
cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium were 
conducted using cells of the same passage number. 
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2.2 Immunocytochemistry 
Cells were cultured in either 12 or 24 well plates on 13 mm coverslips seeded at 
5000 cells/ml.  Once confluent, the cells were washed once in heated 37 oC 
phosphate buffered saline (PBS).  The cells were then fixed with heated 37 oC 4% 
paraformaldehyde (PFA) (4% PFA (w/v) in PBS) for 10 minutes at 37 oC after which 
the cells were washed three times in PBS and permeabilised in 0.3% (v/v) Triton X-
100 in PBS for 3 minutes at room temperature.  The cells were again washed three 
times in PBS and incubated in blocking solution (3% (w/v) bovine serum albumin 
(BSA), 0.01% Tween 20 in PBS) for 1 hour at room temperature.  The cells were 
then incubated in 70 μl primary antibody, Table 2.1, for 2 hours at room 
temperature.  All primary antibodies were made up in blocking solution.  A negative 
control (omission of the primary antibody) and an isotype control were also included 
to confirm antibody specificity.  The isotype control consisted of a specific mouse or 
rabbit IgG (Vector Laboratories) used at the same concentration as the primary 
antibody.   
Antibody Species Dilution Supplier Code 
ALDH1L1 
Rabbit 
Polyclonal 
1:50 Abcam ab79727 
beta-3-
Tubulin 
Chicken 
Polyclonal 
1:1000 Merck Millipore AB9354 
Claudin 5 
Rabbit 
Polyclonal 
1:50 Abcam ab15106 
DDX3X 
Rabbit 
Polyclonal 
1:50 Atlas Antibodies HPA001648 
GFAP 
Rabbit 
Polyclonal 
1:500 Abcam ab7260 
Nestin 
Rabbit 
Polyclonal 
1:250 Abcam ab92391 
Occludin 
Rabbit 
Polyclonal 
1:50 
Thermo Fisher 
Scientific 
71-1500 
Vimentin 
Mouse 
Monoclonal 
IgG1 
1:250 Abcam ab8978 
ZO-1 
Rabbit 
Polyclonal 
1:100 
Thermo Fisher 
Scientific 
40-2200 
Table 2.1: Immunocytochemistry primary antibodies 
The cells were then washed three times in PBS and incubated in the dark with the 
appropriate fluorescent secondary antibody, Table 2.2, for 1 hour at room 
temperature.  All secondary antibodies were made up in blocking solution.   
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Antibody Dilution Supplier Code 
Alexa Fluor® 488 goat anti-mouse 1:500 Thermo Fisher Scientific A11001 
Alexa Fluor® 488 goat anti-chicken 1:500 Thermo Fisher Scientific A11039 
Alexa Fluor® 568 donkey anti-rabbit 1:500 Thermo Fisher Scientific A10042 
Table 2.2: Immunocytochemistry secondary antibodies 
The cells were again washed three times in PBS and incubated in the dark with 
Hoescht 33342 (10 μg/ml) diluted 1:2000 in PBS for 10 minutes at room 
temperature to stain the cell nuclei.  Finally the coverslips were washed three times 
in PBS and mounted onto glass slides using fluorescent mounting medium (DAKO).  
Images were taken using a Nikon microscope and processed using ImageJ and 
Adobe Illustrator software. 
2.3 Whole Cell Lysis for SDS-PAGE 
The cells were cultured in 10 cm tissue culture dishes and lysed once they had 
reached approximately 80% confluency.  The cells were washed twice in ice-cold 
PBS and collected using a cell scraper in 200 μl lysis buffer (100 mM Tris-HCl pH 
7.5, 75 mM NaCl, 0.5% (w/v) SDS, 20 mM sodium deoxycholate, 1% (v/v) Triton X-
100, 2 mM sodium orthovanadate (NaVO4), 1.25 mM sodium fluoride (NaF), 10 mM 
ethylene diamine tetra-acetic acid (EDTA), Protease Inhibitor Cocktail (PIC) (Roche) 
and PhosSTOP (Roche)).  The lysates were transferred into 1.5 ml Eppendorf tubes 
and incubated on ice for 30 minutes, after which they were sonicated for 5 seconds 
using a probe sonicator set to 60% amplitude.  The lysates were subsequently 
centrifuged at 15, 500 x g for 30 minutes at 4 oC.  The supernatants were 
transferred into fresh 1.5 ml Eppendorf tubes, flash frozen in liquid nitrogen and 
stored at -80 oC. 
2.4 Subcellular Fractionation 
Human primary astrocytes were fractionated into cytoplasmic and nuclear fractions 
to investigate protein localisation.  Cells were cultured in 10 cm tissue culture dishes 
and lysed once they had reached approximately 80% confluency.  The cells were 
washed in ice-cold PBS and collected using a cell scraper in 100 μl sterile hypotonic 
lysis buffer (20 mM tris-HCl, 10 mM NaCl, 3 mM MgCl2, 1 mM PMSF, 1 mM DTT, 
pH 7.4, protease inhibitor cocktail and PhosStop).  The lysates were transferred into 
1.5 ml Eppendorf tubes and incubated on ice for 15 minutes.  The cell lysates were 
then mixed with 25 μl of a 10% Nonidet P-40 solution (10% v/v Nonidet P-40 in 
PBS) and centrifuged at 13,000 x g for 5 minutes at 4 oC.  The supernatant 
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(cytoplasmic fraction) was retained and the remaining pellets washed once in 50 μl 
hypotonic buffer before being resuspended in 50 μl cell extraction buffer (Invitrogen, 
supplemented with 1 mM PMSF, 1 mM DTT, protease inhibitor cocktail, PhosStop) 
and incubated on ice for 30 minutes.  During this 30 minute incubation, the lysates 
were vortexed at 10 minute intervals.  The lysates were then centrifuged at 17, 000 
x g for 30 minutes at 4 oC.  The supernatant (nuclear fraction) was retained and the 
pellet containing insoluble proteins and cell debris was discarded.  Both cytoplasmic 
and nuclear fractions were flash frozen in liquid nitrogen and stored at -80 oC. 
2.5 Determination of Protein Concentration 
The protein concentration of whole cell lysates was determined using a 
bicinchoninic acid (BCA) protein assay kit (Pierce) used according to the 
manufacturer’s instructions.  This assay utilises the biuret reaction, in which 
peptides reduce cupric (Cu2+) ions to cuprous (Cu1+) in an alkaline environment 
(Smith et al., 1985).  BCA assays were run in 96 well plates (Sigma).  BSA 
standards (concentration range 0-2 mg/ml) diluted in PBS were included in each 
assay and all lysates were diluted 1:10 in PBS.  Both standards and samples were 
plated out in duplicate.  Colorimetric detection was achieved at 550 nm with a 
FLUOstar Omega microplate reader with Omega software (BMG Labtech). 
The protein concentration for fractionated cell lysates was determined using a 
Bradford assay.  The BCA assay could not be used to determine the protein 
concentration of fractionated samples due to the presence of ethylene glycol-bis(2-
aminoethyl ether)-N,N,N’N’-tetraacetic acid (EGTA) in the cell extraction buffer 
purchased from Invitrogen to lyse cell nuclei.  EGTA is not compatible with the BCA 
assay.  A 1-5 μl sample of cell lysate was added to 1 ml of Bradford reagent mix 
(800 μl H2O, 200 μl Protein Assay Dye Reagent (Bio-Rad)).  Colorimetric detection 
was achieved at 595 nm with a spectrophotometer.  A Bradford reagent mix control 
was also included.  The protein concentration of the cell lysate was determined 
using the following formula: 
Cell lysate protein concentration (mg/ml) =  
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑥 15
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑙𝑦𝑠𝑎𝑡𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝐵𝑟𝑎𝑑𝑓𝑜𝑟𝑑 𝑅𝑒𝑎𝑔𝑒𝑛𝑡 𝑀𝑖𝑥
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2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples containing 20-30 μg of protein were used for SDS-polyacrylamide gel 
electrophoresis.  All samples were made to contain an equal amount of protein.  
Samples were mixed with either 4x Laemmli buffer (200 mM Tris HCl (pH 6.8), 8% 
(w/v) SDS, 40% (v/v) glycerol, 0.4% bromophenol blue, 400 mM DTT) or 6x 
Laemmli buffer (60 mM Tris HCl (pH 6.8), 12% (w/v) SDS, 47% (v/v) glycerol, 
0.06% bromophenol blue, 0.6 M DTT) and boiled at 95 oC for five minutes to 
denature the proteins.  Claudin 5 was found to aggregate when the protein samples 
were boiled at 95 oC, consequently for these experiments the protein samples were 
heated at 70 oC for 10 minutes.  The protein samples were then pulse centrifuged 
and loaded onto 1.5 mm gels, Table 2.3, made in disposable cassettes (Thermo 
Fisher Scientific).  A 10% resolving gel with a 4% stacking gel was used to analyse 
protein samples used for the detection of occludin.  An 8% resolving gel with a 4% 
stacking gel was used to analyse protein samples used for the detection of ZO-1 
due to the high molecular weight (220 kDa) of this protein.  A 15% resolving gel with 
a 6% stacking gel was used to analyse protein samples used for the detection of 
claudin 5 due to the low molecular weight (23 kDa) of this protein.   
Protein samples were run with a Precision Plus Protein Dual Colour Standards 
ladder consisting of 10 reference bands ranging from 10-250 kDa (BioRad).  The 
gels were electrophoresed at 120 V in 1x running buffer (25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS, pH 8.3) using an Invitrogen system.   
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8% Resolving gel pH 8.8 10% Resolving gel pH 8.8 
8% (w/v) acrylamide 10% (w/v) acrylamide 
25% (v/v) resolving buffer 25% (v/v) resolving buffer 
0.1% (w/v) ammonium persulphate (APS) 0.1% (w/v) ammonium persulphate (APS) 
0.1% (v/v) TEMED 0.1% (v/v) TEMED 
12% Resolving gel pH 8.8 15% Resolving gel pH 8.8 
12% (w/v) acrylamide  15% (w/v) acrylamide  
25% (v/v) resolving buffer 25% (v/v) resolving buffer 
0.1% (w/v) ammonium persulphate (APS) 0.1% (w/v) ammonium persulphate (APS) 
0.1% (v/v) TEMED 0.1% (v/v) TEMED 
4% Stacking gel, pH 6.8 6% Stacking gel, pH 6.8 
4% (w/v) acrylamide  6% (w/v) acrylamide  
25% (v/v) stacking buffer 25% (v/v) stacking buffer 
0.1% (w/v) ammonium persulphate (APS) 0.1% (w/v) ammonium persulphate (APS) 
0.1% (v/v) TEMED 0.1% (v/v) TEMED 
Table 2.3: Gel Compositions.  Resolving buffer composition: 1.5 M Tris-HCl, 4% 
(w/v) SDS, pH 8.8.  Stacking buffer composition: 0.5 M Tris-HCl, 4% (w/v) SDS, pH 
6.8.  29:1 acrylamide/bisacrylamide, 30% solution purchased from Geneflow.  
Tetramethylethylenediamine (TEMED) purchased from Melford. 
2.7 Western Blotting 
Proteins were transferred using a BioRad system onto 0.45 μm Hybond-C extra 
nitrocellulose membranes (Amersham Laboratories) at a constant current of 300 mA 
for 2 hours in transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3).  The gel and 
nitrocellulose membrane were held between chromatography paper (Whatman) and 
sponges in a transfer cassette.  Transfer efficiency was determined using Ponceau 
Red (0.1% Ponceau, 5% acetic acid in H2O).  The membranes were blocked in 
either 5% milk blocking buffer (5% (w/v) powdered milk (Marvel), 0.01% Tween 20 
in PBS) or West-EZier blocking buffer (Novus Scientific) for 1 hour at room 
temperature.  The membranes were subsequently probed O/N at 4 oC with primary 
antibody diluted in the appropriate blocking buffer, Table 2.4.   
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Antibody Species Dilution 
Blocking 
Buffer 
Supplier Code 
alpha-Tubulin 
Rabbit 
Polyclonal 
1:1000 West-EZier/Milk Abcam ab4074 
beta-Actin 
Mouse 
Monoclonal 
IgG1 
1:5000 West-EZier/Milk Abcam ab6276 
Claudin 5 
Rabbit 
Monoclonal 
1:1000 West-EZier Abcam ab131259 
Claudin 5 
Rabbit 
Polyclonal 
1:1000 West-EZier Abcam ab15106 
DDX3X 
Rabbit 
Polyclonal 
1:200 West-EZier 
Atlas 
Antibodies 
HPA001648 
DDX3 
Mouse 
Monoclonal 
IgG1 
1:200 West-EZier Abcam ab50703 
eEF2 
Rabbit 
Polyclonal 
1:10000 West-EZier 
Merck 
Millipore 
07-1382 
GFAP 
Rabbit 
Polyclonal 
1:10000 Milk Abcam ab7260 
HNRNPA2B1 
Rabbit 
Polyclonal 
1:1000 West-EZier Proteintech 14813-1-AP 
HNRPA3 
Rabbit 
Polyclonal 
1:1000 West-EZier Abcam ab50949 
Nestin 
Rabbit 
Polyclonal 
1:50 Milk Abcam ab82375 
Occludin 
Rabbit 
Monoclonal 
1:10000 West-EZier Abcam ab167161 
Occludin 
Rabbit 
Polyclonal 
1:500 West-EZier 
Thermo 
Fisher 
Scientific 
71.1500 
Occludin 
Mouse 
Monoclonal 
IgG1 
1:500 West-EZier 
Novus 
Biologicals 
H00004950-
M01 
SSRP1 
Mouse 
Monoclonal 
IgG2b 
1:5000 West-EZier BioLegend 609702 
Vimentin 
Mouse 
Monoclonal 
IgG1  
1:1000 Milk Abcam ab8978 
ZO-1 
Rabbit 
Polyclonal 
1:500 West-EZier 
Thermo 
Fisher 
Scientific 
40.2200 
 Table 2.4: Western blotting primary antibodies. 
The membranes were washed three times at ten minute intervals in 0.01% Tween 
20-PBS and probed for 1 hour at room temperature with the appropriate species-
specific horseradish peroxidase (HRP) conjugated secondary antibody, Table 2.5, 
diluted in 0.01% Tween 20-PBS.  The membranes were again washed three times 
at ten minute intervals in 0.01% Tween 20-PBS.  Protein bands were detected using 
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an EZ-ECL chemiluminescence detection kit (Geneflow) and visualised using a G-
BOX (Syngene).  Images were processed using Adobe Illustrator software. 
Antibody Dilution Supplier Code 
Polyclonal Goat Anti-Mouse Immunoglobulins/HRP 1:10000 Dako P0447 
Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP 1:5000 Dako P0448 
Table 2.5: Western blotting secondary antibodies 
2.8 Histology 
The tissue cohort used in this research was obtained from the Newcastle brain 
bank, which holds and approves the use of tissue as a Human Tissue Authority 
approved brain bank (ethical reference 08/H0906, Newcastle and North Tyneside 
REC).  The cohort consisted of control, mild cognitive impairment (MCI), and AD 
cases, Table 2.6.  Formalin fixed, paraffin embedded (FFPE) temporal cortex blocks 
were cut to 5 μm thickness and collected onto charged slides (Leica).  All 
immunohistochemistry was conducted manually using a standard avidin-biotin 
complex (ABC) method (Vectastain Elite Kit, Vectastain Laboratories) according to 
the manufacturer’s instructions, as detailed below. 
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Category ACATU TRQ Case ID Block ID - 
Temporal 
Disease 
Code 
Age 
(years) 
PM Sex Fixation 
Time 
Braak 
Stage 
Initial No. of 
Slides 
Control 2011060 2013.13 2006_0081 I CA 58 39 F 5w 0 LR 25 
Control 2011060 2013.13 2007_0049 I CA 72 27 F 9w 1 LR 25 
Control 2011060 2013.13 2008_0005 I CA 59 19 F 11w 0 LR 25 
Control 2011060 2013.13 2009_0067 I CA 74 67 F 14w 1 LR 25 
Control 2011060 2013.13 2009_0118 AC CA 55 41 M 14w 0 LR 25 
Control 2011060 2013.13 2010_0729 I CA 70 72 M 11w 0 LR 25 
Control 2011060 2013.13 2011_0272 I CA 78 34 F 8w 0 LR 25 
Control 2011060 2013.13 2011_0524 I PM 83 24 F 8w 1 LR 25 
Control 2011060 2013.13 2011_0891 I CA 73 25 M 9w 0 LR 25 
Control 2011060 2013.13 2011_1016 I CA 74 49 F 12w 1 LR 25 
             
MCI 2011060 2013.13 1999_0217 W CA 105 52 F N/D 4 LR 25 
MCI 2011060 2013.13 1999_0279 R DS 91 17 F N/D 4 LR 25 
MCI 2011060 2013.13 2009_0065 AC CA+ 75 82 M 25w 4 LR 25 
MCI 2011060 2013.13 2010_0251 I CA 86 75 F 7w 4 LR 25 
MCI 2011060 2013.13 2010_0685 I CA 88 22 F 10w 3 LR 25 
MCI 2011060 2013.13 2010_0719 I DS 81 82 M 9w 3 LR 25 
MCI 2011060 2013.13 2010_1067 I CA 98 59 F 9w 3 LR 25 
MCI 2011060 2013.13 2011_0129 I CA 89 34 F 8w 3 LR 25 
MCI 2011060 2013.13 2011_0477 I CA 95 66 F 8w 3 LR 25 
             
AD 2011060 2013.13 2008_0102 I DS 84 47 F N/D 6 LR 25 
AD 2011060 2013.13 2009_0002 I DS 77 63 F 6w 6 LR 25 
AD 2011060 2013.13 2009_0016 I DS 93 53 F 10w 6 LR 25 
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AD 2011060 2013.13 2009_0017 I DS 99 71 F 17w 6 LR 25 
AD 2011060 2013.13 2009_0026 I DS 83 12 M N/D 6 LR 25 
AD 2011060 2013.13 2009_0100 I DS 80 32 F 17w 6 LR 25 
AD 2011060 2013.13 2010_0098 I DS 86 69 F 15w 6 LR 25 
AD 2011060 2013.13 2010_0320 I DS 88 84 M 10w 6 LR 25 
AD 2011060 2013.13 2010_0483 I DS 78 37 M 14w 6 LR 25 
AD 2011060 2013.13 2012_9990 I DS 78 40 F 12w 6 LR 25 
Table 2.6: Temporal Cortex Cohort Information 
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2.8.1 Immunohistochemistry of FFPE Tissue  
The tissue sections were baked onto the slides at 65 oC for 40 mins and left to cool 
for 24 hrs.  The sections were then dewaxed for 5 mins in two xylene solutions and 
rehydrated to water in a graded series of ethanol solutions (2x absolute ethanol, 
95% and 70%) for 5 mins each before being submerged in running water.  The 
sections were incubated for 20 mins in a 3% H2O2-methanol solution to quench 
endogenous peroxidase activity.  Following antigen retrieval, Table 2.7, the sections 
were blocked for 30 minutes at room temperature in 1.5% (v/v) normal serum 
(Vectastain Laboratories) to prevent non-specific binding and then incubated 
overnight in the relevant primary antibody, Table 2.7.  A negative (omission of the 
primary antibody) and isotype control, either an isotype specific mouse or rabbit IgG 
(Vector Laboratories) used at the same concentration as the primary antibody, were 
also included to confirm antibody specificity. 
Antibody Species 
Antigen 
Retrieval 
Dilution (time, temp.) Supplier Code 
Claudin 5 
Mouse 
Monoclonal 
IgG1 
MW 15 
min, EDTA 
pH 8.0 
1:50 (O/N, 4 oC) 
Thermo Fisher 
Scientific 
35.2500 
Occludin 
Rabbit 
Polyclonal 
MW 15 
min, EDTA 
pH 8.0 
1:100 (O/N, 4 oC) 
Thermo Fisher 
Scientific 
71.1500 
ZO-1 
Rabbit 
Polyclonal 
MW 15 
min, EDTA 
pH 8.0 
1:50 (O/N, 4 oC) 
Thermo Fisher 
Scientific 
18.7430 
Table 2.7: Immunohistochemistry Primary Antibodies  This table discloses the 
source and conditions of use for the primary antibodies as well as the antigen 
retrieval method utilised for immunohistochemistry.  
The sections were washed in TBS for 5 minutes and incubated for 1 hour at room 
temperature in 0.5% (v/v) biotinylated secondary antibody (Vectastain Laboratories) 
after which the sections were again washed in TBS and incubated for 30 mins at 
room temperature in an avidin-biotinylated horseradish peroxidase complex solution 
(Vectastain Laboratories) made at least 30 minutes prior to use.  The sections were 
subsequently washed in TBS and incubated for 5 mins at room temperature in 3, 3-
diaminobenzidine (DAB) solution (Vecatstain Laboratories).  DAB is a chromogen 
which, in the presence of peroxidase, oxidises to produce a brown substrate which 
allows the visualisation of the location of antibody binding to the tissue section.  The 
DAB-peroxide reaction was quenched in deionised H2O (dH2O).  The sections were 
incubated for 1 minute in Harris’s Haematoxylin to stain cell nuclei.  The sections 
were then briefly submerged in acid alcohol to remove excess haematoxylin stain 
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from the tissue followed by Scott’s tap water, an alkaline solution which neutralises 
the acid alcohol and blues the haematoxylin stain.  The sections were dehydrated in 
graded ethanol solutions (75%, 95% and 2x absolute ethanol) before being cleared 
in xylene and permanently mounted using distyrene plasticizer xylene (DPX) 
mounting media (Sigma). 
2.8.2 Immunohistochemistry of FFPE Tissue – Dual Immunostaining 
Dual immunostaining was conducted for occludin and GFAP.  Initially, single 
staining for occludin was conducted utilising the same protocol stated in 2.8.1 using 
the anti-occludin polyclonal antibody (Thermo Fisher Scientific 71.1500) at a 1:50 
dilution.  Subsequent to the quenching of the DAB reaction, the sections were 
blocked for 30 minutes at room temperature in 1.5% (v/v) normal serum (Vectastain 
Laboratories).  This solution was removed and the sections incubated for 15 
minutes at room temperature in avidin solution from an avidin-biotin blocking kit 
(Vectastain Laboratories) after which the sections were briefly washed in TBS and 
incubated for 15 minutes at room temperature in biotin solution also from the avidin-
biotin blocking kit (Vectastain Laboratories).  This solution was removed and the 
sections incubated O/N at 4 oC with anti-GFAP rabbit polyclonal antibody (DAKO, 
Z0334) diluted 1:500 in blocking solution.  The sections were washed for 5 minutes 
in TBS and incubated for 1 hour at room temperature in 0.5% (v/v) biotinylated anti-
rabbit IgG secondary antibody, washed again for 5 minutes in TBS and then 
incubated for 1 hour at room temperature in 1.5% (v/v) avidin-biotin complex-
alkaline phosphatase (ABC-AP) solution (Vectastain Laboratories).  This solution 
was made at least 30 minutes prior to use.  The sections were developed for 10-15 
minutes at room temperature in alkaline phosphatase red substrate (Vectastain 
Laboratories) and the reaction quenched in distilled H2O.  The sections were 
incubated for 1 minute in Harris’s Haematoxylin then briefly submerged in acid 
alcohol followed by Scott’s tap water.  The sections were dehydrated in graded 
ethanol solutions (75%, 95% and 2x absolute ethanol) before being cleared in 
xylene and permanently mounted using DPX mounting media (Sigma). 
2.9 Recombinant Protein Generation 
2.9.1 Plasmids 
pCMV-SPORT6 (4396 bp) contained occludin (OCLN) cDNA IMAGE clone. The 
plasmid was purchased from Source Bioscience and was hosted in the DH10B 
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Escherichia coli (E. coli) strain with ampicillin resistance and NotI/EcoRV cloning 
sites. 
pET24b-GB1-6His (5.5 kbp) vector with kanamycin resistance containing a GB1-
6His tag was used for cloning OCLN full length, N- and C-terminal sequences and 
recombinant protein expression in E. coli. 
2.9.2 Primers 
Primers were designed to isolate the N- and the C-terminal domains as well as the 
full length occludin sequence.  All primers were purchased from Sigma. 
Primer Sequence 
OCLN_1_Nde15 5'-GGCGGGCATATGTCATCCAGGCCTCTTGAAAG 
OCLN_271_Nde15 5'-GGCGGGCATATGGACAGGTATGACAAGTCC 
OCLN_522_Xho13 5'-CCCGCCCTCGAGCTATGTTTTCTGTCTATCATAG 
OCLN_65_Xho14 5'-CCCGCCCTCGAGTTAAATCACTCCTGGAGGAGAGGTC 
Table 2.8: Primers 
2.9.3 Bacterial Strains  
E. coli DH5α was used for the molecular cloning of plasmid DNA.  Genotype: F-
80dlacZ M15 (lacZYA-argF) U169 recA1 endA1hsdR17 (rk-, mk+) phoAsupE44-thi-
1 gyrA96relA1. 
E. coli BL21-RP was used for recombinant protein expression.  Genotype: FHUa2 
[Ion] ompT gal (λ DE3) [dcm] ΔhsdS. 
2.9.4 Bacterial Culture Materials 
Luria-Bertani (LB) Broth was purchased from Thermo Fisher Scientific and made 
according to the manufacturer’s instructions (25 g LB in 1 l dH2O).  LB solutions 
were autoclaved prior to use. 
Terrific Broth (TB) for 10 litres: 120 g tryptone, 240 g yeast extract, 23.1 g KH2PO4, 
125.4 g K2HPO4, 40 ml glycerol in dH2O.  TB solutions were autoclaved prior to use. 
2.9.5 PCR Reaction 
A touchdown PCR was conducted to amplify full length occludin, N-terminal and C-
terminal sequences, Table 2.9.  A touchdown PCR is designed to avoid the 
amplification of non-specific sequences by using a cycling program with a range of 
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primer annealing temperatures which encompasses the optimal annealing 
temperature, Table 2.10.   
HerII PCR Reaction 
500 ng c DNA Template 
0.5 μM Forward Primer 
0.5 μM Reverse Primer 
1.6 μM dNTP Mix (Bioline) 
10 μl 5x HerII Reaction Buffer (Agilent) 
5% DMSO (Agilent) 
1.0 μl HerII Fusion DNA Polymerase (Agilent) 
make 50 μl final volume MQ H2O 
Table 2.9 PCR reaction for Herculase II Fusion DNA Polymerase 
HerII PCR Program 
Heated Lid 110 oC 
 
Temperature Step 95 oC 2 mins 
Touchdown 
Denaturing Temperature 95 oC 20 sec 
Max. Annealing Temperature 65 oC 20 sec 
Min. Annealing Temperature 50 oC 
Elongation Temperature 65 oC 2 mins 
Cycles 15 
 
Start Cycle (35x) 
Temperature Step 95 oC 20 sec 
Temperature Step 55 oC 20 sec 
Temperature Step 68 oC 2 mins 
End Cycle 
Temperature Step 68 oC 4 mins 
Hold 10 oC Infinite 
Table 2.10: Touchdown PCR Program for Herculase II Fusion DNA Polymerase  
2.9.6 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate and analyse PCR products.  
Agarose gels (2%) were made by using a microwave to dissolve 4 g agarose 
(Melford) in 200 ml TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA).  Once 
dissolved, 4 μl of 10 mg/ml ethidium bromide (Invitrogen) was added to the solution.  
10 μl 6x Laemmli buffer was added to each PCR sample.   The samples were 
loaded with a GeneRuler Mix Ladder (bands ranging from 100-1000 bp) (Thermo 
Scientific) and run at 80-100 V for 40-60 minutes.  DNA bands were imaged using a 
GENi (Syngene). 
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2.9.7 Gel Extraction 
The DNA bands were visualised using an ultra-violet (UV) transilluminator and 
excised using a clean scalpel blade.  The DNA was extracted from the gel piece and 
purified using the QIAquick Gel Extraction kit (QIAGEN) according to the 
manufacturer’s instructions.  Each excised DNA band was placed in a fresh 1.5 ml 
Eppendorf tube to which was added 900 μl QG buffer.  The tubes were then 
incubated at 50 oC until the gel had dissolved after which 300 μl isopropanol was 
added and the solution transferred to a spin column and centrifuged for 1 minute at 
17, 000 x g.  The flow through was discarded and 500 μl added to the spin column 
which was again centrifuged for 1 minute at 17, 000 x g.  The flow through was 
discarded and 750 μl PE buffer added to the spin column which was centrifuged for 
1 minute at 17, 000 x g.  The spin column was then transferred to a fresh 1.5 ml 
Eppendorf tube.  50 μl EB was added to the spin column and then left to stand for 3 
minutes at room temperature after which it was centrifuged for 1 minute at 17, 000 x 
g. 
2.9.8 PRC Product Restriction Digest 
The purified DNA was digested with the same restriction enzymes used to cut the 
pET24b-GB1-6His plasmid.  Restriction digest reaction: 50 μl DNA, 10 μl 10x Fast 
Digest buffer (Thermo Fisher Scientific),  5 μl NdeI restriction enzyme (10 U/μl) 
(Thermo Fisher Scientific), 5 μl XhoI restriction enzyme (10 U/μl) (Thermo Fisher 
Scientific), 30 μl ultrapure H2O (final reaction volume 100 μl).  The reactions were 
incubated O/N at 37 oC (heat block). 
2.9.9 DNA Precipitation 
Following restriction digestion, 100 μl chloroform was added to each DNA sample, 
vortexed for 1 minute and centrifuged at 17, 000 x g for 3 minutes at room 
temperature. The top phase was transferred to a fresh Eppendorf tube and, if 
necessary, made up to a final volume of 90 μl with ultrapure water after which 10 μl 
3 M sodium acetate (NaAc) and 300 μl ethanol were added.  The DNA samples 
were inverted 5x and incubated for 20 minutes at -20 oC, after which they were 
centrifuged at 17, 000 x g for 20 minutes at room temperature.  The supernatant 
was removed and the DNA pellets were left to air dry.  
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2.9.10 Ligation into pET24b-GB1-6His Plasmid 
The DNA pellets were resuspended in 16 μl ultrapure H2O and transferred to 0.5 ml 
Eppendorfs tubes.  Ligation reaction composition: 16 μl DNA, 1 μl pET24b-GB1-
6His cut vector, 2 μl ligation buffer (Thermo Fisher Scientific), 5 U T4 DNA ligase 
(Thermo Fisher Scientific). The reactions were incubated O/N at 16 oC (PCR 
machine) and stored at -20 oC. 
2.9.11 Transformation of pET24b-GB1-6His plasmid into DH5α 
A heat shock method was used to induce plasmid uptake into the DH5α E. coli 
strain.  10 μl plasmid was incubated with 50 μl DH5α on ice for 10 minutes after 
which the samples were incubated at 37 oC (heat block) for 5 minutes and then 
placed on ice for a further 2 minutes.  950 μl LB was added and the culture 
incubated at 37 oC for 1 hour on a rotary shaker set to 220 rpm.  The culture was 
centrifuged at 4, 700 x g for 1 minute at room temperature.  Most of the supernatant 
was discarded leaving approximately 100 μl which was used to resuspend the 
bacterial pellet.  The bacterial suspension was plated out onto LB agar plates with 
30 μg/ml kanamycin (kanamycin stock conc. 50 mg/ml) which were inverted and 
incubated O/N at 37 oC to allow colony growth.  Individual colonies (transformants) 
from each plate were inoculated in LB broth with kanamycin (1:1000) and incubated 
O/N at 37 oC on a rotary shaker set to 220 rpm. 
2.9.12 Spin Miniprep & Transformant Screen by Restriction Digest 
Spin minipreps were conducted on all inoculated colonies to establish the presence 
of the required insert in the bacteria prior to sequencing.  All spin minipreps were 
conducted using the QIAprep spin miniprep kit (QIAGEN) according to the 
manufacturer’s instructions.  Fast digest reaction: 8 μl DNA, 1 μl 10x fast digest 
buffer, 0.5 μl NdeI, 0.5 μl XhoI.  All reagents from Thermo Fisher Scientific.  
Samples were incubated at 37 oC (heat block) for 20 minutes and run on a 2% 
agarose gel for 40 minutes at 100 V. 
2.9.13 Sanger Sequencing PCR 
Sequencing reaction: 1 μg DNA (500 ng/μl), 1 μl primer, 2 μl 5x BigDye Terminator 
v3.1 Sequencing Buffer (Applied Biosystems), 1 μl BigDye Terminator v3.1 Ready 
Reaction Mix (Applied Biosystems), ultrapure H2O to make 10 μl final volume, Table 
2.11.    
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PCR Program 
Heated Lid 110 oC  
Start Cycle (45x) 
Temperature Step 95 oC 30 sec 
Temperature Ramp 1 oC per second 
Temperature Step 50 oC 15 sec 
Temperature Ramp 1 oC per second 
Temperature Step 60 oC 4 mins 
End Cycle 
Hold 10 oC Infinite 
Table 2.11: PCR program for Sanger Sequencing 
2.9.14 DNA Precipitation 
90 μl 10x Master Mix (MM) (30 μl 3M sodium acetate, 245 μl ultrapure H2O and 625 
μl 100% ethanol) was added to each sample.  Samples were briefly vortexed and 
incubated for 20 minutes at room temperature after which they were centrifuged at 
17, 000 x g for 20 minutes at room temperature.  Samples were washed with 150 μl 
70% ethanol, vortexed briefly and centrifuged at 17, 000 x g for 10 minutes at room 
temperature. The supernatant was discarded and the DNA pellets air dried prior to 
being sent to Source BioScience for analysis.   
2.9.15 Transformation of pET24b-GB1 plasmid into BL21-RP E. coli 
A heat shock transformation was performed in which 50 μl BL21-RP was added to 2 
μl DNA (500 ng/μl) in a 1.5 ml Eppendorf tube and incubated on ice for 7 minutes, 
after which samples were incubated at 37 oC (heat block) for 5 minutes then placed 
on ice for 2 minutes.  950 μl SOC medium was added to the cultures which were 
incubated at 37 oC for 1 hour on a rotary shaker set to 220 rpm and centrifuged at 4, 
700 x g for 1 minute at room temperature.  Most of the supernatant was discarded 
leaving approximately 100 μl which was used to resuspend the bacterial pellet.  The 
bacterial suspension was plated out onto LB agar plates (30 μg/ml kanamycin) 
which were inverted and incubated O/N at 37 oC.  A few colonies were scrapped 
together using a pipette tip which was ejected into a flask containing 50 ml TB, 50 μl 
kanamycin and 50 μl chloramphenicol.  The flasks were incubated O/N at 37 oC on 
a rotary shaker set to 220 rpm.  Glycerol stocks of the N-terminal, C-terminal and 
full length occludin bacterial cultures were made in which 500 μl of each culture was 
mixed with 500 μl 50% glycerol and stored at -80 oC. 
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2.9.16 Recombinant Protein Expression in BL21-RP E. coli 
A 50 ml transformed BL21-RP culture was set up 24 hours prior to protein 
expression.  Using a stripette, 1.5 ml of the 50 ml BL21-RP culture was added to 
750 ml TB and 750 μl kanamycin in a baffled flask.  The baffled flask was incubated 
at 37 oC on a rotary shaker (220 rpm).  Bacterial growth was monitored by 
determining the culture’s optical density using a spectrophotometer until the culture 
had reached OD600 0.7 at which point 300 μl isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was added and the flasks were incubated O/N at room temperature on a 
rotary shaker set to 210 rpm. 
2.9.17 Protein Purification 
The induced cultures were centrifuged at 4500 rpm for 15 minutes at 4 oC.  A 0.25 g 
bacterial pellet was weighed out in a 1.5 ml Eppendorf tube and lysed in 1 ml lysis 
buffer (50 mM Tris, 1 M NaCl, 0.5% (v/v) triton X-100, PIC, pH 8.0).  The pellets 
were sonicated 3x on ice in 30 second cycles (5 seconds sonicated, 25 seconds 
cooled) and the lysates centrifuged at 17, 000 x g for 7 minutes at 4 oC.  The 
supernatant was added to 40 μl slurry TALON Metal Affinity Cobalt Beads (Clontech 
Laboratories) and incubated for 1 hour on a rotary wheel at 4 oC.  Prior to the 
addition of supernatant, the beads were washed twice in 1 ml lysis buffer.  The 
lysates were centrifuged at 0.5 x g for 1 minute and the supernatant discarded.  The 
beads were washed once in 1 ml lysis buffer and twice in 1 ml wash buffer (50 mM 
Tris, 1 M NaCl, 5 mM Imidazole, pH 8.0).  The beads were incubated for 12 minutes 
in 50 μl elution buffer (20 mM Tris, 500 mM NaCl, 200 mM Imidazole, pH 8.0) to 
elute the GB1-tagged protein.  The beads were briefly vortexed every 2 minutes 
during the 12 minute incubation after which they were centrifuged at 0.5 x g for 1 
minute and the supernatant removed and retained.  SDS-polyacrylamide gel 
electrophoresis was used to confirm the size and purity of the recombinant proteins.  
15 μl of each supernatant was added to 5 μl 4x Laemmli buffer and boiled at 95 oC 
for 5 minutes.  The samples were loaded onto a 15% gel along with an SDS-PAGE 
Standards ladder (bands ranging from 6.5-200 kDa) (BioRad) and run at 150 V.  
The bands were visualised with Coomassie Blue. 
Once it had been established that the recombinant proteins were the correct size 
the entire bacterial pellet was lysed in 25 ml lysis buffer.  The pellets were then 
sonicated 6x on ice (30 seconds sonicated, 30 seconds cooled) after which the 
lysates were centrifuged at 4500 rpm for 20 minutes at 4 oC.  3 ml TALON Metal 
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Affinity Cobalt Bead slurry was placed into a column and washed once in 10 ml 
ultrapure H2O and once in 10 ml lysis buffer.  The bacterial lysate was run twice 
over the beads after which the beads were washed once in 10 ml lysis buffer and 
twice in 10 ml wash buffer.  Proteins were eluted from the beads in 3 ml elution 
buffer.  The protein concentration of the eluate was determined using a Bradford 
assay (as detailed in 2.5) and SDS-polyacrylamide gel electrophoresis (2.6) was 
again used to check the size and purity of the recombinant proteins.  The eluate 
was aliquoted, flash frozen in liquid nitrogen and stored at -80 oC.   
2.10 Immunocytochemistry of BL21-RP E. coli 
The E.coli ICC protocol used in this project was developed from a previous study 
(Jose et al., 2005).  100 µl of bacterial culture was placed in each well of a 24 well 
tissue culture plate containing a 13 mm coverslip and incubated at 37 oC until dry.  
To fix the bacteria, 500 μl 4% PFA was added to each well and incubated for 20 
minutes at room temperature.  The coverslips were washed three times in PSB and 
incubated in blocking solution (3% (w/v) bovine serum albumin (BSA), 0.01% Tween 
20 in PBS) for 5 minutes at room temperature.  Anti-occludin rabbit polyclonal 
antibody (Thermo Fisher Scientific) diluted 1:50 in blocking solution was added to 
each well and the plate incubated on ice for 1 hour.  The coverslips were washed 
three times in PBS and the plate incubated on ice in darkness for 1 hour in Alexa-
Fluor® 488 goat anti-rabbit secondary antibody diluted 1:500 in blocking solution.  
The coverslips were again washed three times in PBS and mounted using 
fluorescent mounting medium (DAKO) onto glass slides.  Images were taken using 
a Nikon microscope. 
2.11 Pull-Down Protein Binding Assay 
For each condition, 30 µl IgG bead slurry (GE Healthcare) was blocked in 2% BSA-
wash buffer (150 mM NaCl, 25 mM TrisHCl, pH 8.0) O/N at 4 oC on a rotary wheel.  
Beads were washed 3 times in wash buffer and incubated with 20 µg GB1-OCLN_N 
or GB1-OCLN_C for 1 hour at 4 oC.  A GB1-6His control was also included in each 
experiment.  Prior to lysis, 1321N1 astrocytoma cells cultured in 10 cm dishes were 
treated with 5 mM CaCl2 and 4 μM A23187 calcium ionophore (Sigma) and 
incubated at 37 oC for 15 minutes.  The cells were then washed once in PBS and 
lysed on ice in 500 µl lysis buffer (150 mM NaCl, 25 mM TrisHCl, 1% (v/v) Triton X-
100, 0.05% (w/v) SDS, 10 mM NaF, 1 mM NaVO4, PIC, pH 8.0). 
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Note: During the optimisation of this protocol, pull-down protein binding assays were 
initially conducted using the following buffer compositions: wash buffer (150 mM 
NaCl, 50 mM HEPES, 1 mM DTT, pH 7.5) and lysis buffer (150 mM NaCl, 50 mM 
HEPES, 1 mM DTT, 0.5% (v/v) Triton X-100, 10% (v/v) glycerol, PIC, pH 7.5).   
The lysates were incubated on ice for 30 minutes and passed through a 25 G 
needle 10x before being centrifuged at 17, 000 x g for 5 minutes, after which the 
supernatants were combined and the concentration determined by Bradford assay 
(as detailed in 2.5).  The beads were washed once in wash buffer, twice in lysis 
buffer and transferred to 15 ml falcon tubes.  The lysate was diluted to 1.5 mg/ml 
and divided equally between the beads with a small quantity retained for use as an 
input sample.  The bead-lysate mixture was incubated O/N at 4 oC on a rotary 
wheel.  The tubes were centrifuged at 0.5 x g for 2 minutes and the supernatant 
removed.  The beads were washed twice in lysis buffer and three times in wash 
buffer.  60 µl 2x Laemmli buffer was added to the beads which were subsequently 
boiled at 95 oC for 5 minutes to elute any proteins.  The eluates were analysed by 
SDS-polyacrylamide gel electrophoresis (as detailed in 2.6).  Protein bands were 
visualised with either InstantBlue coomassie (Expedeon) or a SilverXpress® Silver 
Staining Kit (Thermo Fisher Scientific).  This kit was used according to the 
manufacturer’s instructions. 
2.12 Mass Spectrometry  
2.12.1 In-Gel Digest Sample Preparation 
The gel was cut into pieces using a clean scalpel blade.  These pieces were then 
transferred into individual fresh 1.5 ml LoBind Eppendorf tubes (Capitol Scientific).  
The excised gel pieces were incubated in 200 μl 200 mM Ammonium Bicarbonate 
(ABC) solution in 40% Acetonitrile (ACN) at 37 oC for 30 minutes to destain the gel 
after which the supernatant was discarded and this step repeated.  The gel pieces 
were incubated in 100 μl acetonitrile (ACN) at 37 oC for 10 minutes to dehydrate the 
gel.  The gel pieces were incubated in 100 μl reduction buffer (10 mM DTT in 50 
mM ABC solution) at 56 oC for 30 minutes after which they were pulse centrifuged 
and the supernatant discarded.  The gel pieces were incubated in 100 μl alkylation 
buffer (55 mM Iodoacetic acid (IAA) in 50 mM ABC solution) for 30 minutes at room 
temperature in the dark, washed twice in 200 μl 50 mM ABC solution and once in 
200 μl 50 mM ABC solution in 50% ACN after which the pieces were pulse 
centrifuged and dried in 100 μl Acetonitrile (ACN) at 37 oC for 10 minutes.  20 μl 
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(equivalent to 0.4 μg trypsin) trypsin solution (20 μg/ml Trypsin (Sigma), 100 μl 1 
mM HCl, 900 μl 40 mM ABC in 9% ACN) was added to the dehydrated bands and 
incubated for 5 minutes at 4 oC.  Once the trypsin solution had soaked into the gel 
pieces, 50 μl 40 mM ABC in 9% ACN was added and they were incubated at 37 oC 
O/N.  The gel pieces were pulse centrifuged and the supernatants transferred into 
fresh 1.5 ml LoBind Eppendorf tubes.  20 μl ACN was added to the gel pieces which 
were then vortexed and incubated at 37 oC for 15 minutes followed by 50 μl 5% 
formic acid (FA).  The gel pieces were again briefly vortexed and incubated at 37 oC 
for 15 minutes.  The supernatants were then removed and added to the previous 
transfer tubes.  50 μl 50% ACN in 5% FA was added to the gel pieces which were 
briefly vortexed and incubated at 37 oC for 30 minutes.  The gel pieces were pulse 
centrifuged and the supernatants transferred.  The gel pieces were then discarded 
and the supernatants dried in a vacuum concentrator.  The samples were stored at -
20 oC prior to mass spectrometry analysis. 
2.12.2 ESI-MS Analysis 
The peptides were resuspended in 12 μl 0.1% trifluoroacetic acid (TFA) and 
vortexed twice.  The samples were then centrifuged at 17, 000 x g for 6 minutes 
after which 7μl was transferred to snap ring microvials (VWR) and loaded into an 
AmaZon speed (Brucker) ion trap mass spectrometer.  The ESI-MS was conducted 
by a collaborator: Dr. Mark Dickman’s research group in Chemical and Biological 
Engineering of the University of Sheffield. 
Mascot generic files (MGFs) for the data were created using Mascot Distiller 
software and submitted to automated database searching using the Mascot search 
engine, a software package from Matrix Science.  Proteins were identified using a 
significance threshold p < 0.05.  Peptides with a Mascot score ≥ 50 and the number 
of significant queries > 1 were considered to be significant in this project. 
2.13 Co-Immunoprecipitation 
For each condition, 30 µl Protein G Sepharose bead slurry (GE Healthcare) was 
washed once in PBS and blocked in 2% BSA-PBS O/N at 4 oC on a rotary wheel.  
Cells, either HEK and 1321N1 astrocytoma cells (10x 10 cm dishes) or ScienCell 
primary human astrocytes (6x 175 cm2 tissue culture flasks) were washed once in 
PBS and lysed in IP lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 0.5% (v/v) Triton X-100, 10% (v/v) glycerol, PIC, pH 7.5)  The lysates were 
collected using a cell scraper, passed 10x through a 25 G needle and centrifuged at 
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17, 000 x g at 4 oC for 5 minutes.  The supernatants were combined and the 
concentration determined by Bradford assay (as detailed in 2.5).  The supernatant 
was diluted in lysis buffer to a concentration ranging from 0.5-2.0 mg/ml and 
incubated with fresh Protein G Sepharose beads for 1 hour at 4 oC on a rotary 
wheel.  This is known as a pre-clear and is designed to reduce non-specific-binding.  
The blocked beads were washed once in lysis buffer and incubated with the pre-
cleared cell lysate and the relevant antibody, Table 2.12, for 1 hour at 4 oC on a 
rotary wheel.   
Antibody Species Quantity Supplier Code 
Flag M2 Mouse Monoclonal 5 μg Sigma F1804 
DDX3X Rabbit Polyclonal 1.5 μg Atlas Antibodies HPA001648 
DDX3 Mouse Monoclonal 1.5 μg Abcam ab50703 
Occludin Rabbit Polyclonal 3 μg Thermo Fisher Scientific 71-1500 
Occludin Mouse Monoclonal 5 μg Novus Biologicals H00004950-M01 
Table 2.12: Co-immunoprecipitation antibodies.  These are the antibodies which 
were used for immunoprecipitation and co-immunoprecipitation experiments.  The 
flag M2 antibody was used as negative control. 
The beads were centrifuged at 0.5 x g for 2 minutes at 4 oC and the supernatant 
removed.  Samples of the supernatant, known as flow through, were retained as 
well as an input sample.  The beads were washed 5x in IP lysis buffer.  All residual 
buffer was removed and any proteins bound to the bead-antibody complex were 
eluted either by an acid or boil elution.  For an acid elution, 50 µl 100 mM glycine pH 
2.6 was added to the beads and incubated at room temperature for 15 minutes with 
gentle agitation.  The beads were centrifuged at 0.5 x g for 1 minute and the 
supernatant removed and neutralised with 2.5 µl 1 M tris.  For the boil elution, 50 µl 
2x Laemmli buffer was added to the beads and boiled at 95 oC for 5-10 minutes 
after which the beads were centrifuged 0.5 x g for 1 minute and the eluate removed.  
Samples of the eluates along with input and flow through samples were analysed by 
SDS-polyacrylamide gel electrophoresis, 2.6 and western blotting, 2.7. 
2.14 Statistical Analysis – Western blotting 
Western blotting experiments subject to statistical analysis were run in triplicate 
from three independent experiments. Densitometric analysis was conducted using 
ImageJ and the data analysed using an unpaired t test with GraphPad Prism 
software (version 6.02).  Data were plotted as mean immunoreactivity following 
normalisation to a loading control ± standard error of the mean (SEM).  Differences 
were considered statistically significant when p < 0.05. 
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3. Characterisation of Tight 
Junction Protein Expression in 
Astrocytes 
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3.1 Introduction 
Occludin and claudins are tight junction integral membrane proteins whose 
expression is predominantly associated with epithelial and endothelial cells.  The 
localisation of these proteins in these cells is associated with the cell membrane and 
the cytoplasm (Furuse et al., 1998a; Furuse et al., 1993; Furuse et al., 1998b).  ZO-
1 is a tight junction cytoplasmic scaffolding protein which is also typically associated 
with epithelial and endothelial cells.  This protein is cytoplasmic but localises close 
to the cell membrane (Stevenson et al., 1986).  ZO-1 is also known to express 
nuclear localisation and exportation signals and localises to the nucleus in MDCK 
cells (González-Mariscal et al., 1999; González-Mariscal et al., 2006).  These 
proteins are not exclusively expressed in epithelial/endothelial cells and have also 
been shown to be expressed in astrocytes. 
Occludin has been shown to be highly expressed in vitro in undifferentiated murine 
astrocytes whilst differentiated astrocytes express lower levels of this protein  
(Bauer et al., 1999).  Undifferentiated astrocytes in this study are defined as cells 
between passage 2-4 whilst differentiated astrocytes have a higher passage 
number (Bauer et al., 1999).  Occludin is shown to be localised to the cell 
membrane in undifferentiated murine astrocytes and diffusely expressed throughout 
the cytoplasm in differentiated cells (Bauer et al., 1999).  Astrocytic nuclear occludin 
expression has also been seen in vivo in the human frontal cortex (Romanitan et al., 
2007).  Astrocytes were also found to express claudin 5 in vivo in the same cohort 
(Romanitan et al., 2010). 
Human foetal cortical astrocytes have also been shown to express occludin, ZO-1 
and ZO-2 in vitro (Duffy et al., 2000).  The expression of all three of these proteins is 
localised to the cell membrane in these cells (Duffy et al., 2000).  ZO-1 also co-
localises at the cell membrane with connexin 43 in vitro in murine cortical astrocytes 
(Duffy et al., 2004).  In vivo experiments involving mice have also observed the co-
localisation of ZO-1 with Cx30 and Cx43 in astrocytes (Penes et al., 2005). 
This initial aim of this study was to characterise the expression of occludin, claudin 5 
and ZO-1 in human primary astrocytes and 1321N1 astrocytoma cells.  Another aim 
of this study was to define the cellular localisation of these three proteins in the 
temporal cortex and investigate whether the expression of these proteins is altered 
in MCI and AD cases compared with non-neurological controls.  
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3.2 Results 
3.2.1 Astrocyte Culture Medium Comparison 
There is considerable variation within the literature regarding the culture conditions 
for human astrocytes with various different media being used for tissue culture 
(Gibbons and Dragunow, 2010).  It was considered worthwhile to determine the 
ideal culture conditions for ScienCell human primary astrocytes and consequently a 
media comparison was conducted between the ScienCell Astrocyte Medium and 
MEMα/F-10 medium.   
Initial experiments sought to compare the expression of the intermediate filaments 
GFAP, vimentin and nestin in human primary astrocytes cultured in either medium 
by ICC and western blotting.  Experiments comparing human primary astrocytes 
cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium were 
conducted using cells of the same passage number.  The negative and isotype 
controls for these experiments are included in Figure 3.5 and Figure 3.7.  No 
staining was observed in the negative controls or the mouse IgG isotypes control.  
Very weak non-specific background staining was seen in the rabbit IgG isotype 
control.    
Figure 3.1 shows the expression of GFAP in human primary astrocytes cultured in 
either ScienCell Astrocyte Medium or MEMα/F-10 medium.  ICC showed that GFAP 
expression was exclusively cytoplasmic.  It is also clear from the ICC that, in either 
culture medium, only a few astrocytes in the total population were seen to express 
GFAP, Figure 3.1 A.  This would suggest that the majority of human primary 
astrocytes do not express this protein.   
An example western blot comparing GFAP expression in human primary astrocytes 
is shown in Figure 3.1 panel B.  A 50 kDa GFAP protein band was observed in both 
sets of human primary astrocytes.  These protein bands were fainter in the 
MEMα/F-10 medium compared with the ScienCell Medium suggesting that human 
primary astrocytes express higher levels of GFAP in ScienCell Astrocyte Medium.  
Three independent western blot experiments were conducted using three different 
astrocyte cultures to further explore GFAP expression.  These blots were subject to 
densitometric analysis and the data analysed using an unpaired t test.  The results 
were plotted as mean immunoreactivity following normalisation to a loading control 
± standard error of the mean (SEM), Figure 3.1 panel C.  Differences were 
considered statistically significant when p < 0.05.  This analysis concluded, 
62 
 
however, that there was no significant difference in the level of GFAP expression 
between human primary astrocytes cultured in either ScienCell or MEMα/F-10 
medium. 
 
Figure 3.1: GFAP expression in human primary astrocytes cultured in two 
different media.  A) Immunocytochemistry comparing the expression of GFAP in 
human primary astrocytes cultured in either ScienCell Astrocyte Medium or 
MEMα/F-10 medium.  Scale bar 50 μm.  B) Western blot comparing the expression 
of GFAP in human primary astrocytes.  Molecular weight markers are indicated 
(kDa).  GFAP predicted molecular weight 50 kDa.  Loading control β-Actin.  C) Bar 
chart showing GFAP immunoreactivity of astrocytes cultured in either ScienCell or 
MEMα/F-10 media following normalisation to β-Actin loading control.  Values 
represent mean ± SEM n=3, ns means not significant where P > 0.05.  P value = 
0.2257. 
Figure 3.2 shows the expression of vimentin in human primary astrocytes cultured in 
either ScienCell Astrocyte Medium or MEMα/F-10 medium.  ICC showed that 
vimentin was expressed throughout the astrocyte population and was exclusively 
cytoplasmic, Figure 3.2 panel A.  The ICC did not suggest that the level of vimentin 
expression in these cells was affected by the culture medium.  This observation was 
confirmed by western blot as a 57 kDa vimentin protein band of the same intensity 
was observed in human primary astrocytes cultured in either medium, Figure 3.2 
panel B.   
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Figure 3.2: Vimentin expression in human primary astrocytes cultured in two 
different media.  A) Immunocytochemistry comparing the expression of vimentin in 
human primary astrocytes cultured in either ScienCell Astrocyte Medium or 
MEMα/F-10 medium.  Scale bar 50 μm.  B) Western blot comparing the expression 
of vimentin in human primary astrocytes.  Molecular weight markers are indicated 
(kDa).  Vimentin predicted molecular weight 57 kDa.  Loading control β-Actin. 
Figure 3.3 shows the expression of nestin in human primary astrocytes cultured in 
either ScienCell Astrocyte Medium or MEMα/F-10 medium.  ICC showed that nestin 
was expressed throughout the astrocyte population and was both nuclear and 
cytoplasmic, Figure 3.3 panel A.  The ICC did not suggest that the level of nestin 
expression in these cells was affected by the culture medium.  The predicted 
molecular weight for nestin is a single band of 177kDa, however, a 220-250 kDa 
doublet was observed in human primary astrocytes cultured in either medium, 
Figure 3.3 B.  A 240 kDa nestin protein band is observed in the G6 human 
embryonic muscle cell line and is caused by protein glycosylation (Grigelioniene et 
al., 1996).  A nestin doublet between 220-250 kDa is also observed in U373 and 
U251 human glioblastoma cell lines (Messam et al., 2000).  The 220-250 kDa 
doublet observed in human primary astrocytes is therefore likely to be nestin protein 
that has been subjected to post-translational modification.   
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The intensity of this nestin doublet was the same for human primary astrocytes 
cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium.  This 
confirms the ICC observations and demonstrates that nestin expression is 
unaffected by the culture medium. 
 
Figure 3.3: Nestin expression in human primary astrocytes cultured in two 
different media.  A) Immunocytochemistry comparing the expression of nestin in 
human primary astrocytes cultured in either ScienCell Astrocyte Medium or 
MEMα/F-10 medium.  Scale bar 50 μm.  B) Western blot comparing the expression 
of nestin in human primary astrocytes.  Molecular weight markers are indicated 
(kDa).  Nestin predicted molecular weight 177 kDa.  Loading control β-Actin. 
3.2.2 Tight Junction Protein Expression in Human Primary Astrocytes 
The expression of occludin, claudin 5 and ZO-1 in human primary astrocytes 
cultured in either ScienCell Astrocyte Medium or MEMα/F-10 was first investigated 
by immunocytochemistry.  Experiments comparing human primary astrocytes 
cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium were 
conducted using cells of the same passage number.   
Figure 3.4 shows immunocytochemistry staining for occludin, claudin 5 and ZO-1 in 
human primary astrocytes cultured in ScienCell Astrocyte Medium.  The negative 
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and isotype controls for this experiment are shown in Figure 3.5.  Figure 3.6 shows 
immunocytochemistry staining for occludin, claudin 5 and ZO-1 in human primary 
astrocytes cultured in MEMα/F-10 whilst the negative and isotype controls for this 
experiment are shown in Figure 3.7.  No staining was observed in the negative 
controls or the mouse IgG isotypes control for human primary astrocytes cultured in 
either medium.  Very weak non-specific background staining was seen in the rabbit 
IgG isotype control.  The images presented in these figures are representative of 
the staining patterns exhibited by the whole cell population. 
Human primary astrocytes cultured in either ScienCell Astrocyte Medium or 
MEMα/F-10 displayed clear punctate nuclear occludin staining and diffuse 
cytoplasmic staining.  No membrane-associated occludin staining was observed in 
these cells.  Occludin is a tight junction integral membrane protein, consequently the 
absence of membrane-associated staining in human primary astrocytes is 
surprising.  Similarly, the nuclear localisation of this protein is unusual.   
Diffuse claudin 5 staining was observed throughout the cytoplasm and nucleus of 
astrocytes cultured in either medium.  No membrane-associated claudin 5 staining 
was observed in these cells.  Claudin 5 is another tight junction integral membrane 
protein and again the absence of membrane-associated staining in human primary 
astrocytes is surprising.  The apparent nuclear localisation of this protein is also 
unexpected. 
Strong diffuse cytoplasmic and nuclear staining was observed for ZO-1 in human 
primary astrocytes cultured in either medium.  ZO-1 is known to express both 
nuclear localisation and nuclear exportation signals and is known to be diffusely 
expressed throughout the cytoplasm and nucleus of MDCK cells (González-
Mariscal et al., 1999; González-Mariscal et al., 2006).  The nuclear localisation of 
ZO-1 in human primary astrocytes, is, therefore, not unusual for this protein.  
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Figure 3.4: Immunocytochemistry characterising the expression of Occludin, 
Claudin 5 and ZO-1 in human primary astrocytes cultured in ScienCell 
Astrocyte Medium  The human primary astrocytes used in this experiment were 
cultured in ScienCell Astrocyte Medium.  Vimentin was used as a cell marker.  The 
antibodies and dilutions used in this experiment: anti-vimentin mouse monoclonal 
(1:250), anti-occludin rabbit polyclonal antibody (1:50), anti-claudin 5 rabbit 
polyclonal antibody (1:50) and anti-ZO-1 rabbit polyclonal antibody (1:100).  Scale 
bar 10 μm.    
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Figure 3.5: ICC Negative and Isotype controls for human primary astrocytes 
cultured in ScienCell Astrocyte Medium  Negative and isotype controls were 
conducted for both mouse and rabbit antibodies.  The negative control consisted of 
the omision of the primary antibody.  The isotype control was conducted with either 
a mouse or rabbit IgG antibody (Vector Laboratories) used at the same 
concentration as the primary antibody.  The human primary astrocytes used in this 
experiment were cultured in ScienCell Astrocyte Medium.  Scale bar 50 μm except 
for rabbit IgG isotype control images for which scale bar 10 μm. 
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Figure 3.6: Immunocytochemistry investigating the expression of Occludin, 
Claudin 5 and ZO-1 in human prrimary astrocytes cultured in MEMα/F-10 
medium  The human primary astrocytes used in this experiment were cultured in 
MEMα/F-10 medium.  Vimentin was used as a cell marker.  The antibodies and 
dilutions used in this experiment: anti-vimentin mouse monoclonal (1:250), anti-
occludin rabbit polyclonal antibody (1:50), anti-claudin 5 rabbit polyclonal antibody 
(1:50) and anti-ZO-1 rabbit polyclonal antibody (1:100).  Scale bar 10 μm. 
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Figure 3.7: ICC Negative and Isotype controls for human primary astrocytes 
cultured in MEMα/F-10 medium  Negative and isotype controls were conducted for 
both mouse and rabbit antibodies.  The negative control consisted of the omision of 
the primary antibody.  The isotype control was conducted with either a mouse or 
rabbit IgG antibody (Vector Laboratories) used at the same concentration as the 
primary antibody.  The human primary astrocytes used in this experiment were 
cultured in MEMα/F-10 medium.  Scale bar 50 μm except for rabbit IgG isotype 
control images for which scale bar 10 μm. 
Other staining patterns for ZO-1 were also identified by ICC.  A small population of 
human primary astrocytes cultured in ScienCell Astrocyte Medium displayed 
cytoplasmic ZO-1 aggregates which were localised close to the cell membrane, 
Figure 3.8.  Proximate human primary astrocytes cultured in either medium also 
showed ZO-1 to be localised to intercellular strand-like structures, Figure 3.9. 
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Figure 3.8: ZO-1 Aggregates in Human Primary Astrocytes  ZO-1 cytoplasmic 
aggregate staining localised close to the cell membrane is occasionally seen in 
human primary astrocytes.  This staining pattern was only observed in human 
primary astrocytes cultured in ScienCell Astrocyte Medium.  Scale bar 10 μm. 
The ZO-1 aggregates shown in Figure 3.8 resemble the staining pattern produced 
by connexin 43 in primary murine cortical astrocytes (Duffy et al., 2004).  ZO-1 is 
known to bind to connexin 30 and connexin 43 in murine astrocytes, consequently 
this staining may suggest that ZO-1 interacts with gap junction connexin proteins in 
human primary astrocytes (Duffy et al., 2004; Penes et al., 2005).  
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Figure 3.9: ZO-1 Intercellular Contacts in Human Primary Astrocytes  ZO-1 
localises to intercellular contacts formed between proximate human primary 
astrocytes cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium 
(see arrows).  These contacts appear as thread or stand-like structures.  Scale bar 
10 μm. 
The intercellular ZO-1 strands shown in Figure 3.9 are structurally similar to ZO-2 
intercellular contacts made between vascular smooth muscle cells (VSMCs) 
(Tkachuk et al., 2011).  The association of ZO-1 with intercellular contacts is not 
surprising given the function of this protein.  It is, however, unclear with which 
proteins ZO-1 is associated in these intercellular structures. 
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The expression of occludin, claudin 5 and ZO-1 in human primary astrocytes was 
further investigated by western blotting.  Experiments comparing human primary 
astrocytes cultured in either ScienCell Astrocyte Medium or MEMα/F-10 medium 
were conducted using cells of the same passage number.  Occludin has a 
molecular weight of 59 kDa, however, occludin protein bands ranging between 62-
82 kDa are observed in western blots due to protein phosphorylation (Sakakibara et 
al., 1997).  Figure 3.10 shows a western blot characterising the expression of 
occludin in human primary astrocytes cultured in either ScienCell Astrocyte Medium 
or MEMα/F-10 medium.  This experiment was conducted using the anti-occludin 
rabbit polyclonal antibody.  The predicted molecular weight of occludin using this 
antibody is between 65-79 kDa.   
 
Figure 3.10: Western blot characterising Occludin expression in human 
primary astrocytes cultured in ScienCell Astrocyte Medium and MEMα/F-10 
Medium  This experiment was conducted using an anti-occludin rabbit polyclonal 
antibody (Thermo 71-1500).  This blot includes a HUVEC positive control and an α-
Tubulin loading control.  Molecular weight markers are indicated (kDa).  
A clear 65 kDa protein band at the predicted molecular weight for occludin was 
observed in human primary astrocytes cultured in ScienCell Astrocyte Medium and 
the HUVEC positive control.  This supports the immunocytochemistry staining and 
confirms the expression of occludin in human primary astrocytes.  The molecular 
weight of this band suggests that occludin is phosphorylated in these cells.   A very 
faint 65 kDa band is present in astrocytes cultured in MEMα/F-10 medium.  
Although the ICC staining for occludin in either medium appears similar, the western 
blot suggests that this protein is not highly expressed in astrocytes cultured in 
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MEMα/F-10 medium.  A 40 kDa protein band was also observed in every astrocyte 
sample as well as the HUVEC positive control.  This band could be the product of 
proteolysis or non-specific binding.   
The nuclear localisation of occludin which was identified by ICC was further 
investigated by subcellular fractionation.  This experiment was conducted using 
human primary astrocytes cultured in ScienCell Astrocyte Medium as the cells 
appear to express higher levels of occludin when cultured in this medium.  The cells 
were fractionated into cytoplasmic and nuclear lysates, Figure 3.11. 
 
Figure 3.11: Subcellular Localisation of Occludin in Human Primary 
Astrocytes  Western blot of fractionated cytoplasmic and nuclear lysates from 
human primary astrocytes cultured in ScienCell Astrocyte Medium.  This experiment 
was conducted using an anti-occludin rabbit polyclonal antibody (Thermo 71-1500).  
The enrichment of cytoplasmic and nuclear fractions was determined using anti-
eEF2 and anti-SSRP1 antibodies resectively.  Molecular weight markers are 
indicated (kDa). 
The nuclear fraction exhibited occludin protein bands ranging between 65-75 kDa.  
A faint 75 kDa protein band was observed in the cytoplasmic fraction as well as two 
lower molecular weight protein bands between 45-55 kDa which were not previously 
observed in the whole cell lysate western blot, Figure 3.10.  These bands may be 
degradation products.  This would again suggest that occludin is phosphorylated in 
human primary astrocytes.   A strong 50 kDa protein band exclusive to the 
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cytoplasmic fraction was also observed.  The 40 kDa protein bands previously 
identified in Figure 3.10 was present in both cytoplasmic and nuclear fractions.   
Eukaryotic translation elongation factor 2 (eEF2) and structure specific recognition 
protein 1 (SSRP1) were used to determine the enrichment of the cytoplasmic and 
nuclear fractions.  eEF2 is a cytoplasmic protein involved in protein translation whilst 
SSRP1 is a nuclear protein which is a component of the FACT (facilitates chromatin 
transcription) complex (Belotserkovskaya et al., 2004; Browne and Proud, 2002).  
An SSRP1 protein band was exclusive to the nuclear fraction and demonstrated that 
there was no nuclear contamination present in the cytoplasmic fraction.  There 
were, however, faint eEF2 bands present in the nuclear fraction indicative of some 
cytoplasmic contamination. 
Claudin 5 is a 23 kDa protein.  The phosphorylation of claudin 5 is, however, known 
to produce higher molecular weight protein bands in western blotting experiments.  
21 kDa, 25 kDa, 31 kDa, 42 kDa and 62 kDa protein bands were previously 
observed in claudin 5 western blots using primary porcine brain capillary endothelial 
cell lysates (Ishizaki et al., 2003).  Phosphoamino acid analysis showed that the 25 
kDa band was due to claudin 5 serine phosphorylation whilst the 31 kDa protein 
band is due to threonine phosphorylation (Ishizaki et al., 2003).  It was speculated 
that the 42 and 62 kDa protein bands may be caused by claudin dimerisation, 
although this was not experimentally confirmed (Ishizaki et al., 2003).  A 27 and 29 
kDa claudin 5 doublet was also observed in Sprague-Dawley rat alveolar type II 
cells (Wang et al., 2003).  The 27 kDa protein band was considered to be claudin 5 
whilst the 29 kDa form was not subjected to any further investigation but was 
speculated to be a possible claudin 5 isoform or a product of post-translational 
modification (Wang et al., 2003).   
Figure 3.12 shows western blots characterising the expression of claudin 5 in 
human primary astrocytes cultured in either ScienCell Astrocyte Medium or 
MEMα/F-10 medium.  Panel A was produced with anti-claudin 5 rabbit monoclonal 
antibody (ab131259) whilst panel B was produced with anti-claudin 5 rabbit 
polyclonal antibody (ab15106).   
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Figure 3.12: Western blots of claudin 5 expression in human primary 
astrocytes cultured in ScienCell Astrocyte Medium and MEMα/F-10 Medium  
A) This experiment was conducted using an anti-claudin 5 rabbit monoclonal 
antibody (Abcam ab131259).  B) This experiment was conducted using anti-claudin 
5 rabbit polyclonal (Abcam ab15106).  Both blots include a HUVEC positive control 
and a β-Actin loading control.  Molecular weight markers are indicated (kDa). 
A 23 kDa claudin 5 protein band was seen only in the HUVEC positive control in 
both western blots, suggesting that claudin 5 is not expressed in human primary 
astrocytes.  This conclusion is, however, not supported by the immunocytochemistry 
staining which suggests that claudin 5 is diffusely expressed throughout the 
cytoplasm and nucleus of these cells.   
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The anti-claudin 5 rabbit polyclonal antibody (ab15106) was used in the ICC 
experiments and for the western blot shown in Figure 3.12 panel B.  The company 
datasheet for this antibody acknowledges the presence of additional 35 kDa protein 
bands which are attributed to possible non-specific binding.  Bands of around this 
molecular weight were observed in human primary astrocytes, Figure 3.12 panel B, 
and may be the result of non-specific binding.   
These bands are, however, of a similar molecular weight to the 31 kDa threonine 
phosphorylated claudin 5 protein band seen in primary porcine brain capillary 
endothelial cells (Ishizaki et al., 2003).  This might suggest that human primary 
astrocytes express phosphorylated claudin 5.  Given the current evidence, however, 
and in the absence of further investigation, it seems more likely that the claudin 5 
ICC staining is non-specific and that claudin 5 is not expressed in human primary 
astrocytes.  
ZO-1 is a 195 kDa protein, however, higher molecular weight forms of this protein 
have been observed in western blots due to protein phosphorylation (Anderson et 
al., 1988; Howarth et al., 1994).  Figure 3.13 shows a western blot characterising 
the expression of ZO-1 in human primary astrocytes cultured in either ScienCell 
Astrocyte Medium or MEMα/F-10 medium.  
 
Figure 3.13: Western blot of ZO-1 expression in human primary astrocytes 
cultured in ScienCell Astrocyte Medium and MEMα/F-10  This experiment was 
conducted using an anti-ZO-1 rabbit polyclonal antibody (Thermo 40-2200) This blot 
includes a HUVEC positive control and an α-Tubulin loading control.  Molecular 
weight markers are indicated (kDa). 
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A clear band of 250 kDa was observed in human primary astrocytes and the 
HUVEC positive control.  This supports the immunocytochemistry staining and 
confirms the expression of ZO-1 in human primary astrocytes.  The expression of 
this protein was not affected by the culture medium.  Several lower molecular weight 
protein bands were observed in astrocyte and HUVEC protein samples.  The 
antibody datasheet for the anti-ZO-1 rabbit polyclonal antibody used in this 
experiment acknowledges the presence of several lower molecular weight protein 
bands which are attributed to degradation products but may also be caused by 
shorter ZO-1 isoforms. 
3.2.3 Tight Junction Protein Expression in 1321N1 Astrocytoma cells 
The expression of occludin, claudin 5 and ZO-1 was also investigated in 1321N1 
human astrocytoma through immunocytochemistry and western blotting techniques.  
Figure 3.14 shows immunocytochemistry staining for occludin, claudin 5 and ZO-1 
in 1321N1 astrocytoma cells.  The negative and isotype controls for this experiment 
are shown in Figure 3.15. 
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Figure 3.14: Immunocytochemistry characterising the expression of Occludin, 
Claudin 5 and ZO-1 in 1321N1 human astrocytoma cells  Immunocytochemistry 
characterising the expression of occludin, claudin 5 and ZO-1 in the 1321N1 human 
astrocytoma cell line.  ALDH1L1 was included as an astrocyte marker.  The 
antibodies and dilutions used in this experiment: anti-ALDH1L1 rabbit polyclonal 
antibody (1:50), anti-occludin rabbit polyclonal antibody (1:50), anti-claudin 5 rabbit 
polyclonal antibody (1:50) and anti-ZO-1 rabbit polyclonal antibody (1:100).   Scale 
bar 10 μm. 
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Figure 3.15: ICC Negative and Isotype controls for 1321N1 Astrocytoma Cells  
Negative and isotype controls were conducted for rabbit antibodies.  The negative 
control consisted of the omision of the primary antibody.  The isotype control was 
conducted with a rabbit IgG antibody (Vector Laboratories) used at the same 
concentration as the primary antibody.  Scale bar 50 μm. 
1321N1 astrocytoma cells exhibited similar staining patterns for all three tight 
junction proteins to those previously seen in human primary astrocytes.  Occludin 
again presented with distinct nuclear punctate staining and diffuse cytoplasmic 
staining.  1321N1 astrocytoma cells did not exhibit any membrane-associated 
occludin staining.   
Claudin 5 was diffusely expressed throughout the cytoplasm and nucleus of 1321N1 
astrocytoma cells and again no membrane-associated claudin 5 staining was 
observed in these cells whilst ZO-1 presented with strong nuclear and cytoplasmic 
staining.  No staining was observed in the negative control and a very weak non-
specific background staining was seen in the rabbit IgG isotype control.  The 
expression of occludin, claudin 5 and ZO-1 in 1321N1 astrocytoma cells was further 
investigated by western blotting, Figure 3.16. 
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Figure 3.16: Western blots characterising the expression of Occludin, Claudin 
5 and ZO-1 in 1321N1 astrocytoma cells  A) Occludin western blot using anti-
occludin rabbit polyclonal antibody.  B) ZO-1 western blot using anti-ZO-1 rabbit 
polyclonal antibody.  C) Claudin 5 blot using anti-claudin 5 rabbit monoclonal 
antibody (ab131259).  D) Claudin 5 blot using anti-claudin 5 rabbit polyclonal 
antibody (ab15106).  All blots include a HUVEC positive control and either an α-
Tubulin or β-Actin loading control.  Molecular weight markers are indicated (kDa).   
Figure 3.16 panel A shows the western blot characterising the expression of 
occludin in 1321N1 astrocytoma cells.  A 75 kDa occludin protein band was 
observed in 1321N1 astrocytoma cells and the HUVEC positive control.  This 
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supports the immunocytochemistry staining and confirms the expression of occludin 
in 1321N1 astrocytoma cells.  The molecular weight of this protein band suggests 
that occludin is phosphorylated in these cells.  Higher molecular weight protein 
bands ranging from 100-150 kDa and a protein band just below 50 kDa were also 
observed in this blot.  The presence of these bands may indicate that this antibody 
is not very specific and that these bands are the result of non-specific antibody 
binding, however, these bands may also be caused by occludin dimers or 
oligomers. 
A study investigating occludin oligomerisation using protein extracts from rat 
cerebral microvessels showed western blots in which multiple high molecular weight 
protein bands above 100 kDa are present (McCaffrey et al., 2008).  These 
experiments used the same anti-occludin rabbit polyclonal antibody as the one used 
in the current project.  In this previous study, bands greater than 150 kDa were 
defined as occludin oligomers, whilst bands ranging from 100-120 kDa were 
considered to be occludin dimers (McCaffrey et al., 2008).  The higher molecular 
weight bands in Figure 3.16 panel A may, therefore, be produced by occludin 
dimers. 
Figure 3.16 panel C was produced with the anti-claudin 5 rabbit monoclonal 
antibody (ab131259) whilst panel D was produced with the anti-claudin 5 rabbit 
polyclonal antibody (ab15106).  A 23 kDa claudin 5 protein band was only seen in 
the HUVEC positive controls of both blots whilst the 1321N1 astrocytoma cells 
exhibited a non-specific protein band around 50 kDa.  These blots demonstrate that 
claudin 5 is not expressed in 1321N1 astrocytoma cells and suggest that the 
staining seen in Figure 3.14 is unlikely to be specific.  
A clear band of 250 kDa was observed in 1321N1 astrocytoma cells and the 
HUVEC positive control, Figure 3.16 panel B.  This supports the 
immunocytochemistry staining and confirms the expression of ZO-1 in these cells.  
Lower molecular weight bands were also observed in these cells and are likely to be 
caused by degradation products 
3.2.4 Tight Junction Protein Expression in Human Tissue 
Non-endothelial cell expression of occludin, claudin 5 and ZO-1 was investigated in 
vivo in the temporal cortex.  Details of the tissue cohort used for these experiments 
are disclosed in Table 2.6 .  This cohort consisted of 10 non-neurological control 
cases, 9 MCI cases and 10 AD cases.  
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3.2.4.1. Occludin Expression in vivo 
Figure 3.17 shows the immunoreactive profile of occludin in the temporal cortex in 
non-neurological control, MCI and AD cases.  The negative and isotype controls for 
this experiment are shown in Figure 3.18.  Neither of the controls exhibited any 
positive immunoreactivity.  Positive immunoreactivity associated with blood vessels 
was observed throughout the whole tissue cohort and in all cases.  This observation 
is expected given that occludin in a tight junction protein and a component of the 
blood brain barrier.   
Positive immunoreactivity was also observed in large pyramidal neurons localised to 
the cytoplasm and nucleus.  Examples of this staining pattern were also seen 
throughout the entire cohort and in all cases.  Positive nuclear immunoreactivity was 
also observed for occludin throughout the temporal cortex in all cases.  It was not 
possible to determine the type of cells with which these positive nuclei were 
associated with single-labelling alone.   
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Figure 3.17: Occludin Expression in the Temporal Cortex  Occludin expression 
in the human temporal cortex in non-neurological control, MCI and AD cases.  The 
anti-occludin rabbit polyclonal antibody (1:100) was used for this experiment.  
Positive occludin immunorecativity was observed in pyramidal neurones, blood 
vessels and nuclei in the cortex of control, MCI and AD cases.  Scale bar 50 μm. 
 
Figure 3.18: IHC Negative and Isotype Controls for Occludin  The occludin IHC 
experiment used an anti-occludin rabbit polyclonal antibody.  A negative and isotype 
control was conducted for this rabbit antibody.  The negative control consisted of the 
omision of the primary antibody.  The isotype control was conducted with a rabbit 
IgG antibody (Vector Laboratories) used at the same concentration as the primary 
antibody.  Scale bar 50 μm. 
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Dual-labelling immunohistochemistry was conducted to establish if occludin 
immunoreactivity co-localised with the astrocytic marker GFAP, Figure 3.19.  
Occludin-positive nuclei were found to co-localise with GFAP-positive astrocytes, 
Figure 3.19 panel B.  This demonstrates that occludin is expressed in the nucleus in 
human astrocytes in vivo.  Not all cases demonstrated this pattern of co-localisation 
and not all GFAP-positive cells co-localised with occludin immunoreactivity, Figure 
3.19 A. 
 
Figure 3.19: Astrocytic expression of Occludin in vivo  A) A case in which dual-
labelling shows no co-localisation of occludin (brown) with GFAP (red).  Scale bar 
50 μm.  B) A case in which dual-labelling shows co-localisation of occludin (brown) 
with GFAP (red), as indicated by the arrows.  Scale bar 50 μm.  
3.2.4.2. ZO-1 Expression in vivo 
Figure 3.20 shows the expression of ZO-1 in the temporal cortex in non-neurological 
controls, along with MCI and AD cases.  The negative and isotype controls for this 
experiment are shown in Figure 3.21.  Neither of the controls exhibited any positive 
immunoreactivity.  This observation is again expected given that ZO-1 is a tight 
junction protein and a component of the blood brain barrier.   
Positive immunoreactivity associated with blood vessels was observed throughout 
the whole tissue cohort and in all cases.  Positive immunoreactivity was also 
observed in large pyramidal neurons localised to the cytoplasm and nucleus.  
Examples of this staining pattern were seen throughout the entire cohort and in all 
cases. 
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Figure 3.20: ZO-1 Expression in the Temporal Cortex  ZO-1 expression in the 
human temporal cortex in non-neurological control, MCI and AD cases.  The anti-
ZO-1 rabbit polyclonal antibody (1:50) was used for this experiment.  Positive ZO-1 
immunorecativity was observed in pyramidal neurones, blood vessels and nuclei in 
the cortex of control, MCI and AD cases.  Scale bar 50 μm. 
 
Figure 3.21: IHC Negative and Isotype Controls for ZO-1  The ZO-1 IHC 
experiment used an anti-ZO-1 rabbit polyclonal antibody.  A negative and isotype 
control was conducted for this rabbit antibody.  The negative control consisted of the 
omision of the primary antibody.  The isotype control was conducted with a rabbit 
IgG antibody (Vector Laboratories) used at the same concentration as the primary 
antibody.  Scale bar 50 μm. 
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3.2.4.3. Claudin 5 Expression in vivo 
Figure 3.22 shows the expression of claudin 5 in the temporal cortex in non-
neurological controls, MCI and AD cases.  The negative and isotype controls for this 
experiment are shown in Figure 3.23.  Neither of the controls exhibited any positive 
immunoreactivity.  Claudin 5 immunoreactivity was associated exclusively with 
blood vessels.  No apparent immunoreactivity was associated with pyramidal 
neurons.   
 
Figure 3.22: Claudin 5 Expression in the Temporal Cortex  Claudin 5 expression 
in the human temporal cortex in non-neurological control, MCI and AD cases.  The 
anti-claudin 5 mouse monoclonal antibody (1:50) was used for this experiment.  
Positive claudin 5 immunorecativity was exclusively associated with blood vessels in 
the temporal cortex of control, MCI and AD cases.  Scale bar 50 μm. 
 
Figure 3.23:  IHC Negative and Isotype Controls for Claudin 5  The claudin 5 
IHC experiment used an anti-claudin 5 mouse monoclonal antibody.  A negative and 
isotype control was conducted for this mouse antibody.  The negative control 
consisted of the omision of the primary antibody.  The isotype control was 
conducted with a mouse IgG antibody (Vector Laboratories) used at the same 
concentration as the primary antibody.  Scale bar 50 μm. 
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3.2.5 Tight Junction Protein Expression in Neurons 
The neuronal staining observed in the tissue cohort for occludin and ZO-1 was 
further explored in vitro using Lund human mesencephalic (LUHMES) cells.  
LUHMES are neuronal precursor cells which have been immortalised by 
transformation with a myc oncogene.  These cells can be differentiated into post-
mitotic neurons following the introduction of factors which inhibit the myc transgene 
(Lotharius et al., 2005; Schildknecht et al., 2009).  LUHMES were cultured and 
provided by Irina Vasquez-Villasenor.   
Immunocytochemistry experiments were conducted to investigate neuronal 
expression of occludin, claudin 5 and ZO-1 in differentiated LUHMES cells, Figure 
3.24.  The negative and isotype controls for this experiment are shown in Figure 
3.25.  Occludin was diffusely expressed in the cytoplasm of the neuronal cell body 
with distinct nuclear punctate staining.  Claudin 5 and ZO-1 were diffusely 
expressed throughout the nucleus and cell body of the LUHMES.  All three proteins 
also showed axonal staining.  No staining is seen in either the omission of the 
primary antibody or the isotype control. 
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Figure 3.24: Immunocytochemistry characterising the expression of Occludin, 
Claudin 5 and ZO-1 in LUHMES  Immunocytochemistry characterising the 
expression of occludin, claudin 5 and ZO-1 in LUHME cells. β-3-Tubulin was used 
as a cell marker.  The antibodies and dilutions used in this experiment: anti- β-3-
tubulin chicken polyclonal (1:1000), anti-occludin rabbit polyclonal antibody (1:50), 
anti-claudin 5 rabbit polyclonal antibody (1:50) and anti-ZO-1 rabbit polyclonal 
antibody (1:100).  Scale bar 10 μm. 
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Figure 3.25: ICC Negative and Isotype controls for LUHMES  Negative and 
isotype controls were conducted for rabbit antibodies and a neagtvie control was 
conducted for the chicken antibody.  A chicken IgG isotype could not be conducted 
due to the inavailability of an chicken IgG antibody.  The negative controls consisted 
of the omision of the primary antibody.  The rabbit isotype control was conducted 
with a rabbit IgG antibody (Vector Laboratories) used at the same concentration as 
the primary antibody.  Scale bar 50 μm. 
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3.3 Discussion 
The initial aims of this study were to characterise the expression of occludin, claudin 
5 and ZO-1 in human primary astrocytes and 1321N1 astrocytoma cells as well as 
to define the cellular localisation of these proteins in the temporal cortex and 
investigate whether the expression of these proteins is altered in MCI and AD cases 
compared with controls.   
3.3.1 Astrocyte Culture Medium  
The level of expression of both vimentin and nestin were the same in human 
primary astrocytes cultured in either ScienCell Astrocyte Medium MEMα/F-10 
medium.  The level of GFAP expressed by human primary astrocytes appears to 
fluctuate but overall there is statistically no significant difference in the expression of 
this protein between human primary astrocytes cultured in either ScienCell 
Astrocyte Medium or MEMα/F-10 medium.   
The ICC for GFAP showed that only a small proportion of astrocytes in the 
population expressed this protein.  Although GFAP is a commonly used astrocyte 
marker, not all human astrocytes are GFAP-positive (Sofroniew and Vinters, 2010).  
Currently there is no definitive marker capable of labelling all human astrocyte 
populations.  GFAP is the major intermediate filament expressed in the adult human 
brain whilst vimentin is the major intermediate filament in the neonatal brain 
(Middeldorp and Hol, 2011).  Studies vary regarding the age at which GFAP begins 
to be expressed in glia in the foetal brain and it appears that the expression of this 
protein also varies between brain areas (Middeldorp and Hol, 2011).  The human 
primary astrocytes used in the current project are embryonic cells isolated from the 
cerebral cortex.  This may account for the limited GFAP staining observed in these 
cells as, being embryonic, they may not have developed sufficiently for GFAP 
expression.   
The expression of occludin in human primary astrocytes was affected by the culture 
medium as western blotting showed higher levels of this protein to be expressed in 
cells cultured in ScienCell Astrocyte Medium compared with MEMα/F-10 medium.  
ZO-1 expression does not appear to be affected by the cell culture medium.  The 
difference in occludin expression may be attributable to the differences in media 
composition.  ScienCell Astrocyte Medium contains 10 mM of L-glutamine whilst 
MEMα/F-10 medium only contains 1.5 mM.  L-Glutamine is an amino acid which is 
essential for cell growth and has been identified, along with glucose, as an 
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important substrate for the progression of the cell proliferation cycle (Colombo et al., 
2011).  The amount of glucose is the same in both media but higher levels of 
glutamine may enhance the proliferation of astrocytes cultured in ScienCell 
Astrocyte Medium which in turn may have an effect upon the level of occludin 
expressed in these cells. 
3.3.2 Occludin Expression in Astrocytes 
The ICC and western blotting data demonstrate that occludin is expressed in both 
human primary astrocytes and in the 1321N1 astrocytoma cell line.  The western 
blots would also suggest that occludin is phosphorylated in these cells.  Occludin is 
a tight junction integral membrane which is predominantly associated with cell 
membrane in endothelial cells (Furuse et al., 1993; Kohaar et al., 2010).  Neither 
human primary astrocytes nor 1321N1 astrocytoma cells, however, appeared to 
exhibit any membrane-associated occludin expression.  Instead occludin presented 
with nuclear punctate staining in both human primary astrocytes and 1321N1 
astrocytoma cells. 
The astrocytic nuclear expression of occludin observed in vitro is supported by 
observations in vivo as occludin was seen to co-localise with GFAP-positive 
astrocytes in the temporal cortex.  This project’s in vivo findings confirm that the 
astrocytic occludin expression observed in vitro is not an artefact of cell culture and 
is a real physiological observation.  Nuclear astrocytic occludin expression has been 
previously observed in a study investigating occludin expression in the frontal cortex 
and basal ganglia of control, VD and AD cases (Romanitan et al., 2007).  
The mechanism by which occludin is able to translocate across the nuclear 
membrane is not known.  The PSORTII program was used to analyse the occludin 
peptide sequence for possible nuclear localisation sequences, however, none were 
identified (Surapornsawasd et al., 2015).  Similarly occludin is not known to express 
any nuclear export signals.  The mechanism by which occludin is able to enter the 
nucleus therefore remains to be established.  It is possible that occludin may be 
able to translocate between the cytoplasm and the nucleus by binding to proteins 
which themselves have NLS or NES signals. 
Human primary astrocytes and 1321N1 astrocytoma cell occludin western blots also 
exhibited other bands.  These bands may simply be due to nonspecific antibody 
binding, but some of them correspond to the molecular weights of known occludin 
isoforms.  The datasheet for the anti-occludin rabbit polyclonal 71.1500 antibody 
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used for the ICC and western blotting experiments in this study does not disclose 
any information concerning occludin isoforms.  The immunogen used to generate 
this antibody was a fusion protein containing the C-terminal membrane-distal 
domain of human occludin protein.  Occludin isoform OCLN-ex3p-9pdel has 
completely lost the membrane-distal C-terminal domain (Kohaar et al., 2010), 
therefore the antibody used in this study will not detect this isoform.  All other 
occludin isoforms express this domain, except for isoforms OCLN-ex7ext which 
lacks amino acids 476-522 causing the partial loss of the membrane distal C-
terminal domain (Kohaar et al., 2010).  The ability of this antibody to detect this 
occludin isoform is, therefore, uncertain. 
The ICC images show cytoplasmic occludin localisation.  There are also strong 
bands around 50 kDa in the cytoplasm and not in the nucleus in the fractionation 
blot.  These bands could be attributable to occludin isoforms OCLN-ex4del or 
OCLN-ex7ext which are 52 and 54 kDa are respectively.  In the case of OCLN-
ex4del, amino acids 244-297 are missing resulting in the loss of the fourth 
transmembrane domain (Kohaar et al., 2010).  The cellular localisation of occludin 
isoforms in transfected HeLa cells shows that OCLN-ex7ext predominantly localises 
at the cell membrane, whilst isoforms lacking either part or the entirety of the 
MARVEL domain tend to be localised in the cytoplasm (Kohaar et al., 2010).  The 
astrocytic expression of OCLN-ex4del, therefore, appears more likely as the ICC 
does not show any membrane-associated occludin localisation in astrocytes.  The 
localisation of occludin to both the cytoplasm and nucleus but not the cell 
membrane is perhaps indicative of a complete or partial loss of the MARVEL 
domain in astrocytic occludin.    
Similar to human primary astrocytes, a band of around 50 kDa is also present in the 
1321N1 astrocytoma cell line.  This band is also present within the HUVEC positive 
control and may suggest the presence of either OCLN-ex4del or OCLN-ex7ext.    
A 40 kDa band was also observed in the human primary astrocyte whole cell lysate 
blot as well as in the cytoplasmic and nuclear fractions of the fractionation blot.  
Occludin isoform OCLN-ex3del is 31 kDa and lacks amino acids 1-251 resulting in 
the complete loss of the MARVEL domain.  It is possible that this isoform may be 
expressed in astrocytes.  It is, however, possible that astrocytes express unique 
isoforms which have not yet been characterised.   
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3.3.3 Claudin 5 Expression in Astrocytes 
The current project concludes that claudin 5 is not expressed in either human 
primary astrocytes of 1321N1 astrocytoma cells.  The ICC suggests that claudin 5 is 
diffusely expressed throughout the cytoplasm and nucleus in both human primary 
astrocytes and the 1321N1 astrocytoma cells, however, the western blots do not 
corroborate this expression and would suggest that the ICC staining is non-specific.  
Although there are higher molecular weight bands present in some of the claudin 5 
western blots which may be accounted for by post-translational modifications and 
the possible dimerisation of this protein, the current evidence would suggest that 
claudin 5 is not expressed in these cells.  
This conclusion is supported by the current in vivo study and previous research in 
which claudin 5 expression is exclusively associated with endothelial cells (Simpson 
et al., 2010).  Another study, however, contradicts this conclusion as claudin 5 has 
been shown to be expressed in both astrocytes and neurons in the frontal cortex of 
both AD and VD cases as well as non-neurological controls (Romanitan et al., 
2010).  This study found no significant increase in the ratio of astrocytes expressing 
claudin 5 between AD and VD cases compared with non-neurological controls 
(Romanitan et al., 2010).  The study did not conduct any dual-labelling 
immunohistochemistry and the criteria by which astrocytic occludin-positive nuclei 
were distinguished from other cells in human tissue was not disclosed; 
consequently it is not certain if claudin 5 expression co-localises with astrocytes in 
this study (Romanitan et al., 2010).  
3.3.4 ZO-1 Expression in Astrocytes 
The ICC and western blotting data confirm that ZO-1 is expressed in both human 
primary astrocytes and 1321N1 astrocytoma cells.  The diffuse nuclear staining of 
ZO-1 exhibited by these cells is similar to the staining pattern seen in MDCK cells 
for this protein (González-Mariscal et al., 1999).  The nuclear expression of ZO-1 is 
confirmed by the in vivo study.  The astrocytic expression of ZO-1 in vivo has been 
previously confirmed by dual-labelling immunohistochemistry which shows the co-
localisation of ZO-1 with GFAP-positive astrocytes in human post-mortem tissue 
(Simpson et al., 2011). 
A small population of human primary astrocytes cultured in ScienCell Astrocyte 
Medium also exhibited cytoplasmic ZO-1 aggregates which were localised close to 
the cell membrane.  ZO-1 co-localises with connexin 43 aggregates in murine 
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cortical astrocytes which are structurally similar to the ZO-1 aggregates observed in 
the current study (Duffy et al., 2004).  ZO-1 also co-localises with connexin 30 and 
connexin 43 in murine astrocytes in vivo (Penes et al., 2005).  It is possible that ZO-
1 similarly localises with gap junction protein in human primary astrocytes.  
3.3.5 Tight Junction Protein expression in Neurons 
The current study shows occludin and ZO-1 to be expressed in the cytoplasm and 
nucleus of pyramidal neurons in vivo.  Occludin has previously been shown to be 
expressed in pyramidal neurons in human post-mortem tissue (Romanitan et al., 
2007).  ZO-1 is also expressed in neurons in mouse brain and co-localises with 
connexin 36 in these cells (Li et al., 2004).   
The identification of occludin and ZO-1 expression in human pyramidal neurons in 
vivo was further explored in vitro using LUHME cells.  Occludin exhibited the same 
punctate nuclear staining in these cells as that previously seen in astrocytes for this 
protein.  Occludin was also expressed diffusely throughout the cytoplasm and also 
appeared to be expressed in the neuronal axons of LUHME cells.   
ZO-1 exhibited a strong diffuse cytoplasmic and nuclear staining throughout LUHME 
cells.  ZO-1 also appeared to be expressed in the neuronal axons.  ZO-1 has 
previously been shown to be expressed in the dendrites of murine hippocampal 
neurons in vitro (Inagaki et al., 2003).  This protein has also been shown to be 
diffusely expressed throughout the cell body, axon and dendrites of rat hippocampal 
neurons in vitro (Komaki et al., 2013). 
The neuronal expression of claudin 5 remains uncertain.  The in vivo study shows 
that claudin 5 expression is exclusively associated with endothelial cells, however, 
this observation is contradicted by previous research in which claudin 5 is shown to 
be expressed in both pyramidal neurons and astrocytes in the frontal cortex 
(Romanitan et al., 2010).   
In vitro, claudin 5 appears to be expressed throughout the cytoplasm, nucleus and 
axons of LUHME cells.  The reliability of this staining is, however, uncertain as the 
LUHMES ICC experiment was conducted using the same anti-claudin 5 rabbit 
polyclonal antibody (ab15106) which was previously used in the ICC experiments 
characterising the expression of claudin 5 in human primary astrocyte and 1321N1 
astrocytoma cells.  The staining produced by this antibody in both human primary 
astrocyte and 1321N1 astrocytoma cells was not supported by the western blots, 
95 
 
consequently it was concluded that the staining produced by the anti-claudin 5 
rabbit polyclonal antibody (ab15106) was non-specific.  The claudin 5 staining 
exhibited in the LUHME cells may, therefore, also be a result of non-specific 
antibody binding.  Future research into the neuronal expression of tight junction 
proteins should include western blotting experiments.  Given the current evidence, 
however, it must be concluded that the neuronal expression of claudin 5 remains 
unknown. 
3.3.6 Tight Junction Protein Expression and Alzheimer’s Disease 
Another of this study’s aims was to investigate whether there were any changes in 
tight junction protein expression in MCI and AD cases compared with controls.  
Previous research has shown that there is a significant increase in the ratio of 
neurons which express occludin in the frontal cortex and basal ganglia in AD and 
VD cases compared with controls (Romanitan et al., 2007).  A qualitative analysis 
also concluded that there are more occludin positive astrocytes in AD and VD cases 
compared with non-neurological controls (Romanitan et al., 2007).  The same 
cohort was also used to investigate the expression of claudin 2, claudin 5 and 
claudin 11 in the frontal cortex (Romanitan et al., 2010).  This study found that there 
was a significant increase in the ratio of pyramidal neurons expressing all three 
claudins in AD and VD cases compared with controls whilst there was a significant 
increase in the ratio of astrocytes expressing claudin 2 and claudin 11, but not 
claudin 5, in AD and VD cases compared with controls (Romanitan et al., 2010).   
Both of these studies suggest that the pathogenesis of two neurological diseases 
may be associated with an increase in tight junction protein expression in astrocytes 
and neurons.  Neither of these studies, however, conducted any dual-labelling 
immunohistochemistry and the criteria by which astrocytic nuclei were distinguished 
from other cells in human tissue was not disclosed.  The size of the cohort used in 
these studies was also very small. 
The cohort used in the current project was larger than the ones used in previous 
research and it was hoped that a greater understating of tight junction protein 
expression in relation to AD pathogenesis might be obtained.  The poor and often 
faint quality of the IHC staining obtained in this project meant, however, that the 
staining was too difficult to quantify and consequently this research objective could 
not be fulfilled. 
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In summary, the current study has shown the cytoplasmic and nuclear expression of 
occludin and ZO-1 in human primary astrocytes and 1321N1 astrocytoma cells.  
The astrocytic and nuclear expression of occludin is further supported by an in vivo 
study involving human post-mortem tissue.  The in vivo study also shows occludin 
and ZO-1 to be expressed in pyramidal neurons, an observation which is 
corroborated by the expression of these two proteins in cultured human neurons.  
There is considerable contradictory evidence, both in vitro and in vivo, concerning 
the astrocytic and neuronal expression of claudin 5 however this study concludes 
that claudin 5 is not expressed in human astrocytes. 
The nuclear expression of occludin was particularly interesting and function of this 
protein in astrocytes was the focus of further investigation.  The subsequent aim of 
this project was to elucidate the function(s) of this protein in astrocytes through the 
identification of protein binding partners. 
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4. Recombinant Proteins & Pull-
Down Assay Development 
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4.1 Introduction 
In vitro characterisation of TJP expression demonstrated both cytoplasmic and 
nuclear expression of occludin and ZO-1 in human primary astrocytes and 1321N1 
astrocytoma cells.  The function(s) of these proteins in astrocytes, however, remains 
undetermined.  The absence of membrane association suggests that these proteins 
do not form tight junction complexes in astrocytes.  It is known that ZO proteins do 
not function solely as scaffolding proteins but localise to the nucleus and interact 
with many different nuclear proteins including transcription factors in MDCK cells 
(Betanzos et al., 2004; Huerta et al., 2007).  The nuclear localisation of occludin 
indicates that this protein may have functional capabilities beyond the tight junction 
complex.  The potential involvement of occludin in nuclear processes such as 
transcription is supported by the ELL homology in the membrane-distal domain of 
occludin’s C-terminus (Li et al., 2005b).   
Having demonstrated the astrocytic and nuclear expression of occludin in vitro and 
in vivo, the current study aimed to elucidate possible functions of occludin in 
astrocytes by identifying binding partners for this protein.  Previous research has 
used either antibodies or tagged-proteins to develop co-immunoprecipitation or 
binding assays to identify binding partners for TJPs.  Cx30 and Cx43 were found to 
co-immunoprecipitate with ZO-1 from homogenised mouse brain tissue in 
experiments utilising a ZO-1 antibody and protein A-coated agarose beads (Penes 
et al., 2005).  Epsin-1, Esp15 and Hrs were found to co-immunoprecipitate with 
occludin from BREC lysates using an occludin antibody and protein G-sepharose 
beads (Murakami et al., 2009). 
The region within the C-terminal domain of occludin which binds to ZO-1 was 
identified though a pull-down binding assay involving GST fusion proteins of wild 
type and mutant human occludin (aa371-522) (Li et al., 2005b).  The interaction 
between occludin and dynamin was also established by co-transfecting FLAG-
tagged occludin domains with GFP-tagged dynamin into 293T cells, a human kidney 
epithelial cell line.  Immunoprecipitation experiments involving anti-FLAG M2 affinity 
resin demonstrated that some of the FLAG-occludin proteins precipitate GFP-
dynamin. (Liu et al., 2010).   
In the experiments outlined in Chapter 2, co-immunoprecipitation was trialled to 
identify novel binding partners of occludin in astrocytes.  These experiments utilised 
two commercially available anti-occludin antibodies but neither were able to reliably 
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immunoprecipitate occludin from either human primary astrocyte or 1321N1 
astrocytoma cell lysates.  Consequently this line of investigation was terminated.  
The subsequent approach was to develop a pull-down protein binding assay using 
GB1-6His-tagged recombinant occludin proteins and IgG beads.  GB1 is derived 
from protein G and binds with a high affinity to IgG.  This allows for stringent 
washing during the pull-down protein binding assay experiment thus reducing the 
likelihood of non-specific protein binding.  The presence of six histidines (6His) 
within this tag allows for the efficient purification of the tagged recombinant proteins. 
Initially an IMAGE clone of the occludin cDNA sequence was purchased and 
primers were designed to PCR amplify full length occludin (OCLN 1-522) as well as 
the cytoplasmic N-terminal (OCLN 1-65) and C-terminal (OCLN 271-522) domains 
using a pET24b-GB1-6His plasmid and the DH5α E. coli strain.  GB1-6His-tagged 
recombinant proteins for occludin aa1-522 (GB1-OCLN), occludin N-terminal 
domain aa1-65 (GB1-OCLN_N) and occludin C-terminal domain aa271-522 (GB1-
OCLN_C) were subsequently generated by the BL21-RP E. coli strain.  These 
proteins were then extracted and purified for use in the development of a pull-down 
protein binding assay in which any proteins which bound to the occludin constructs 
were eluted, subjected to SDS-polyacrylamide gel electrophoresis and identified by 
mass spectrometry analysis.  This chapter highlights the detailed strategic approach 
through which the recombinant proteins were generated and outlines the 
optimisation of the pull-down protein binding assay protocol.
100 
 
4.2 Results 
4.2.1 Molecular Cloning of Occludin constructs 
Figure 4.1 shows the successful PCR amplification of full length occludin (OCLN 1-
522), N-terminal (OCLN 1-65) and C-terminal (OCLN 271-522) domain sequences.  
OCLN 1-65 is 195 bp, OCLN 1-522 is 1566 bp and OCLN 271-522 is 753 bp.  The 
N-terminal band appears less intense because it is masked by the dye front 
produced by the 6x Laemmli buffer.  These bands were excised and purified as 
described in 2.9.7.   
 
Figure 4.1: PCR for OCLN 1-65, OCLN 1-522 and OCLN 271-522  This agarose 
gel shows the successful amplification of the DNA sequences for the occludin N-
terminal domain (OCLN 1-65), occludin full length (OCLN 1-522) and occludin C-
terminal domain (OCLN 271-522).  OCLN 1-65 is 195 bp, OCLN 1-522 is 1566 bp 
and OCLN 271-522 is 753 bp.  Ladder markers in bp. 
The three occludin DNA sequences were digested using NdeI and XhoI enzymes 
and ligated into the pET24b-GB1-6His vector followed by transformation into the 
DH5α E. coli strain.  Transformants were inoculated and analysed through a spin 
miniprep and restriction digest to establish the presence of the correct insert.  Figure 
4.2 shows the restriction digestion of three OCLN 1-65 transformants.  A 195 bp 
DNA band was present in all three transformants confirming the presence of the 
OCLN 1-65 insert.  Each lane also contained a larger 5.5 kbp DNA band produced 
by the pET24b-GB1-6His plasmid.  The DNA sequences of all three inserts were 
verified by Sanger sequencing prior to recombinant protein expression in the BL21-
RP E. coli strain.  The Sanger sequencing was conducted by Source Bioscience. 
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Figure 4.2: NdeI/XhoI restriction digest of bacterial transformants  This 
agarose gel shows the restriction digest of three DH5α colonies after bacterial 
transformation with pET24b-GB1-6His-OCLN 1-65 using by NdeI/XhoI restriction 
enzymes.  All three colonies have the correct insert for OCLN 1-65 with a band of 
195 bp.  The 5.5 kbp DNA band is the pET24b-GB1-6His vector.  Ladder markers in 
bp. 
4.2.2 Recombinant Protein Expression  
The plasmids containing OCLN 1-65, OCLN 1-522 and OCLN 271-522 DNA 
sequences were transformed into the BL21-RP E. coli strain.  This bacterial strain 
was used to express full length occludin (GB1-OCLN) occludin N-terminal domain 
(GB1-OCLN_N) and occludin C-terminal domain (GB1-OCLN_C) recombinant 
proteins.  These proteins were purified from the bacteria and analysed by SDS-
polyacrylamide gel electrophoresis. 
GB1-OCLN_N and GB1-OCLN_C recombinant proteins were successfully purified 
from the bacteria, Figure 4.3 panel A.  Occludin’s N-terminal domain is 7.57 kDa 
and occludin’s C-terminal domain is 29.39 kDa whilst the GB1-6His tag has a 
molecular weight of 10 kDa, consequently GB1-OCLN_N should produce a 17 kDa 
protein band whilst GB1-OCLN_C should produce a protein band around 40 kDa.  
Panel A shows that the GB1-OCLN_C recombinant protein produced a single 
protein band of around 45 kDa.  The GB1-OCLN_N recombinant protein produced 
several protein bands the highest band of which is the correct molecular weight for 
GB1-OCLN_N (17 kDa) the lower protein bands are probably due to protein 
degradation.   
Figure 4.3 panel B shows the purification of GB1-OCLN.  It was anticipated that 
difficulties would be encountered in the purification of GB1-OCLN due to the size 
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and hydrophobicity of the occludin protein.  Consequently, a sample of the bacterial 
pellet was also analysed in this experiment.  The purified GB1-OCLN recombinant 
protein should weigh approximately 69 kDa.  There were faint bands around this 
height in the purified sample.  A strong band of this molecular weight was also 
present within the bacterial pellet which suggests that most of the GB1-OCLN 
recombinant protein is insoluble.  The inclusion of a bacterial pellet from uninduced 
cells in this experiment, however, would have given a clearer indication of bacterial 
protein expression.   
There were also many other bands present within the purified GB1-OCLN lane 
indicating that this protein is not stably expressed by the bacteria.  These bands 
may be the product of protein degradation or could be the product of abortive 
translation as occludin is a large protein for E. coli expression. 
 
Figure 4.3: Purified recombinant proteins  A) Purified GB1-OCLN_N and GB1-
OCLN_C recombinant proteins which were expressed by BL21-RP E. coli.  B) 
Purification of GB1-OCLN.  This recombinant protein was insoluble and remained in 
the bacterial pellet.  Molecular weight markers are indicated (kDa). 
Western blots utilising antibodies with epitopes located in either the N- or C-terminal 
domain of occludin were also used to confirm the size and successful expression of 
GB1-OCLN_ N and GB1-OCLN_C recombinant proteins.  A protein sample of GB1-
OCLN_N was used to produce western blot which was probed with the anti-occludin 
rabbit monoclonal antibody (ab167161) Figure 4.4 panel A. The epitope for this 
antibody is located in in the N-terminal domain of occludin.  A protein sample of 
GB1-OCLN_C was similarly used to produce western blot which was probed with 
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the anti-occludin rabbit polyclonal antibody (71.1500) Figure 4.4 panel B.  The 
epitope for this antibody is located in the C-terminal domain of occludin.   
The GB1-OCLN_N recombinant protein was recognised by its specific antibody and 
produced a protein band just above 15 kDa.  There were also two lower molecular 
weight bands which are possibly due to protein degradation.  Faint bands around 30 
kDa were also visible.  The GB1-OCLN_C recombinant protein was also recognised 
by its specific antibody and produced a protein band of approximately 45 kDa which 
corresponds with the size of the protein seen in Figure 4.3 panel A.  Lower 
molecular weight bands were also present and are likely to be the result of protein 
degradation. 
 
Figure 4.4: Western blots of GB1-OCLN_N and GB1-OCLN_C  A) Western blot 
of GB1-OCLN_N probed with anti-occludin rabbit monoclonal antibody (ab167161).  
B) Western blot of GB1-OCLN_C probed with anti-occludin rabbit polyclonal 
antibody (71-1500).  Molecular weight markers are indicated (kDa). 
4.2.3 GB1-OCLN localisation in BL21-RP Bacteria 
The difficulties encountered in purifying the GB1-OCLN recombinant protein 
suggest that this protein may be trapped in inclusion bodies in the bacteria.  
Inclusion bodies are dense insoluble protein aggregates located typically within the 
bacterial cytoplasm which are generated during high levels of heterologous protein 
expression (Singh and Panda, 2005).  The aggregates are generated by the 
oligomerisation of partially folded or misfolded proteins although proteins containing 
disulphide bonds are particularly susceptible to aggregation because the reducing 
environment of the bacterial cytosol disrupts the formation of these bonds (Langley 
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et al., 1987; Singh and Panda, 2005).  Protein hydrophobicity is another factor 
which contributes to inclusion body formation with highly hydrophobic proteins being 
more susceptible to aggregation (Singh and Panda, 2005).  The hydrophobicity of 
occludin due to the MARVEL domain and the presence of a conserved disulphide 
bridge within ECL2 suggests that the GB1-OCLN protein may be vulnerable to 
aggregation and entrapment within inclusion bodies.  It could also be hypothesised 
that, due to the hydrophobicity of occludin, the GB1-OCLN recombinant protein may 
localise to the bacterial cell envelope.  An exploratory ICC experiment was trialled to 
investigate the localisation of the GB1-OCLN recombinant protein in these cells.   
The method for this experiment is outlined in 2.10.  Figure 4.5 shows a panel of ICC 
images for GB1-OCLN expression in BL21-RP E. coli.  The rod-shaped appearance 
of the bacterial cells was clearly defined and a faint punctate staining extending out 
from the bacterial envelope reminiscent of bacterial flagella was also observed, 
Figure 4.6 panel C and D.  The method used to stain bacteria was adapted from a 
previous study and the images shown in Figure 4.4 suggest that this method is 
successful (Jose et al., 2005).  This experiment has limitations, however, as 
negative and isotype controls were not included.  Any future experiments should 
include these controls to confirm that the bacterial staining is specific.  Although 
these images suggest that GB1-OCLN protein is expressed in these cells, the 
localisation of this protein cannot be determined as the microscope used was 
insufficiently powerful to define either the bacterial cell envelope or identify inclusion 
bodies.  Further exploration of GB1-OCLN bacterial protein expression should utilise 
a confocal microscope.   
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Figure 4.5: Immunocytochemistry of BL21-RP E.coli expressing GB1-OCLN  
Panels A and B show possible localisation of GB1-OCLN protein in the bacterial 
envelope of BL21-RP E. coli.  Panels C and D show punctate staining extending out 
from the bacterial envelope possibly indicating localisation of the GB1-OCLN protein 
with bacterial flagella.  Scale bar 10 μm    
4.2.4 Pull-down Assay Development 
The successful purification of GB1-OCLN_N and GB1-OCLN_C recombinant 
proteins enabled the development of a pull-down protein binding assay to identify 
occludin protein binding partners in astrocytes.  Every pull-down protein binding 
assay was conducted using 1321N1 astrocytoma cell lysates.  
4.2.4.1. The effect of the presence or absence of EDTA or CaCl2  
The aim of this experiment was to determine whether protein binding to either GB1-
OCLN_N or GB1-OCLN_C was affected in the presence or absence of EDTA or 
CaCl2.  Prior to 1321N1 lysis, either 1 mM EDTA or 1 mM CaCl2 was added to the 
lysis buffer.  The samples were analysed by SDS-polyacrylamide gel 
electrophoresis and the gel was initially stained with InstantBlue coomassie, Figure 
4.6 A, followed by a silver stain, Figure 4.6 B.   
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Figure 4.6: Pull-down assay using GB1-OCLN_N and GB1-OCLN_C in the 
presence or absence of EDTA or CaCl2  This figure shows a pull-down assay gel 
in which either EDTA or CaCl2 was added to the lysis buffer to determine the effect 
on the eluted proteins.  The gel was initially stained with InstantBlue coomassie (A) 
and then a silver stain (B).  This experiment was condicted using a 12% resolving 
gel with a 4% stacking gel.  Molecular weight markers are indicated (kDa). 
Figure 4.6 panel B shows that higher molecular weight protein bands located 
between the 66.2 and 116.6 kDa ladder markers were detected with the silver stain 
which were absent in the coomassie stained gel.  The silver stain also detected 
more protein bands between the 14.4 and 21.5 kDa ladder markers compared with 
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the InstantBlue coomassie.  This is due to the fact that the silver stain is a more 
sensitive method for protein detection.  There were, however, no bands specific to 
either GB1-OCLN_N or GB1-OCLN_C compared with the GB1 control.  This may 
suggest that the proteins observed in this experiment are not binding to occludin but 
are instead binding to the GB1-6His tag.   
A comparison between the EDTA and CaCl2 samples does not appear to show any 
differences when stained with InstantBlue coomassie, Figure 4.6 panel A.  The 116 
kDa band detected by the silver stain in panel B is more intense in CaCl2 treated 
lysates for both GB1-OCLN_N and GB1-OCLN_C, which may suggest that calcium 
enhances protein binding to occludin.  This band is, however, also present in the 
GB1 control, consequently another interpretation is that the 116 kDa protein binds to 
GB1 and that this interaction is enhanced in the presence of calcium.  These 
experiments did not include a CaCl2-treated GB1 control.  In the absence of this 
control, it is not possible to determine whether calcium enhances protein binding 
specifically to occludin or non-specifically to the GB1 tag.  Consequently, the effect 
of CaCl2 on occludin protein binding remains ambiguous.  
4.2.4.2. Buffer Composition Optimisation 
Buffer compositions were trialled during the development of this assay to determine 
the optimal conditions for protein identification and detection.  Figure 4.7 shows a 
silver stained gel produced from a pull down assay using different buffer 
compositions.  1321N1 astrocytoma cells were treated with 5 mM CaCl2 and 4 μM 
A23187 prior to lysis. 
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Figure 4.7: GB1-OCLN_C Pull-down assay  This figure shows a silver stained gel 
produced from a pull-down assay utilising a different wash buffer and lysis buffer 
composition.  The 1321N1 cells used in this experiment were treated with 5 mM 
CaCl2 and 4 μM A23187 prior to lysis.  This experiment was conducted using a 12% 
resolving gel with a 4% stacking gel.  Molecular weight markers are indicated (kDa). 
4.2.4.3. Mass Spectrometry Analysis – Gels 
Figure 4.8 shows the two gels which were submitted for mass spectrometry 
analysis.  Panel A shows the pull-down binding assay conducted using GB1-
OCLN_C whilst panel B was conducted using GB1-OCLN_N.  Both assays were run 
with a GB1-6His control which was also subjected to mass spectrometry analysis.  
The silver stain is not compatible with mass spectrometry analysis, consequently, 
although this stain was used during pull-down protein binding assay optimisation, 
the gels sent for mass spectrometry analysis were stained with InstantBlue 
coomassie.     
Although there are no clear differences between either of the occludin-tagged 
eluates and the GB1-6His control, subtle difference beyond the detection of the 
InstantBlue coomassie may be present, consequently these gels were taken 
forward for exploratory mass spectrometry analysis to identify candidate occludin 
binding partners.  
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Figure 4.8: GB1-OCLN_C and GB1-OCLN_N pull-down protein binding assay 
gels sent for Mass Spectrometry Analysis  A) GB1-OCLN_C pull-down protein 
binding assay gel.  B) GB1-OCLN_N pull-down protein binding assay gel.  Both gels 
were stained with InstantBlue coomassie.  These experiments were conducted 
using a 12% resolving gels with a 4% stacking gel.  Molecular weight markers are 
indicated (kDa). 
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4.3  Discussion 
The data presented in this chapter outlines the detailed, strategic approach used to 
generate GB1-6His tagged recombinant occludin proteins and develop a pull-down 
protein binding assay designed to find putative occludin binding partners in 
astrocytes.  The pull-down protein binding assays were conducted using 1321N1 
astrocytoma cell lysates instead of human primary astrocytes due to time 
constraints and financial implications associated with difficulties in obtaining 
sufficient material from human primary astrocytes for the assay.   
4.3.1 Pull-down Protein Binding Assay Optimisation 
Calcium was incorporated into the pull-down protein binding assay optimisation 
experiments to explore the effect of this ion on protein binding.  Calcium is 
fundamental to astrocytic function as it through calcium transients that astrocytes 
are able to functionally engage in the tripartite synapse and in neurovascular 
coupling signalling mechanisms.   
Initially, 1321N1 astrocytoma cell lysates were treated either with EDTA and CaCl2.  
EDTA is a chelator capable of sequestering metal ions including Ca2+ whilst CaCl2 
stimulates the cells.  In this experiment more proteins were detected in the pull-
down assay in the presence of CaCl2 ions.  This may suggest that calcium 
enhances protein binding to occludin, however, because this experiment did not 
include a CaCl2-treated GB1 control the effect of CaCl2 on occludin protein binding 
remains ambiguous.  Despite this ambiguity, the pull-down assay protocol was 
adapted to incorporate a cellular incubation prior to lysis with CaCl2 and A23187, an 
ionophore.   
Ionophores are lipophilic complexing agents which are capable of reversibly binding 
ions and transporting them across membranes (Bakker et al., 1997).  A23187 has 
been previously used in research exploring the physiological effects of Ca2+ ions.  
A23187 was utilised in research investigating the role of Ca2+ on the interaction 
between amyloid precursor protein (APP) and Homer3 in HEK293 cells (Kyratzi and 
Efthimiopoulos, 2014).  This ionophore was also used in research involving primary 
rat cortical astrocytes and C6 rat glioma cells exploring the effect of Ca2+ on 
signalling mechanisms (Köller et al., 2001; Oya et al., 2013).  
Research investigating mitochondrial function in primary rat cortical astrocytes has 
used 4-BrA23187, another calcium ionophore (Kahraman et al., 2011; Tan et al., 
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2011).  This ionophore, however, has a lower selectivity for Ca2+ ions and a higher 
selectivity for other divalent cations, Zn2+ and Mn2+, compared with A23187 (Erdahl 
et al., 1996; Wang et al., 1998).  Consequently, A23187 was considered to be the 
more suitable agent and was used in the pull-down assay to enhance astrocytic 
activation in response to CaCl2. 
The compositions of both the wash buffer and lysis buffer used in the pull-down 
assay were developed from a published protein binding assay protocol which was 
used in the identification of the ZO-1 binding surface in occludin (Li et al., 2005b).  
The lysis buffer used in the current study is compositionally identical to the 
published buffer except for the omission of 10 mM sodium pyrophosphate tetrabasic 
(Na4P2O7).  This compound was found to generate a white precipitate in the 
presence of CaCl2 which masked the beads, making it impossible to complete the 
assay. 
4.3.2 GB1-OCLN Purification  
Difficulties were encountered in the purification of the GB1-OCLN recombinant 
protein from the BL21-RP E. coli stain.  This may be due to the entrapment of this 
protein in inclusion bodies or the localisation of this protein to the bacterial 
envelope.  An ICC experiment was trialled to investigate the localisation of this 
protein within the bacteria and provide an explanation for the extraction difficulties.  
The rod-like structure of E. coli bacteria was clearly defined in this experiment 
suggesting that this protein is expressed by the bacteria.  The specificity of the 
staining observed in this experiment is not certain, however, in the absence of a 
negative and isotype control.   
The purpose of this experiment was to determine the localisation of GB1-OCLN in 
the bacterial cells.  It was not possible to establish the localisation of this protein, 
however, as the microscope used in this experiment was insufficiently powerful to 
define either the bacterial cell envelope or identify inclusion bodies.  Further 
exploration of GB1-OCLN bacterial protein expression should utilise a confocal 
microscope.   
The cell envelope of gram-negative bacteria such as E. coli is formed from two 
concentric membranes known as the inner and outer membranes (IM and OM), 
which are separated by a periplasmic space containing a peptidoglycan cell wall 
(Silhavy et al., 2010).  The IM is formed from a phospholipid bilayer predominantly 
composed of phosphatidylethanolamine and phosphatidylglycerol (Raetz and 
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Dowhan, 1990).  The inner leaflet of the OM is similarly composed of phospholipids 
the outer leaflet, however, is formed from glycolipids, predominantly 
lipopolysaccharide (LPS) (Raetz and Dowhan, 1990).  The integral membrane 
proteins of these two membranes are structurally distinct as the transmembrane 
domains of IM proteins are composed of α-helices whilst the OM contains fewer 
proteins whose transmembrane regions are formed from β-barrel motifs (Weiner 
and Li, 2008). 
Future experiments could focus on extracting the GB1-OCLN protein from the 
bacteria.  A proteomics study investigating the protein composition of the E. coli cell 
envelope successfully solubilised many membrane proteins from the JM109 strain 
(Fountoulakis and Gasser, 2003).  The application of the same methodology to the 
BL21-RP E. coli strain may succeed in the purification of the GB1-OCLN protein.  
OM proteins have also been extracted from E. coli using a twostep protocol 
involving anion exchange and size exclusion chromatography (Beis et al., 2006).  
The protein complexes from both the IM and OM of BL21-RP E. coli have also been 
analysed in another proteomics study (Stenberg et al., 2005).  The methodology 
used in this study to isolate the two bacterial membranes and purify their respective 
proteins may also aid in the purification of GB1-OCLN and confirm the localisation 
of GB1-OCLN.   
The recovery of a functionally active protein from inclusion bodies is an extensive 
process.  Initially the inclusion bodies must be isolated and the proteins solubilised 
using strong protein denaturants, such as organic solutes, and a reducing agent 
after which the proteins are refolded in the presence of an oxidising agent and 
subsequently purified (Singh and Panda, 2005).  The various methodologies used to 
extract proteins from inclusion bodies may also be of use in developing a protocol to 
successfully solubilise and purify GB1-OCLN (Palmer and Wingfield, 2012; Singh 
and Panda, 2005).  
In summary, this chapter details the successful development of a pull-down protein 
binding assay utilising GB1-OCLN_N and GB1-OCLN_C recombinant proteins.  
Difficulties were encountered in purifying the GB1-OCLN recombinant protein from 
the BL21-RP E. coli strain for which the structure of the occludin protein is likely to 
be accountable.  The gels produced from the GB1-OCLN_N and GB1-OCLN_C 
pull-down protein binding assays were subsequently subjected to mass 
spectrometry analysis to identify putative occludin binding partners in astrocytes.  
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5. Occludin Binding Partner 
Identification & Validation 
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5.1 Introduction 
GB1-OCLN_N and GB1-OCLN_C recombinant proteins were successfully 
generated and utilised to develop a pull-down protein binding assay.  The gels 
produced from this assay were submitted for mass spectrometry analysis in order to 
identify putative protein binding partners for occludin and consequently elucidate 
putative function(s) of this protein in astrocytes.  The mass spectrometry was 
conducted by a collaborator: Dr. Mark Dickman’s research group in Chemical and 
Biological Engineering of the University of Sheffield. 
Mass spectrometry has previously been used to analyse the composition of the tight 
junction proteome by identifying proteins proximal to both occludin and claudin 4 in 
the tight junction complex (Fredriksson et al., 2015).  This research fused myc-
tagged biotin ligase (BL) to full length occludin and claudin 4 proteins.  The BL was 
placed at either the N-terminal or the C-terminal domain of occludin and at the N-
terminal domain of claudin 4.  These constructs were transfected into MDCK II cells 
which were subsequently incubated with biotin.  Any proteins proximate to the 
respective domains of occludin or claudin 4 were biotinylated by BL.  The cells were 
then lysed and the biotinylated proteins purified on streptavidin resin.  These 
proteins were then subjected to SDS-PAGE electrophoresis and identified through 
mass spectrometry analysis (Fredriksson et al., 2015).  Aside from numerous 
proteins known be components of the tight junction complex, various signalling and 
trafficking proteins were also identified from this study, consequently expanding the 
known constituents of the tight junction proteasome (Fredriksson et al., 2015).   
The current study has used a similar approach by utilising mass spectrometry 
analysis to identify proteins from astrocyte lysates which bind to either the N- or C-
terminal domain of occludin.  Validation was subsequently undertaken to verify the 
protein interactions identified from this study through co-immunoprecipitation.  This 
chapter presents the proteins identified as putative binding partners for the occludin 
N- and C-terminal domains and shows the initial validation undertaken to confirm 
these interactions.
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5.2 Results 
Mascot was used to analyse and interpret the mass spectral data obtained from the 
AmaZon speed (Brucker) ion trap mass spectrometer for the GB1-OCLN_C and 
GB1-OCLN_N pull-down protein binding assays.  Mascot compares the spectral 
data to a protein database and identifies peptide matches to specific proteins.  Each 
protein identified from this analysis is assigned an overall protein score which 
reflects the combined scores of all the peptide spectra which were matched to this 
protein.  The Mascot protein score, consequently, indicates the confidence of the 
match.  The number of spectra or queries matched to a protein also determines the 
confidence of the result.  A protein with a high score and multiple queries suggests 
a reliable and confident match.  Peptides with a Mascot score ≥ 50 and the number 
of significant queries > 1 were considered to be significant in this project. 
5.2.1 Mass Spectrometry Protein Binding Partners: C-terminal domain 
This experiment included GB1-OCLN_C and GB1 control samples.  Any matches 
which were identified in both GB1-OCLN_C and the GB1 control were discounted 
as being non-specific.  Keratin is a contaminant and all matches for this protein 
were discarded.  Table 5.1 shows the nine specific proteins identified as putative 
occludin C-terminal domain binding partners.  Occludin was identified in this 
experiment as a protein binding partner with the highest protein score.  Although 
occludin is known to dimerise and oligomerise, the very high protein score for 
occludin is attributable to the presence of GB1-OCLN_C in the samples submitted 
for mass spectrometry analysis.   
The second highest match is 60S ribosomal protein.  Ribosomal subunit proteins 
and histones are commonly identified in spectral analysis and generally considered 
to be unreliable matches due to their prevalence.  The 60S ribosomal protein match 
was, therefore, not pursued further.  Actin and ZO-1 were also identified in this 
experiment.  Both of these proteins are known to bind to occludin’s C-terminal 
domain (Li et al., 2005b; Wittchen et al., 1999).  The identification of these binding 
partners validates the experimental methodology used in this project.   
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Accession Name Score Mass (Da) Description 
OCLN_HUMAN Occludin 1629 59505 
An integral membrane 
protein of the TJC 
RLA0_HUMAN 
60S acidic 
ribosomal protein 
P0 
202 34423 
A structural component of 
the ribosome 
ACTB_HUMAN 
Actin, 
cytoplasmic 1 
141 42052 
A component of the cellular 
cytoskeleton 
DDX3X_HUMAN 
ATP-dependent 
RNA helicase 
DDX3X 
87 73597 
Involved in many stages of 
gene expression including 
transcription 
PCBP1_HUMAN 
Poly(rC)-binding 
protein 1 
78 37987 
Single-stranded nucleic 
acid binding protein 
G3P_HUMAN 
Glyceraldehyde-
3-phosphate 
dehydrogenase 
77 36201 
Participates in nuclear 
events including 
transcription, RNA 
transport, DNA replication 
and apoptosis 
LMNA_HUMAN Prelamin-A/C 58 74380 
A component of the nuclear 
lamina 
HORN_HUMAN Hornerin 56 283140 
A component of the 
epidermal cornified cell 
envelope 
ZO1_HUMAN 
Tight junction 
protein ZO-1 
56 195682 
A cytoplasmic scaffolding 
protein of the TJC 
Table 5.1: Putative C-terminal Domain Occludin Binding Partners  These 
proteins were identified by mass spectrometry analysis from a gel produced by a 
pull-down protein binding assay using GB1-OCLN_C.  None of these proteins was 
present in the GB1 control and are, therefore, specific to the occludin C-terminal 
domain.  Known occludin binding partners are shown in red. 
The interaction between occludin and ZO-1 was validated by western blot.  Protein 
samples from two separate pull-down protein binding assay experiments utilising 
1321N1 astrocytoma cell lysates were analysed by gel electrophoresis and the 
membrane probed with anti-ZO-1 antibody, Figure 5.1.  A clear 250 kDa ZO-1 
protein band was observed in the input and GB1-OCLN_C eluate but absent in the 
GB1 control for both sample sets.  This confirms the specificity of the interaction 
between occludin and ZO-1.   
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Figure 5.1: A Western Blot confirming the interaction between Occludin and 
ZO-1  This experiment was conducted using protein samples from two separate 
pull-down protein binding assays.  The assays were both conducted using 1321N1 
astrocytoma cell lysates.  The membrane was probed with anti-ZO-1 antibody.  A 
ZO-1 protein band is present in the input and GB1-OCLN_C eluate but absent in the 
GB1 control, confirming the interaction between occludin and ZO-1.  Molecular 
weight markers are indicated (kDa). 
After occludin, S60 ribosomal protein and actin, the protein with the highest score 
was DDX3X, DEAD-box helicase 3, X-linked.  DDX3X is a nucleocytoplasmic ATP-
dependent RNA helicase.  This protein was selected for further investigation as a 
putative occludin binding partner due to the high Mascot score and the 
nucleocytoplasmic functions of this protein. 
Initially, the expression of DDX3X in both human primary astrocytes and 1321N1 
astrocytoma cells was characterised by immunocytochemistry, Figure 5.2.  The 
human primary astrocytes used in this experiment were cultured in ScienCell 
Astrocyte Medium.  A strong diffuse staining was observed throughout the 
cytoplasm in both human primary astrocytes and 1321N1 astrocytoma cells.  Faint 
diffuse nuclear staining was also seen in these cells.  The specificity of this staining 
was confirmed by a negative and isotype control in which no staining was observed.   
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Figure 5.2: DDX3X Expression in Astrocytes  The expression of DDX3X was 
characterised in human primary astrocytes and 1321N1 astrocytoma cells.  The 
human primary astrocytes used for this experiment were cultured in ScienCell 
Astrocyte Medium.  Scale bar 10 μm. 
The putative interaction between occludin and DDX3X was initially investigated by 
western blot.  Protein samples from a pull-down protein binding assay utilising 
1321N1 astrocytoma cell lysates were analysed by gel electrophoresis and the 
membrane probed with anti-DDX3X antibody, Figure 5.3.  A strong 73 kDa DDX3X 
protein band was observed in the input whilst a fainter 73 kDa protein band was 
seen in both the GB1-OCLN_C and GB1 control.  This suggests that the interaction 
between occludin and DDX3X is non-specific. 
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Figure 5.3: A Western Blot investigating the putative interaction between 
Occludin and DDX3X   This experiment was conducted using protein samples from 
a pull-down protein binding assay.  This assay was conducted using 1321N1 
astrocytoma cell lysates.  The membrane was probed with anti-DDX3X antibody.  
Molecular weight markers are indicated (kDa). 
5.2.2 Co-Immunoprecipitation Validation  
The putative interaction between occludin and DDX3X was investigated further by 
co-immunoprecipitation.  Co-immunoprecipitation experiments were conducted 
using lysates from human primary astrocytes and 1321N1 astrocytoma cells to 
ensure that the putative interaction was not specific to the astrocytoma cell line.  
The human primary astrocytes used for these experiments were cultured in 
ScienCell Astrocyte Medium.  
5.2.2.1. Trialling Occludin Antibodies for Immunoprecipitation 
Initially, the capability of two commercially available anti-occludin antibodies to 
immunoprecipitate occludin protein was trialled using HEK 293 cell lysates, Figure 
5.4.  This experiment utilised an anti-occludin rabbit polyclonal antibody and an anti-
occludin mouse monoclonal antibody.  Proteins were eluted from the Protein G 
Sepharose beads initially with an acid elution and then a boil elution to determine 
which elution method was more efficient.  A boil elution is more stringent than an 
acid elution, however, the boil elution can also elute antibody fragments.  This 
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experiment included an anti-flag negative control.  Input, flow through (FT) and 
eluate samples were included for every antibody used in this experiment.  The 
membrane was probed with the anti-occludin rabbit polyclonal antibody. 
A faint 65 kDa occludin protein band was observed in all input and FT samples.  A 
strong 65 kDa occludin protein band was also seen in both the acid and boil elution 
samples for the anti-occludin rabbit polyclonal antibody demonstrating that this 
antibody is capable of immunoprecipitating occludin from HEK 293 cell lysates.  
Conversely no 65 kDa occludin band was present in either the acid or boil elution 
samples for the anti-occludin mouse monoclonal antibody indicating that this 
antibody is unable to immunoprecipitate occludin from HEK 293 cell lysates.  The 
absence of the 65 kDa protein band from the anti-flag control eluates confirms the 
specificity of the anti-occludin rabbit polyclonal antibody occludin IP.  The anti-
occludin rabbit polyclonal antibody was subsequently selected for use in future IP 
and Co-IP experiments.   
Appendix 7.1 shows examples of unsuccessful occludin IP experiments from 
1321N1 astrocytoma cell lysates.  In these experiments, occludin was detected in 
the inputs, however, the same banding pattern was present in both the negative 
control and occludin antibody and consequently the IP was not specific.       
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Figure 5.4: Occludin Immunoprecipitation from HEK 293 cells  Occludin was 
successfully immunoprecipitated from HEK 293 cell lysates with the anti-occludin 
rabbit polyclonal antibody.  The anti-occludin mouse monoclonal antibody was 
unable to immunoprecipitate occludin.  An anti-flag antibody was included as a 
negative control.  This experiment was conducted using a 12% resolving gel and a 
4% stacking gel.  The membrane was probed with anti-occludin rabbit polyclonal 
antibody (Thermo Fisher Scientific).  A BLUeye Prestained Protein Ladder (bands 
ranging from 11-245 kDa) (Geneflow) was used for this western blot.  Molecular 
weight markers are indicated (kDa). 
5.2.2.2. Trialling DDX3X Antibodies for Immunoprecipitation  
The capability of two commercially available anti-DDX3X antibodies to 
immunoprecipitate DDX3X and co-immunoprecipitate occludin was initially trialled 
using human primary astrocyte cell lysates, Figure 5.5.  The human primary 
astrocytes used for this experiment were cultured in ScienCell Astrocyte Medium.  
This experiment utilised an anti-DDX3X rabbit polyclonal antibody and an anti-
DDX3X mouse monoclonal antibody.  The anti-occludin rabbit polyclonal antibody 
was also included in this experiment and an anti-flag antibody was used as a 
negative control.  The protein samples produced from this experiment were run on 
two separate 12% gels.  One gel was used to produce a blot which was probed with 
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anti-occludin rabbit polyclonal antibody, Figure 5.5 panel A.  The other gel was used 
to produce a blot which was probed with anti-DDX3X mouse monoclonal antibody, 
Figure 5.5 panel B.   
 
Figure 5.5: The Immunoprecipitation/Co-immunoprecipitation of Occludin and 
DDX3X from Human Primary Astrocytes  Immunoprecipitation/co-
immunoprecipitation of occludin and DDX3X from human primary astrocyte cell 
lysates.  Human pritmary astrocytes were cultured in ScienCell Astrocyte Medium. 
This experiment utilised an anti-occludin rabbit polyclonal antibody, an anti-DDX3X 
rabbit polyclonal antibody and an anti-DDX3X mouse monoclonal antibody.  An anti-
flag negative control was also included in this experiment.  12% resolving gels with 
4% stacking gels were used in this experiment.  The two blots shown here were 
produced from separate gels.  A) Blot probed with the anti-occludin rabbit polyclonal 
antibody.  B) Blot probed with the anti-DDX3X mouse monoclonal antibody.  
Molecular weight markers are indicated (kDa). 
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In panel A, a 75 kDa protein band was observed in every elution sample including 
the anti-flag negative control.  No corresponding protein band of this height was 
observed in any of the input samples, consequently, although the molecular weight 
of this band corresponds to occludin the absence of this protein in the input samples 
means that the identity of the band in the eluate samples is not certain.  It cannot, 
therefore, be determined from this experiment whether the anti-occludin rabbit 
polyclonal antibody is able to immunoprecipitate occludin from human primary 
astrocyte protein lysates.  Similarly it cannot be determined from this experiment if 
either of the anti-DDX3X antibodies are able to co-immunoprecipitate occludin from 
these cells. 
In panel B, a faint 73 kDa DDX3X protein band was observed in all input samples.  
This protein band was also present in the anti-flag and anti-occludin FT samples but 
not in either of the anti-DDX3X FT samples.  The anti-flag control displayed a clear 
73 kDa DDX3X protein band in the eluate suggesting that this protein binds non-
specifically to either GB1 or the Protein G Sepharose beads.  A more intense 73 
kDa protein band was observed, however, in both the anti-DDX3X eluates 
suggesting that DDX3X is enriched in these samples compared with the anti-flag 
control.  This enrichment is supported by the absence of a 73 kDa DDX3X protein 
band in either of the anti-DDX3X antibody FT samples and would suggest that both 
the rabbit polyclonal and mouse monoclonal DDX3X antibodies are capable of 
immunoprecipitating this protein from human primary astrocytes.  This enrichment 
would also suggest that the protein band in the anti-flag control eluate represents 
background binding to the Protein G Sepharose beads.  A 73 kDa protein band was 
seen in the anti-occludin eluate, however, this band is of a similar intensity to the 
one exhibited in the anti-flag control consequently this band is also likely to the 
product of non-specific background binding and not an indication that the anti-
occludin antibody is capable of co-immunoprecipitating DDX3X.  
Some of the eluates in both of these blots also exhibited a 50 kDa protein band and 
a 23 kDa protein band which were produced by the antibody IgG heavy and light 
chains respectively.  A 50 kDa heavy chain band was seen in the anti-occludin 
rabbit polyclonal eluate and the anti-DDX3X rabbit polyclonal eluate in panel A.  
This band was observed in these two eluates because this blot was probed with an 
antibody which was raised in the same species (rabbit).  Similarly, a 50 kDa IgG 
heavy chain band and a 23 kDa IgG light chain band were observed in the anti-flag 
and anti-DDX3X mouse monoclonal eluates in panel B because this blot was 
probed with an antibody the anti-DDX3X mouse monoclonal antibody. 
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5.2.2.3. Non-specific Binding 
The presence of a 73 kDa DDX3X protein band in the anti-flag eluate suggests that 
this protein binds non-specifically to the beads.  This non-specific binding was 
investigated further in an experiment in which the cell lysate was incubated with just 
blocked Protein G Sepharose beads and no antibody.  This was known as the no 
antibody control.  This experiment was conducted using 1321N1 astrocytoma cell 
lysates and also included an anti-flag control, a DDX3X co-IP using anti-occludin 
rabbit polyclonal antibody and a DDX3X IP using anti-DDX3X mouse monoclonal 
antibody, Figure 5.6.   
 
Figure 5.6: DDX3X Immunoprecipitation and Co-immunoprecipitation from 
1321N1 Astrocytoma cells.  DDX3X immunoprecipitation and co-
immunoprecipitation from 1321N1 astrocytoma cell protein lysates.  This experiment 
was conducted using an anti-occludin rabbit polyclonal antibody and an anti-DDX3X 
mouse monoclonal antibody. A no antibody control consisting of blocked protein G 
Sepharose beads as well as an anti-flag negative control were also included in this 
experiment.  The blot was probed with anti-DDX3X mouse monoclonal antibody.  A 
12% resolving gel with 4% stacking gel was used in this experiment.  Molecular 
weight markers are indicated (kDa). 
A faint 73 kDa DDX3X protein band was observed in all inputs.  This protein band 
was also present in the no antibody, anti-flag and anti-occludin eluates and was 
enriched in the anti-DDX3X eluate.  This experiment reflects the results shown in 
Figure 5.5 panel B as DDX3X again appears to be enriched by the anti-DDX3X 
antibody.  The presence of a 73 kDa protein band in both the no antibody and anti-
flag controls suggests that there is non-specific background protein binding to the 
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Protein G Sepharose beads.  The 73 kDa protein band present in the anti-occludin 
eluate is of a similar intensity to the protein band exhibited in both control eluates 
which suggests that it is the product of non-specific binding rather than a co-IP.  A 
50 kDa IgG heavy chain protein band and a 23 kDa IgG light chain protein band 
were observed in the anti-flag and anti-DDX3X eluates.     
5.2.2.4. The Effect of Calcium Treatment  
The effect of calcium on DDX3X immunoprecipitation was also investigated by pre-
treating human primary astrocytes cultured in ScienCell Astrocyte Medium with 5 
mM CaCl2 and 4 μM A23187 for 15 mins at 37oC prior to lysing the cells.  This 
experiment was conducted using the anti-DDX3X mouse monoclonal antibody and 
an anti-flag negative control, Figure 5.7.   
 
Figure 5.7: DDX3X Immunoprecipitation from Human Primary Astrocytes pre-
treated with Calcium  DDX3X immunoprecipitation from human primary astrocytes 
pre-treated with 5 mM CaCl2 and 4 μM A23187 calcium ionophore.  The human 
primary astrocytes used for this experiment were cultured in ScienCell Astrocyte 
Medium.  This experiment was conducted using a 12% resolving gel and a 4% 
stacking gel.  The blot was probed with anti-DDX3X mouse monoclonal antibody.  
Molecular weight markers are indicated (kDa). 
A faint 73 kDa DDX3X protein band was observed in both inputs.  This band was 
again present in the anti-flag eluate and enriched in the anti-DDX3X eluate.  The 
calcium pre-treatment does not appear to alter the protein binding pattern.  A 50 
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kDa IgG heavy chain protein band and a 23 kDa light chain protein band were 
observed in both antibody eluates.     
5.2.3 Mass Spectrometry Protein Binding Partners: N-Terminal Domain 
Any matches which were identified in GB1-OCLN_N and the GB1 control were 
discounted as being non-specific.  Keratin is a contaminant and all matches for this 
protein were discarded.  Table 5.2 shows the forty-one specific proteins identified as 
putative occludin N-terminal domain binding partners.  This list includes Itch and 
Nedd4-2 both of which have previously been shown to interact with occludin at the 
PPPY motif located in the N-terminal domain of this protein (Raikwar et al., 2010; 
Traweger et al., 2002).  Again, the identification of known occludin binding partners 
validates the experimental methodology used in this project.  This list of putative 
binding partners contains many histones and ribosomal proteins.  These proteins 
are commonly identified in mass spectral analysis and were consequently regarded 
as unreliable matches. 
 
Accession Name Score 
Mass 
(Da) 
Description 
MYH10_HUMAN Myosin-10 685 229827 Involved in cytokinesis 
H2B1K_HUMAN 
Histone H2B type 
1-K 
1347 13882 
Component of the 
nucleosome 
H4_HUMAN Histone H4 613 11360 
Component of the 
nucleosome 
H32_HUMAN Histone H3.2 468 15436 
Component of the 
nucleosome 
DHX9_HUMAN 
ATP-dependent 
RNA helicase A 
396 142181 
Unwinds duplex DNA and 
RNA 
HNRPC_HUMAN 
Heterogeneous 
nuclear 
ribonucleoproteins 
C1/C2 
295 33707 
Binds to pre-mRNA and is 
involved in the formation 
of hnRNP particles 
PPIB_HUMAN 
Peptidyl-prolyl cis-
trans isomerase B 
247 23785 Facilitates protein folding 
SFPQ_HUMAN 
Splicing factor, 
proline- and 
glutamine-rich 
190 76216 
Binds DNA and RNA and 
is involved in several 
nuclear processes 
NONO_HUMAN 
Non-POU domain-
containing 
octamer-binding 
protein 
88 54311 
Binds DNA and RNA and 
is involved in several 
nuclear processes 
ITCH_HUMAN 
E3 ubiquitin-protein 
ligase Itchy 
homolog 
186 103593 
An E3 ubiquitin protein 
ligase 
127 
 
TOP2A_HUMAN 
DNA 
topoisomerase 2-
alpha 
185 175017 
Enzyme which catalyses 
the breakage and 
reannealing of DNA 
TOP2B_HUMAN 
DNA 
topoisomerase 2-
beta 
145 184122 
Enzyme which catalyses 
the breakage and 
reannealing of DNA 
SMCA5_HUMAN 
SWI/SNF-related 
matrix-associated 
actin-dependent 
regulator of 
chromatin 
subfamily A 
member 5 
181 122513 
ATP-dependent helicase 
involved in the 
remodelling of 
nucleosomes 
HNRPU_HUMAN 
Heterogeneous 
nuclear 
ribonucleoprotein U 
152 91269 
Binds to RNA and is 
specific to the nucleus 
ROA3_HUMAN 
Heterogeneous 
nuclear 
ribonucleoprotein 
A3 
140 39799 
RNA-binding protein 
possibly involved in 
mRNA nuclear export 
ML12A_HUMAN 
Myosin regulatory 
light chain 12A 
134 19839 Involved in cytokinesis 
ROA2_HUMAN 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1 
133 37464 
RNA-binding protein 
possibly involved in 
mRNA nuclear export 
U520_HUMAN 
U5 small nuclear 
ribonucleoprotein 
200 kDa helicase 
131 246006 RNA helicase 
NOP56_HUMAN 
Nucleolar protein 
56 
119 66408 
Involved in ribosomal 
subunit biogenesis 
HNRPL_HUMAN 
Heterogeneous 
nuclear 
ribonucleoprotein L 
114 64720 Splicing factor 
H14_HUMAN Histone H1.4  112 21852 Histone 
NPM_HUMAN Nucleophosmin 112 32726 
Multifunctional protein 
involved in ribosome 
biogenesis and transport 
RS14_HUMAN 
40S ribosomal 
protein S14 
96 16434 
Component of the 
ribosome 
NOP58_HUMAN 
Nucleolar protein 
58 
95 60054 
Involved in ribosomal 
subunit biogenesis 
PSIP1_HUMAN 
PC4 and SFRS1-
interacting protein 
95 60181 Transcriptional coactivator 
DCD_HUMAN Dermcidin 92 11391 An anti-microbial peptide 
NEDD4_HUMAN 
E3 ubiquitin-protein 
ligase NEDD4 
83 150276 
An E3 ubiquitin protein 
ligase 
RBMX_HUMAN 
RNA-binding motif 
protein, X 
chromosome 
81 42306 RNA-binding protein 
DDX21_HUMAN 
Nucleolar RNA 
helicase 2 
79 87804 RNA helicase 
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ARPC4_HUMAN 
Actin-related 
protein 2/3 
complex subunit 4 
72 19768 
An actin-binding 
component which is 
involved in actin 
polymerisation 
RL40_HUMAN 
Ubiquitin-60S 
ribosomal protein 
L40 
72 15004 
Component of the 
ribosome 
U5S1_HUMAN 
116 kDa U5 small 
nuclear 
ribonucleoprotein 
component 
70 110336 
A component required for 
pre-RNA splicing 
RS6_HUMAN 
40S ribosomal 
protein S6 
68 28834 Ribosomal Protein 
DHX15_HUMAN 
Putative pre-
mRNA-splicing 
factor ATP-
dependent RNA 
helicase DHX15 
66 91673 
A factor involved in pre-
mRNA processing 
H2AY_HUMAN 
Core histone 
macro-H2A.1 
66 39764 Histone 
RS25_HUMAN 
40S ribosomal 
protein S25 
65 13791 Ribosomal Protein 
ILF2_HUMAN 
Interleukin 
enhancer-binding 
factor 2 
63 43263 
Appears to interact with 
ILF3 and may regulate IL2 
gene transcription  
HNRPD_HUMAN 
Heterogeneous 
nuclear 
ribonucleoprotein 
D0 
59 38581 RNA-binding protein 
NCBP1_HUMAN 
Nuclear cap-
binding protein 
subunit 1 
56 92864 
A component in 
complexes involved in 
RNA processing 
ELAV1_HUMAN ELAV-like protein 1 55 36240 RNA-binding protein 
RS18_HUMAN 
40S ribosomal 
protein S18 
50 17708 Ribosomal Protein 
Table 5.2: Putative N-terminal Domain Occludin Binding Partners.  Proteins 
identified by mass spectrometry analysis from a gel produced by a pull-down protein 
binding assay conducted using GB1-OCLN_N.  None of these proteins was present 
in the GB1 control and are, therefore, specifically interact with the occludin N-
terminal domain.  Known occludin binding partners are shown in red. 
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5.3 Discussion 
Mass spectrometry analysis was utilised to identify the putative occludin binding 
partners which were obtained through pull-down protein binding assays.  Nine 
proteins were identified as putative occludin C-terminal domain binding partners 
from the GB1-OCLN_C pull-down assay whilst 41 proteins were identified from the 
GB1-OCLN_N assay.  The occludin binding partners identified in this study include 
proteins which have previously been shown to bind to occludin.  Both ZO-1 and 
actin, which were identified in the GB1-OCLN_C pull-down protein binding assay, 
are known to interact with occludin at the C-terminal domain (Li et al., 2005b; 
Wittchen et al., 1999).  Similarly the E3 ubiquitin ligases Itch and Nedd4-2, which 
have previously been shown to interact with occludin at the N-terminal domain, were 
identified as occludin binding partners in the GB1-OCLN_N pull-down protein 
binding assay (Raikwar et al., 2010; Traweger et al., 2002).  The identification of 
these known occludin binding partners from the respective pull-down assay 
validates the experimental methodology used in this research.   
A key limitation of these experiments is that, due to time constraints, only one set of 
pull-down protein binding assays were subjected to mass spectrometry analysis.  
Ideally these experiments should have been run in triplicate with the protein 
matches common to all three data sets considered to be putative binding partners 
and taken forward for validation.     
5.3.1 DDX3X – Structure and Function  
DEAD-box helicase 3, X-linked (DDX3X) is a protein identified in the current study 
as a putative occludin binding partner interacting at the C-terminal domain of this 
protein.  Due to a high MASCOT score, and the various nucleocytoplasmic functions 
of this protein, DDX3X became the initial focus for validation.   
DDX3X is a 662 amino acid, 73 kDa nucleocytoplasmic ATP-dependent RNA 
helicase.  Helicases are classified by six superfamilies (SFs) of which eukaryotic 
helicases belong to SF1 and SF2 (Jankowsky, 2011).  Eukaryotic helicases are 
structurally defined by a highly conserved helicase core consisting of two domains 
connected by a flexible linker.  DEAD box helicases belong to SF2 and are 
characterised by the Asp-Glu-Ala-Asp (DEAD) motif which is one of twelve motifs 
located within the helicase core of these proteins (Fairman-Williams et al., 2010; 
Linder et al., 1989). 
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Most DEAD-box helicases also have an N- and C-terminal domain which flank the 
helicase core (Fairman-Williams et al., 2010).  The function of these terminal 
accessory domains remains to be fully established, although it is possible that they 
enable DEAD-box helicases to interact with other proteins or enhance RNA binding 
(Fairman-Williams et al., 2010).  The N-terminal domain of DDX3X contains an NES 
which binds to chromosomal maintenance 1 (CRM1), also known as exportin-1 
(XPO1), a nuclear export protein (Yedavalli et al., 2004).  The C-terminal domain 
includes a region rich in arginine and serine residues (aa 582-632).  This region is 
known as the RS-like domain as it resembles the RS domain present in splicing 
factors such as serine/arginine-rich splicing factors 1 and 2 (SRSF1 and SRSF2) 
(Owsianka and Patel, 1999). 
DEAD-box helicases have a diverse range of cellular functions.  These proteins bind 
to RNA and ATP through motifs located in the helicase core domain and catalyse 
the unwinding of duplex RNA (Putnam and Jankowsky, 2013).  RNA is subject to 
various metabolic processes including transcription, RNA splicing, RNA transport 
and translation.  These processes are mediated by numerous proteins which bind to 
RNA and form ribonucleoprotein complexes (RNPs) in which many DEAD-box 
helicases are functional components (Jankowsky, 2011; Marintchev, 2013).  Some 
DEAD-box helicases are able to clamp to RNA and act as a nucleation centre at 
which other proteins assemble to generate larger RNP complexes (Putnam and 
Jankowsky, 2013).  A notable example is DDX48, also known as eukaryotic 
initiation factor 4A-III (eIF4A-III), which is a component of the exon junction complex 
(EJC) (Shibuya et al., 2004).  The EJC binds at the junction of two spliced exons 
during pre-mRNA splicing and is functionally involved in RNA metabolic processes 
including RNA localisation and translation (Lee et al., 2009). 
mRNA is exported from the nucleus in a complex known as the messenger 
ribonucleoprotein (mRNP) complex.  DDX3X directly interacts with another nuclear 
export protein and component of the mRNP complex known as tip-associated 
protein (TAP) which functions as a heterodimer with NFT2-related export protein 1, 
also known as p15 (Guzik et al., 2001; Lai et al., 2008).  The interaction between 
DDX3X and TAP is mediated by the C-terminal domain (aa 536-661) of the DDX3X 
protein (Lai et al., 2008).  DDX3X also directly interacts with mRNA (Lai et al., 
2008).  These interactions associate DDX3X with the process of mRNA export, 
however, the extent to which DDX3X is functionally involved in the exportation 
mechanism remains to be established. 
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There is also evidence to suggest that DDX3X is involved in translation initiation.  
The eukaryotic initiation factor 4F (eIF4F) complex is a heterotrimeric protein 
complex which acts to recruit the 5’ cap of mRNA to the 40S small ribosomal 
subunit (Hinnebusch, 2014).  The eIF4F complex instigates translation initiation and 
facilitates the recruitment of other factors to form the 43S pre-initiation complex 
which is responsible for ribosomal scanning to identify the initiation codon in the 
mRNA transcript (Hinnebusch, 2014). 
The eIF4F complex is composed of eIF4A-I, eIF4E and eIF4G.  eIF4A-I is a DEAD-
box RNA helicase which binds to mRNA and unwinds double-stranded RNA 
secondary structures which form in the 5’ untranslated region (5’-UTR) of mRNA, a 
region directly upstream from the initiation codon (Hinnebusch, 2014).  eIF4E binds 
to the RNA 5’ cap and eIF4G functions as a protein scaffold due to its multiple 
binding domains.  These domains enable eIF4G to bind other protein components 
involved in the translation mechanism including the poly(A)-binding protein (PABP), 
a protein which binds to the poly(A) tail located at the 3’ end of mRNA (Hinnebusch, 
2014). 
DDX3X interacts directly with eIF4G and PABP within the eIF4F complex and has 
also been shown to bind to the 5’-UTR and destabilise secondary structures (Soto-
Rifo et al., 2012).  DDX3X is not an essential transcription factor, however, this 
protein does facilitate translation initiation as it promotes the interaction between the 
eIF4F complex and mRNA transcripts which have complex secondary structures 
(Soto-Rifo et al., 2012).  DDX3X also appears to be involved in the functional 
assembly of 80S ribosomes (Geissler et al., 2012). 
DDX3X is also implicated in the pathogenesis of viruses.  Hepatitis C virus (HCV) is 
an enveloped, positive sense, single-stranded RNA virus of the Flaviviridae family 
(Dubuisson and Cosset, 2014).  HCV requires DDX3X for viral replication as 
DDX3X knockdown in human hepatoma Huh 7-derived cells infected with HCV 
results in a reduction in viral RNA replication (Ariumi et al., 2007; Dubuisson and 
Cosset, 2014).  The functional role of this protein in viral replication, however, 
remains to be determined (Ariumi et al., 2007). 
The viral RNA genome encodes a single polyprotein which is cleaved by both host 
and viral proteases to generate ten viral proteins which can be subdivided into 
structural and non-structural proteins (Penin et al., 2004).  The structural viral 
proteins consist of a core protein and two glycoproteins known as E1 and E2 (Penin 
et al., 2004).  The core protein forms a structure which contains the viral genome 
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known as the nucleocapsid.  The nucleocapsid is coated by a lipid membrane 
known as the viral envelope within which the two glycoproteins are situated (Penin 
et al., 2004). 
DDX3X interacts directly with the HCV core protein (Mamiya and Worman, 1999; 
Owsianka and Patel, 1999).  This interaction occurs between residues 1-59 located 
in the N-terminal of the core protein and residues 553-622 in the DDX3X C-terminal 
domain (Owsianka and Patel, 1999).  The involvement of DDX3X in HCV replication 
may, however, be independent of this interaction.  HuH-7 cells transfected with 
either a wildtype or core mutant HCV strain, in which the mutation prevents the core 
interacting with DDX3X, show similar levels of viral RNA replication (Angus et al., 
2010).  A similar reduction in the level of intracellular viral RNA also occurs in HuH-7 
cells infected with either mutant or wildtype subsequent to DDX3X knockdown.  This 
demonstrates that DDX3X is required for HCV replication but suggests that the 
mechanism by which DDX3X facilitates this process is independent of the 
interaction between this protein and the viral core protein (Angus et al., 2010). 
Human immunodeficiency virus-1 (HIV-1) is an enveloped, positive sense, single-
stranded RNA lentivirus which also utilises DDX3X in its replication cycle.  Rev is a 
HIV-1 viral protein involved in the exportation of unspliced and partially spliced viral 
transcripts from the host nucleus (Malim et al., 1989).  Rev localises to the host 
nucleus through an arginine-rich NLS which enables the viral Rev protein to bind 
directly to the host nuclear import receptor, importin-β (Henderson and Percipalle, 
1997; Truant and Cullen, 1999).  The Rev NLS overlaps with the RNA-binding 
domain of this protein, consequently the NLS domain is obscured when this protein 
binds to a region in unspliced and partially spliced viral transcripts known as the Rev 
response element (REE) (Henderson and Percipalle, 1997; Kjems et al., 1991; 
Malim et al., 1989).  The exportation of Rev from the nucleus is mediated by the 
host protein CRM1 which Rev is able to recruit through a NES (Askjaer et al., 1998). 
DDX3X may act as a Rev cofactor facilitating viral mRNA export as an endogenous 
knockdown of DDX3X in human peripheral blood mononuclear cells (PBMCs) 
inhibits HIV-1 replication (Yedavalli et al., 2004).  DDX3X has also been implicated 
in facilitating HIV-1 mRNA translation mediated by interactions with a 5’-UTR 
structure in the viral mRNA known as the trans-activating response element (TAR) 
and Trans-activator of transcription (Tat), another viral protein (Lai et al., 2013). 
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5.3.2 Validation of the Interaction between Occludin and DDX3X 
In HeLa cells DDX3X is predominantly localised to the nucleus exhibiting a speckled 
staining pattern which excludes nucleoli, and weak cytoplasmic staining (Owsianka 
and Patel, 1999).  In the current study, ICC demonstrates cytoplasmic and nuclear 
expression of DDX3X in both human primary astrocytes and 1321N1 astrocytoma 
cells.  The localisation of this protein in astrocytes is predominantly cytoplasmic.  
The HeLa cell images were obtained using confocal microscopy, consequently the 
DDX3X speckled nuclear staining is clearly visible.  Confocal microscopy would be 
required to determine if DDX3X exhibits the same staining pattern in astrocytic 
nuclei.  Dual-staining astrocytes for occludin and DDX3X to investigate co-
localisation was not possible as the only available antibodies which successfully 
stained the cells for either of these proteins were raised in the same species.  
An initial experiment designed to validate the putative interaction between DDX3X 
and occludin involved a western blot using pull-down protein binding assay protein.  
This experiment failed to confirm the putative interaction between these two proteins 
as a DDX3X protein band was present not only in GB1-OCLN_C but also in the 
GB1 control which suggests that DDX3X binds non-specifically to GB1.  The 
putative interaction between occludin and DDX3X was investigated further by co-
immunoprecipitation. 
Occludin was successfully immunoprecipitated from HEK 293 cells, however, this IP 
was not replicable with either 1321N1 astrocytoma cells or human primary 
astrocytes.  The principal issue encountered with the occludin IP from astrocytes 
was that the negative control eluate displayed the same banding pattern as the 
occludin antibody eluate.  This occurred in both anti-flag and anti-myc negative 
controls.   
It was concluded from the immunoprecipitation experiments for DDX3X that this 
protein binds non-specifically to the Protein G sepharose beads, producing a level 
of background binding which was present in all negative controls.  The clear 
enrichment of the DDX3X protein band in IP experiments with anti-DDX3X 
antibodies, however, suggests that the IP does work.  Unfortunately the DDX3X 
protein band present in the co-IP with anti-occludin antibody is probably due to the 
background protein binding consequently the putative interaction between occludin 
and DDX3X could not be validated. 
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As neither occludin nor DDX3X could be immunoprecipitated from astrocytic cell 
lysates with any specificity, the interaction between these two proteins could not be 
verified using the current methodology and, due to time constraints, neither could 
this method be further optimised nor any other experimental avenues explored 
through which this interaction might be verified.  
Although the initial attempts to validate the interaction between occludin and DDX3X 
were unsuccessful, the validation process is only in its inception and further 
research is required before definitive conclusions can be drawn regarding occludin 
and the binding partner candidates identified in this study.  It would, therefore, be 
premature to conclude that occludin does not interact with DDX3X based on the 
validation difficulties encountered in this study  
5.3.3 Occludin Nuclear Translocation 
It can be hypothesised from the subcellular localisation of occludin in astrocytes that 
this protein may be functionally involved in nuclear processes.  The proteins 
identified in this study as putative occludin binding partners support this hypothesis 
as many of them are involved in different RNA metabolic processes.  Some of the 
proteins identified from this study are nucleocytoplasmic proteins which are 
implicated in the nuclear exportation of mRNP complexes.  The mechanism by 
which occludin is able to translocate between the cytoplasm and nucleus is yet to be 
established as this protein does not appear to contain a NLS or NES.  An insight 
into this mechanism may be provided by conducting further research into the 
nucleocytoplasmic proteins identified as putative occludin binding partners in the 
current study. 
CRM1 and the TAP-p15 heterodimer are both nuclear export proteins which 
facilitate the exportation of proteins and mRNA from the nucleus through the NPC.  
The mechanism by which CRM1 is imported into the nucleus remains to be 
established, whilst the N-terminal domain of TAP contains a NLS which enables the 
TAP-p15 heterodimer to bind to a nuclear import protein known as transportin 
(Bachi et al., 2000; Katahira et al., 1999).  Neither CRM1 nor TAP-15 were identified 
from the mass spectrometry analysis as binding to occludin, however both of these 
proteins are known to interact with DDX3X (Lai et al., 2008; Yedavalli et al., 2004).  
It is possible that DDX3X may act as an adaptor protein connecting occludin with 
nuclear transport proteins which would enable occludin to translocate between the 
cytoplasm and nucleus.  The interaction between occludin and DDX3X may also 
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suggest that occludin might be a component of the mRNP complex, although this 
would undoubtedly require further investigation. 
Several heterogeneous nuclear ribonucleoproteins (hnRNPs) were also identified as 
putative occludin N-terminal domain binding partners.  19 hnRNP genes have 
currently been identified, of which there are numerous isoforms, however, the total 
number of proteins within the hnRNP family remains to be determined as putative 
hnRNPs have not yet been characterised (Carpenter et al., 2006).  hnRNPs are 
functionally defined by the presence of RNA-binding motifs such as RNA recognition 
motifs (RRMs), hnRNP K homology domains (KHs) or arginine/glycine-rich box 
(RGG) (Krecic and Swanson, 1999).  These proteins interact with pre-mRNAs and 
function as components of RNP complexes facilitating RNA metabolic processes 
including mRNA export (Dreyfuss et al., 2002).   
hnRNP A2/B1 is one of the hnRNPs identified in this study as a putative occludin 
binding partner.  hnRNP A2 (38 kDa) and hnRNP B1 (36kDa) are two isoforms 
encoded by the HNRNPA2B1 gene which are produced through alternative splicing 
(Kozu et al., 1995).  Two other isoforms, A2b and B1b, have been identified in mice 
and rats (Hatfield et al., 2002; Kamma et al., 1999).  hnRNP A2/B1 is part of a 
hnRNP A/B subfamily which structurally consists of two tandem N-terminal RRMs 
with a C-terminal glycine-rich domain (GRD) (Burd et al., 1989).  A 38-residue motif 
known as the M9 motif located in the GRD acts as a dual nucleocytoplasmic 
transport signal which mediates both the nuclear import and export of hnRNP A2/B1 
(Bogerd et al., 1999; Matthew Michael et al., 1995; Piñol-Roma, 1997; Pollard et al., 
1996).   
hnRNP A3 was also identified in the current study.  This protein has a similar amino 
acid sequence to hnRNP A1 and displays a domain similar to the M9 motif 
suggesting that this protein is also capable of translocation between the nucleus 
and the cytoplasm (Ma et al., 2002).  The M9 motif acts as a dual nuclear transport 
signal mediating both nuclear import and export, consequently the translocation of 
occludin between the nucleus and cytoplasm of astrocytes may be mediated by 
hnRNP A2/B1 or hnRNP A3. 
5.3.4 Occludin and Viral Pathogenesis 
The cellular entry of HCV particles is mediated by attachment factors and receptors 
located on the cell surface of hepatocytes which enables the clathrin-mediated 
endocytosis of the virus into these cells (Dubuisson and Cosset, 2014).  Occludin 
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has been identified as one of the factors required for HCV entry (Liu et al., 2009; 
Ploss et al., 2009).  Occludin is not the only tight junction protein which acts as a 
HCV attachment factor as claudin-1 is also involved in mediating viral entry (Evans 
et al., 2007).  Occludin knockdown reduces the viral infection in two cell lines which 
are naturally permissive to HCV, Hep3B and Huh-7.5 cells (Ploss et al., 2009).  The 
HCV-resistant renal carcinoma cell line 786-O expresses high levels of other entry 
factors but low levels of occludin and the overexpression of occludin in these cells 
enhances HCV infection (Ploss et al., 2009).   
Endogenous occludin co-immunoprecipitates HCV E2 protein in infected hepatoma 
cells suggesting that the interaction between occludin and HCV is mediated by the 
E2 viral protein (Liu et al., 2009).  This interaction occurs at the second occludin 
extracellular loop and is dependent upon dynamin II, a GTPase involved in 
endocytosis (Liu et al., 2010).  The interaction between occludin and dynamin II is 
abrogated in the absence of the ECL2 indicating that this domain is necessary for 
the interaction between these two proteins (Liu et al., 2010).  HCV entry is inhibited 
in Huh7 cells which have been treated with the dynamin inhibitor dynasore; similarly 
dynamin II knockdown in Huh7.5.1 cells decreases the level of HCV infection 
demonstrating that HCV entry occurs by a dynamin-dependent mechanism (Liu et 
al., 2010; Liu et al., 2009).  The interaction between occludin and dynamin II, 
however, presents with a logistical difficulty as dynamin II is a cytoplasmic protein 
whilst the occludin ECL2 is located in the extracellular domain.  It is possible that 
the interaction between occludin and dynamin II is mediated by another currently 
unidentified protein.   
Both occludin and DDX3X are implicated in different stages of HCV pathogenesis.  
Occludin is involved in the entry of this virus into cells whilst DDX3X is involved in 
viral replication (Ariumi et al., 2007; Liu et al., 2010; Liu et al., 2009).  An interaction 
between DDX3X and occludin, if verified, may suggest that occludin not only 
facilitates viral entry but also functions as an adaptor protein facilitating the 
interaction between HCV particles and a host protein known to be required for viral 
replication.    
In summary the mass spectrometry analysis identified putative occludin binding 
partners which interact with either the N-terminal or C-terminal domain of this 
protein.  DDX3X was one of the proteins identified as binding to the occludin C-
terminal domain and was the initial focus for validation.   Co-immunoprecipitation 
experiments were conducted in an attempt to confirm this interaction, however, 
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optimisation difficulties were encountered and consequently the interaction between 
occludin and DDX3X was not verified using this method and unfortunately, due to 
time constraints, further validation studies could not be pursued.  
The binding partners identified in this study have various functions many of which 
relate to RNA binding, RNA splicing, mRNA transport and translation initiation.  
Although it was not possible to fully investigate and verify these proteins as occludin 
binding partners, the identification of these proteins does implicate occludin in many 
cellular processes beyond forming the tight junction complex.  The findings from this 
study, therefore, provide a platform upon which future research can be constructed 
to further investigate the functional role(s) of occludin. 
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6. Discussion and Future Work 
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6.1 Astrocytic Tight Junction Protein Expression 
The initial aim of this project was to characterise the expression of occludin, claudin 
5 and ZO-1 in human primary astrocytes and 1321N1 astrocytoma cells and to 
define the cellular localisation of these proteins in the temporal cortex.  This project 
has succeeded in demonstrating that both occludin and ZO-1 are expressed in the 
cytoplasm and nucleus of human primary astrocytes and 1321N1 astrocytoma cells.  
The astrocytic nuclear expression of occludin is also confirmed in vivo by the co-
localisation of occludin immunoreactivity with GFAP-positive astrocytes in human 
post-mortem tissue from the temporal cortex.  The in vivo study confirms the nuclear 
expression of ZO-1 and the astrocytic expression of ZO-1 is supported in a previous 
study which shows the co-localisation of ZO-1 immunoreactivity with GFAP-positive 
astrocytes in human post-mortem tissue (Simpson et al., 2011).  
This project concludes that claudin 5 is not expressed in either human primary 
astrocytes or 1321N1 astrocytoma cells.  The current in vivo study supports this 
conclusion as claudin 5 expression was found to be exclusively associated with 
endothelial cells.  The same observations have also been made in previous 
research in which the expression of claudin 5 is shown to be exclusively associated 
with endothelial cells in human tissue (Simpson et al., 2010).   
The conclusion that claudin 5 is not expressed in astrocytes is, however, 
contradicted by another study which shows this protein to be expressed in human 
astrocytes, oligodendrocytes and pyramidal neurons in vivo (Romanitan et al., 
2010).  This previous study, however, did not include any dual-labelling, 
consequently the co-localisation of claudin 5 with astrocytes is not certain.  Based 
on the evidence from the current project, claudin 5 does not appear to be expressed 
in astrocytes. 
Future research could investigate the astrocytic expression of other claudin 
proteins.  Claudin 2 and claudin 11 have also been shown to be expressed in 
human astrocytes in vivo (Simpson et al., 2010).  Again, no dual-labelling was 
conducted in this study for either of these claudin proteins so this could be 
addressed in future research to confirm the astrocytic expression of these two 
claudin proteins in vivo.  The expression of either of these claudin proteins could 
also be investigated in vitro in human primary astrocytes and 1321N1 astrocytoma 
cells through ICC and western blotting. 
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6.2 Astrocytic & Neuronal Tight Junction Protein Expression and Alzheimer’s 
Disease 
Changes in the astrocytic and neuronal expression of tight junction proteins has 
been implicated in the pathogenesis of neurodegenerative diseases.  A previous in 
vivo study using a human tissue cohort concluded that there is a significant increase 
in the expression of occludin in pyramidal neurons in AD and VD cases compared 
with controls (Romanitan et al., 2007).  The same cohort was used to investigate 
changes in the expression of claudin 2, claudin 5 and claudin 11 (Romanitan et al., 
2010).  All three of these claudin proteins were found to be expressed in astrocytes 
and pyramidal neurons.  This study found that there was a significant increase in the 
ratio of pyramidal neurons expressing all three claudins in AD and VD cases 
compared with controls whilst there was a significant increase in the ratio of 
astrocytes expressing claudin 2 and claudin 11, but not claudin 5, in AD and VD 
cases compared with controls (Romanitan et al., 2010).  These studies suggest that 
an increase in tight junction protein expression is associated with AD and VD.   
Conversely, however, a significant reduction in astrocytic transcripts which encode 
for TJPs is associated with increasing Alzheimer-type pathology (Simpson et al., 
2011).  Another aim of this study was to investigate possible changes in the 
expression of occludin, claudin 5 and ZO-1 in MCI and AD cases compared with 
control.  The staining identified in this study was sufficient to characterise the 
cellular localisation of these proteins in vivo, however, it was not possible to quantify 
and analyse.  Consequently the possible role of these tight junction proteins in AD 
pathology was not addressed in this project. 
Although there is evidence to suggest that astrocytic tight junction protein 
expression is altered in AD, it is not known how these proteins may be functionally 
involved in the pathogenesis of this disease or even if these changes are causally 
linked to AD progression.  It is undeniable that future research is required into the 
role of tight junction proteins in AD, however, until the functional role(s) of these 
proteins in astrocytes are fully understood, their possible involvement in disease will 
remain unclear.  
6.3 The Function of Tight Junction Proteins in Astrocytes 
The function(s) of occludin in astrocytes was investigated by the identification of 
putative protein binding partners using a pull-down protein binding assay and mass 
spectrometry analysis.  Subsequent validation of the proteins identified in this study 
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was limited due to time constraints and unfortunately these interactions remain 
unconfirmed in a physiological context.  
The candidates identified in this study as putative occludin binding partners have a 
variety of different functions, many of which pertain to RNA metabolic processes, 
including RNA binding, RNA splicing, mRNA transport and translation initiation.  The 
possibility that occludin interacts with these proteins is an exciting prospect as it 
implicates occludin in cellular processes with which this protein has not previously 
been associated and supports the hypothesis that occludin is functionally involved in 
processes beyond the tight junction complex.     
The putative binding partners identified in this study may also offer an insight into 
the currently unresolved issue of the mechanism by which occludin is able to 
translocate into the nucleus.  Occludin is considered to be a membrane-associated 
protein, however, in astrocytes this protein appears to be nucleocytoplasmic.  
Occludin is not known to contain any nuclear localisation or nuclear export signals, 
the absence of which would suggest that this protein is unable to directly interact 
with nuclear transport proteins.  It can be hypothesised, therefore, that the 
translocation of occludin across the nuclear envelope may be mediated by proteins 
which are themselves capable of interacting with nuclear transport proteins. 
This hypothesis is supported by some of the proteins identified as putative occludin 
binding partners in this study.  DDX3X and hnRNP A2/B1 are both 
nucleocytoplasmic proteins which are known to interact with nuclear transport 
proteins.  Consequently the association of occludin with these proteins may provide 
an explanation for how occludin translocates between the cytoplasm and nucleus in 
astrocytes. 
Future research should initially repeat the pull-down protein binding assay and mass 
spectrometry analysis in triplicate for both GB1-OCLN_C and GB1-OCLN_N.  Any 
matches common to all three data sets should be subject to validation with priority 
given to any nucleocytoplasmic putative binding partners to try and understand the 
mechanism by which occludin translocates across the nuclear envelope. 
This project attempted to validate the putative interaction between occludin and 
DDX3X through endogenous co-immunoprecipitation experiments.  As difficulties 
were encountered with these experiments, it may be worth conducting co-
immunoprecipitation experiments with human primary astrocytes or 1321N1 
astrocytoma cells transfected with occludin to investigate putative binding partner 
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interactions in future research.  As some of the putative occludin binding partners 
identified in this project are able to bind directly to DNA or RNA, it would also be 
interesting to investigate whether occludin is also capable of interacting with either 
of these molecules.  This could be achieved by conducting DNA- and RNA-binding 
assays for occludin. 
Future research could also investigate whether full length or processed forms of 
occludin are localised to the nucleus.  There are several examples of integral 
membrane proteins which are involved in cell signalling pathways subsequent to 
proteolytic cleavage.  Consequently the possibility that occludin may be cleaved into 
fragments which are functionally involved in cell signalling mechanisms is worth 
pursuing.  
Notch proteins are a family of cell surface receptor integral membrane proteins 
which are structurally composed of a large extracellular domain, a single 
transmembrane domain and an intracellular domain (Fortini, 2002).  The proteolytic 
cleavage of notch liberates the intracellular domain which translocates to the 
nucleus and regulates gene expression through interactions with transcription 
factors (Fortini, 2002).  The release of the notch intracellular domain is mediated by 
γ- secretase, a multi-subunit intramembrane proteolytic complex which is also 
implicated in the proteolytic processing of amyloid precursor protein (APP) (Fortini, 
2002).  APP is another cell surface transmembrane protein the cleavage of which by 
γ- secretase produces β-amyloid, the principle component of amyloid plaques, one 
of the neuropathological hallmarks of AD (Fortini, 2002). 
Intercellular barriers are not formed solely by tight junctions but also by adherens 
junctions (AJs).  Adherens junctions are also multiprotein complexes which are 
architecturally similar to tight junctions as they are composed of transmembrane 
proteins, known as cadherins, and cytoplasmic proteins, known as catenins (Meng 
and Takeichi, 2009).  Catenins function similarly to tight junction cytoplasmic 
scaffolding proteins as they connect the membrane-associated cadherins with the 
actin cytoskeleton (Meng and Takeichi, 2009). 
Classical cadherins are a family of cadherin proteins which structurally consist of an 
extracellular domain, a single transmembrane domain and a cytoplasmic domain 
(Shapiro and Weis, 2009).  The extracellular domain is composed of five repeat 
subdomains known as extracellular cadherin (EC) domains with three calcium-
binding site located at each interdomain region (Shapiro and Weis, 2009).  The 
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extracellular domain mediates the calcium-dependent trans-oligomerisation of 
classical cadherin proteins (Shapiro and Weis, 2009). 
Epithelial cadherin (E-cadherin) and neural cadherin (N-cadherin) are members of 
the classical cadherin family.  The extracellular domain of E-cadherin is cleaved by 
matrix metalloproteases (MPPs) to produce E-cadherin N-terminal fragment 1 (E-
cad/NTF1) and E-cadherin C-terminal fragment 1 (E-cad/CTF1) (Marambaud et al., 
2002).  E-cad/CTF1 consists of the E-cadherin transmembrane and cytoplasmic 
domains and remains associated with the cell membrane.  E-cad/CTF1 is cleaved 
by γ-secretase to produce the cytoplasmic E-cadherin C-terminal fragment 2 (E-
cad/CTF2) which has been shown to translocate to the nucleus in HEK 293 and 
MDCK cells (Ferber et al., 2008; Marambaud et al., 2002).  The nuclear localisation 
of E-cad/CTF2 is enhanced by p120, a catenin protein (Ferber et al., 2008).  The 
interaction with p120 enables E-cad/CTF2 to bind to DNA and also form a complex 
with the transcriptional repressor Kaiso which acts to suppress Kaiso as it prevents 
this transcription factor from binding to DNA (Ferber et al., 2008).  
N-cadherin is also cleaved by γ-secretase to produce the cytoplasmic N-cadherin C-
terminal fragment 1 (N-cad/CTF1) which binds to the CREB-binding protein (CBP) 
in the cytoplasm (Marambaud et al., 2003).  CBP is a coactivator for the cyclic AMP 
response element binding protein (CREB) transcription factor.  The interaction 
between N-cad/CTF1 and CBP promotes the degradation of this coactivator and the 
down-regulation of CREB-dependent transcription (Marambaud et al., 2003).   
It would be worthwhile investigating whether occludin is cleaved in astrocytes.  
Occludin is known to be cleaved by MPPs resulting in a disruption of the 
intercellular barrier, however, the fragments produced by MPPs do not translocate 
to the nucleus (Casas et al., 2010; Nava et al., 2013).  A possible interaction 
between occludin and γ-secretase could be explored given that this enzyme 
complex is involved in the proteolytic cleavage of other integral membrane proteins, 
although γ-secretase is considered to exclusively cleave single transmembrane 
proteins and occludin has a four-transmembrane MARVEL domain (Tolia and De 
Strooper, 2009).  Calpains and caspases are also known to cleave integral 
membrane proteins so the relationship between occludin and these enzymes could 
also be explored. 
Given that p120 catenin is implicated in the translocation of the E-cadherin fragment 
E-cad/CTF2 to the nucleus and enhances the interaction of this fragment with 
transcription factors, it might be possible that some tight junction cytoplasmic 
144 
 
scaffolding proteins might perform a similar function for occludin.  ZO proteins are 
known to possess nuclear localisation and export signals and both ZO-1 and ZO-2 
localise to the nucleus of MDCK cells (González-Mariscal et al., 1999; González-
Mariscal et al., 2006; Islas et al., 2002).  This study has also shown ZO-1 to localise 
to the nucleus of astrocytes.  ZO-2 is also known to interact with the transcription 
factors Jun, Fos and C/EBP, as well as the pre-mRNA splicing protein SC-35 
(Betanzos et al., 2004; Islas et al., 2002).  The astrocytic expression of ZO-2 and 
the possible involvement of this protein in occludin nuclear translocation might be an 
interesting avenue to pursue in future research.   
Initially, the expression of ZO-2 in astrocytes could be determined through ICC and 
western blotting.  The possible co-localisation of occludin and ZO-2 in the nucleus of 
astrocytes could also be investigated by ICC.  The subcellular localisation of E-
cad/CTF2 was established by transfecting HEK 293 and MDCK cells with HA-
tagged E-cad/CTF2 and immunostaining with an anti-HA antibody (Ferber et al., 
2008).  A similar approach could be used to determine the localisation of full length 
occludin and potential cleaved fragments such as occludin N- and C-terminal 
domains in astrocytes.  
6.4 Neuronal TJP expression 
The in vivo study also showed the cytoplasmic and nuclear expression of both 
occludin and ZO-1 in pyramidal neurons.  The neuronal expression of occludin, 
claudin 5 and ZO-1 was subsequently investigated in human neuronal cells, 
LUHMES, by ICC.  This in vitro study showed both occludin and ZO-1 to be 
expressed in the cytoplasm, nucleus and axons of LUHME cells, confirming the in 
vivo study.   
The expression of tight junction proteins in neurons raises the same functional 
questions as the expression of these proteins in astrocytes, therefore, the same 
methodological approach utilised in this study could be applied to investigate the 
function of occludin in neurons.  The pull-down protein binding assay developed in 
this study could be conducted using neuronal cell lysates and mass spectrometry 
analysis could again be utilised to identify putative protein binding partners for 
occludin in neurons.  It would be particularly interesting to compare the putative 
occludin binding partner candidates identified from both astrocytes and neurons. 
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6.5 Concluding Remarks    
This thesis has shown that tight junction proteins are expressed in non-epithelial 
cells and that these proteins possess functions beyond the tight junction complex.  
This study has succeeded in identifying putative occludin binding partners in 
astrocytes and although these findings have not been validated they provide a 
platform upon which future research into the function(s) of tight junction proteins in 
non-epithelial cells can be constructed.   
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7. Appendix
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7.1 Occludin Immunoprecipitation 
This section discloses a few examples of unsuccessful experiments to IP occludin 
from 1321N1 astrocytoma cells using the anti-occludin rabbit polyclonal antibody 
(Invitrogen) which had previously worked with HEK cells.  Buffer composition for 
these experiments: 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% 
(v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, PIC, pH 7.5.  2 mg/ml of cell 
lysate and a boil elution was utilised in these experiments. 
Figure 7.1 shows an occludin IP from 1321N1 astrocytoma cells in which a Rabbit 
IgG (vector laboratories) was used as a negative control.  12 μg of both antibodies 
was used in this IP.  The negative control and occludin eluates are identical showing 
that the IP is not specific.  Figure 7.2 shows an occludin IP from 1321N1 
astrocytoma cells in which an anti-myc antibody (Abcam) was used as a negative 
control.  10 μg of both antibodies was used in this IP.  The negative control and 
occludin eluates are again identical showing that the IP is not specific. 
 
Figure 7.1: Occludin Immunoprecipitation from 1321N1 Astrocytoma Cells  An 
occludin IP from 1321N1 astrocytoma cells using the anti-occludin rabbit polyclonal 
antibody.  A rabbit IgG antibody was used as a negative control.  The blot was 
probed with anti-occludin mouse monoclonal antibody. 
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Figure 7.2: Occludin Immunoprecipitation from 1321N1 Astrocytoma Cells  An 
occludin IP from 1321N1 astrocytoma cells using the anti-occludin rabbit polyclonal 
antibody.  An anti-myc antibody was used as a negative control.  The blot was 
probed with anti-occludin mouse monoclonal antibody.  
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